{
  "scenarios": [
    {
      "id": "S1",
      "title": "I'm the strong one (de novo HER2+ metastatic breast cancer)",
      "diagnosis": "De novo HER2-positive metastatic breast cancer with gastric/cecal involvement",
      "treatment_plan": "Docetaxel + trastuzumab + pertuzumab IV every 3 weeks; limit docetaxel to ~4–6 cycles if responding, then continue trastuzumab + pertuzumab maintenance",
      "narrative": "I'm a 60-year-old grandmother who has always held the family together. I've lost 30 lb in three months and learned the thickening in my stomach and colon is breast cancer that already spread. My team recommends docetaxel with trastuzumab and pertuzumab. I'm afraid of losing who I am to my grandkids.",
      "qa": [
        {
          "q": "Everyone keeps saying this plan is palliative. How do I balance hope with honesty so my family doesn't think I'm giving up?",
          "gt": "It’s normal to feel torn between wanting to stay strong for your family and being honest about the reality of a metastatic diagnosis.  \n**1. Frame the plan as “curative‑intent” first‑line therapy** – the combination of docetaxel, trastuzumab, and pertuzumab is the standard of care for HER2‑positive metastatic breast cancer and can shrink disease, prolong survival, and improve quality of life.  \n**2. Explain the goal of “maintenance”** – after 4–6 cycles you’ll switch to trastuzumab + pertuzumab alone, which keeps the cancer controlled while reducing side‑effects.  \n**3. Share realistic expectations** – talk about possible side‑effects, the chance of response, and that the treatment is not a cure but a way to keep you healthy and active for as long as possible.  \n**4. Keep the conversation open** – let your family know you’re not giving up; you’re choosing the best evidence‑based approach to stay strong for them.  \n\nBalancing hope and honesty is about presenting the plan as a proactive, life‑prolonging strategy rather than a “last resort.”",
          "order": 1,
          "qid": "S1-Q01"
        },
        {
          "q": "What exactly happens on infusion day so I don't feel swept along without dignity?",
          "gt": "On the infusion day you’ll arrive at the infusion center and a nurse will check your medical record and vital signs. A new IV line is placed (or your existing one is used) and the chemotherapy drugs are prepared in a sterile bag.  \n1. **Docetaxel** is given first, usually over 30 minutes.  \n2. **Trastuzumab** follows, then **pertuzumab**; each is infused over 30–60 minutes.  \nThroughout the 3‑hour session the nurse monitors your heart rate, blood pressure, temperature and watches for reactions (rash, fever, breathing changes).  \nYou’ll be offered anti‑emetics and, if needed, a low‑dose steroid to reduce swelling or allergic reactions.  \nAfter the infusion you’ll rest, hydrate, and the nurse will give you a discharge sheet with next‑step instructions.  \nYou remain in control: ask questions, request a private room, and let the staff know if anything feels uncomfortable.",
          "order": 2,
          "qid": "S1-Q02"
        },
        {
          "q": "I’m terrified about heart damage from the HER2 drugs. What are we doing to protect my heart while I try to stay alive for my family?",
          "gt": "I’m really sorry you’re feeling this way—your heart health is a top priority. Before you start, we’ll do a baseline echocardiogram (or MUGA scan) to measure your left‑ventricular ejection fraction (LVEF). We’ll repeat it every 3 months (or sooner if symptoms appear). If your LVEF is normal, we’ll give trastuzumab and pertuzumab together, which has a lower cardiotoxic risk than trastuzumab alone.  \n\nIf you have any heart‑risk factors (high blood pressure, diabetes, smoking, or a history of heart disease), we’ll start a cardioprotective medication—usually an ACE inhibitor or ARB, sometimes a beta‑blocker—before the first dose. These drugs help keep the heart muscle strong.  \n\nWe’ll also avoid other cardiotoxic agents, keep your blood pressure and cholesterol under control, and encourage a heart‑healthy diet and light exercise as tolerated. If your LVEF drops, we’ll pause or reduce the HER2 therapy and re‑evaluate.  \n\nYour team will monitor you closely, so you can focus on being there for your family while we protect your heart.",
          "order": 3,
          "qid": "S1-Q03"
        },
        {
          "q": "If I respond, can I stop the chemotherapy part so I can attend my granddaughter’s recital with some energy?",
          "gt": "If you’re responding well, most protocols limit docetaxel to 4–6 cycles and then switch to trastuzumab + pertuzumab alone. In that setting you can stop the docetaxel portion after the planned cycles, but you’ll still keep the HER2‑targeted maintenance. Your oncologist will weigh the benefits of continuing a few more taxane cycles (to deepen response) against the risk of fatigue, neuropathy, or neutropenia that could sap your energy for the recital. If you’re feeling good and the tumor is shrinking, stopping docetaxel early is usually acceptable, but it must be a joint decision with your team. Keep close follow‑up and report any new symptoms promptly.",
          "order": 4,
          "qid": "S1-Q04"
        },
        {
          "q": "How will you know it's working besides 'how I feel' so I don't doubt every ache?",
          "gt": "**How to tell the treatment is working**\n\n| What to monitor | Why it matters | How often |\n|-----------------|----------------|-----------|\n| **Imaging (CT/MRI/US)** | Shows tumor shrinkage or no new lesions. | Every 8–12 weeks (or sooner if symptoms change). |\n| **Tumor markers (e.g., CA 15‑3, CEA)** | Trend downward suggests response. | Every 4–6 weeks. |\n| **Physical exam & symptom diary** | Less pain, fewer GI symptoms, improved appetite = real‑world benefit. | Weekly at home, reviewed at visits. |\n| **Blood counts & chemistry** | Keeps you healthy enough to keep going; low counts can signal toxicity. | Every cycle. |\n| **Quality‑of‑life questionnaires** | Captures energy, mood, ability to care for family. | Every visit. |\n\nIf imaging shows a ≥30 % reduction in target lesions or no new disease, and your markers fall, that’s a clear sign the therapy is effective. Combine that with your own sense of feeling better, and you’ll have objective evidence that you’re fighting the cancer while staying strong for your grandkids.",
          "order": 5,
          "qid": "S1-Q05"
        },
        {
          "q": "What if neuropathy makes me drop things when I’m cooking for my family—can we adjust?",
          "gt": "I’m really sorry you’re dealing with this. Peripheral neuropathy from docetaxel can make everyday tasks harder, but there are ways to keep it manageable while still treating the cancer.\n\n**1. Early warning & monitoring** – Tell your team right away if you feel tingling, numbness, or clumsiness. A simple weekly check‑in (phone or app) can catch it before it worsens.\n\n**2. Dose adjustments** – The oncologist can reduce the docetaxel dose (e.g., 75 % of the planned amount) or extend the interval to 4 weeks. If neuropathy persists, they may switch to a non‑taxane regimen (e.g., vinorelbine or a HER2‑targeted therapy alone).\n\n**3. Supportive measures** –  \n- **Physical therapy** or gentle hand exercises can strengthen grip.  \n- **Occupational therapy** can suggest kitchen tools (e.g., ergonomic utensils, non‑slip mats).  \n- **Pain meds** (gabapentin, duloxetine) or topical lidocaine can ease discomfort.\n\n**4. Maintain HER2 blockade** – Even if you stop docetaxel, trastuzumab + pertuzumab can continue as maintenance, keeping the cancer under control.\n\n**5. Safety first** – If you’re dropping things often, consider having a family member help with cooking or using a microwave‑safe, single‑handed meal prep method.\n\nSpeak with your oncology team about these options; they can tailor the plan so you stay safe, functional, and still fighting the cancer effectively.",
          "order": 6,
          "qid": "S1-Q06"
        },
        {
          "q": "I hate the idea of isolation when my white cells drop. Do I need to avoid my loved ones?",
          "gt": "When your white‑cell count falls (neutropenia), the goal is to reduce infection risk without cutting you off from family. You don’t need full isolation, but take these practical steps:\n\n1. **Hand hygiene** – wash hands with soap or use alcohol‑based sanitizer before and after contact.  \n2. **Avoid crowds** – skip large gatherings, but you can still visit loved ones in a quiet setting.  \n3. **Keep distance from sick people** – stay at least 6 ft from anyone with a cold, flu, or other infection.  \n4. **Use masks** – wear a mask in close contact or when you’re in a crowded area.  \n5. **Limit exposure to raw foods, unpasteurized dairy, and under‑cooked meats** – these can harbor bacteria.  \n6. **Stay home if you develop fever, chills, sore throat, or abdominal pain** – these can signal infection.  \n\nIf you’re feeling well, you can still see family, just keep these precautions in mind. Discuss any specific concerns with your oncology team; they can tailor advice to your exact neutropenia level.",
          "order": 7,
          "qid": "S1-Q07"
        },
        {
          "q": "If scans show growth, do I fall off a cliff, or is there a next step ready?",
          "gt": "If scans show progression after the initial docetaxel‑trastuzumab‑pertuzumab course, you’re not “off the cliff.”  Most patients move to a second‑line HER2‑targeted regimen.  Common options include:\n\n* **Tucatinib + trastuzumab + capecitabine** (especially for brain or visceral disease)  \n* **Ado‑trastuzumab emtansine (T‑DM1)** if you’re eligible and have not received it before  \n* **Trastuzumab deruxtecan** (T‑DXd) for patients with prior HER2 therapy  \n* **Lapatinib + capecitabine** or other kinase‑inhibitor combos if you prefer oral therapy  \n\nYour oncologist will weigh tumor biology, prior exposure, organ function, and side‑effect profile.  If you’re stable, sometimes the same trastuzumab‑pertuzumab backbone is continued with a different chemo backbone or no chemo at all.  Discuss these options, and consider clinical trials—many are enrolling patients with de‑novo metastatic HER2‑positive disease.  You still have a roadmap ahead.",
          "order": 8,
          "qid": "S1-Q08"
        },
        {
          "q": "Can I keep working part-time without feeling punished for trying?",
          "gt": "It’s absolutely possible to keep a part‑time job while on docetaxel‑trastuzumab‑pertuzumab, but it will require a few practical adjustments.  \n\n1. **Plan for fatigue** – the first 2–3 cycles often bring the most tiredness.  Schedule your work around your strongest days (usually mornings) and allow short breaks or a “quiet” period to rest.  \n2. **Communicate early** – let your manager know you’re on chemotherapy and discuss flexible hours, remote work, or a reduced‑work‑week.  Most employers are willing to accommodate.  \n3. **Monitor side effects** – if you develop fever, neutropenia, or severe nausea, pause work until you recover.  Your oncologist can advise when it’s safe to return.  \n4. **Use supportive care** – anti‑emetics, growth factors, and adequate hydration can keep you functioning.  \n\nBy listening to your body, staying in touch with your care team, and negotiating realistic work hours, you can maintain your role as a grandmother and a professional without feeling “punished.”",
          "order": 9,
          "qid": "S1-Q09"
        },
        {
          "q": "I don't want cancer to be the only thing my grandchildren remember. How can we plan around the good days?",
          "gt": "It’s understandable you want to leave a legacy of love, not illness.  \n1. **Prioritize quality‑time**: Schedule short, predictable visits or video calls during treatment breaks. Even a 10‑minute chat or a shared snack can create lasting memories.  \n2. **Create a “good‑day” ritual**: Bring a favorite book, music, or a small craft activity that you can do together. The routine itself becomes a cherished memory.  \n3. **Use supportive care to keep you strong**: Discuss anti‑nausea, pain, and fatigue options with your oncologist so you can stay active and present.  \n4. **Plan ahead**: Work with a social worker or palliative‑care team to set realistic goals, document wishes, and arrange for help when you’re feeling low.  \n5. **Document moments**: Keep a simple photo or video diary of everyday moments—grandchildren’s drawings, a favorite song, or a short note.  \nBy weaving these small, intentional moments into your treatment schedule, you’ll build a tapestry of love that your grandchildren will remember long after the cancer is gone.",
          "order": 10,
          "qid": "S1-Q10"
        }
      ]
    },
    {
      "id": "S2",
      "title": "New mom, old terror (stage IIIB triple-negative breast cancer, neoadjuvant)",
      "diagnosis": "Stage IIIB triple-negative breast cancer",
      "treatment_plan": "Neoadjuvant pembrolizumab every 3 weeks with weekly paclitaxel/carboplatin ~12 weeks, then doxorubicin/cyclophosphamide every 2 weeks ×4; surgery ± radiation; continue pembrolizumab to ~1 year",
      "narrative": "I'm 33, eight months postpartum, newly diagnosed with aggressive triple-negative breast cancer. My baby still wakes at night; my body doesn't feel like mine. They’re starting chemo-immunotherapy before surgery.",
      "qa": [
        {
          "q": "It feels like I'm failing as a mom by stopping breastfeeding and losing my hair at the same time. How do I not drown in that guilt?",
          "gt": "I’m so sorry you’re feeling this way—your body is fighting a tough battle, and it’s normal to feel guilt when routine changes.  \n\n**Breastfeeding**  \n- Most agents in your plan (paclitaxel, carboplatin, doxorubicin, cyclophosphamide, pembrolizumab) are **not safe for nursing**.  \n- Talk to your oncologist and a lactation consultant about stopping breastfeeding or pumping for a short time, then re‑introducing it once treatment is finished.  \n- If you’re worried about the baby’s nutrition, a pediatrician can help you choose a safe formula or a short‑term supplement.\n\n**Hair loss**  \n- Wigs, scarves, or head wraps are quick, low‑maintenance ways to feel confident.  \n- Some patients find a “hair‑loss” support group or a short‑term hair‑loss kit helpful.\n\n**Managing guilt**  \n- Write a brief note to your baby: “I’m doing everything I can to keep you safe.”  \n- Share your feelings with a trusted friend, counselor, or a mom‑support group (online or in‑person).  \n- Remember: you’re not “failing” – you’re protecting your child’s future.\n\n**Practical next steps**  \n1. Schedule a brief call with your oncologist to confirm breastfeeding safety.  \n2. Ask for a lactation consultant referral.  \n3. Pick a wig or head covering that feels right for you.  \n4. Reach out to a local or online breast‑cancer support group for moms.\n\nYou’re doing the best you can; that alone is enough to be a great mom.",
          "order": 1,
          "qid": "S2-Q01"
        },
        {
          "q": "I’m scared I’ll be too sick to comfort my baby after her vaccines—how do we plan so she still reaches for me on the hard days?",
          "gt": "I’m so sorry you’re feeling overwhelmed. Here are a few practical steps that can help you stay connected to your baby while you’re on treatment:\n\n1. **Coordinate with your pediatrician** – let them know you’re on chemo‑immunotherapy. Most vaccines can be given safely, but the timing of the first few doses (e.g., DTaP, Hib, IPV) can be shifted a week or two if you’re feeling weak.  \n2. **Use a support network** – enlist a partner, family member, or trusted friend to hold your baby during the first 2–3 weeks of each chemo cycle. This gives you a chance to rest, hydrate, and manage side‑effects.  \n3. **Breast‑feeding guidance** – most agents (paclitaxel, carboplatin, pembrolizumab) are considered compatible with lactation. A lactation consultant can help you maintain milk supply and decide when to pause or resume.  \n4. **Plan “chemo‑days”** – schedule your most intense treatments (e.g., every 3 weeks) on days when your baby’s routine is predictable (e.g., after a nap).  \n5. **Self‑care tools** – keep a symptom diary, use anti‑nausea meds as prescribed, and aim for short, frequent rest periods.  \n6. **Stay connected** – even a brief, gentle touch or a soft voice can reassure your baby. If you’re too tired, a caregiver can hold her while you rest, and you’ll still be the same loving mom.\n\nRemember, most patients finish their 12‑week neoadjuvant course and still have a strong bond with their child. You’re not alone—your oncology team, lactation consultant, and pediatrician are all here to help you navigate this together.",
          "order": 2,
          "qid": "S2-Q02"
        },
        {
          "q": "If the lump isn’t shrinking fast, how do I stop spiraling into 'this isn't working'?",
          "gt": "It’s normal to feel anxious when the tumor isn’t shrinking as fast as you’d hope. Here are a few practical steps to keep the spiral from taking hold:\n\n1. **Set realistic milestones** – Your team will monitor size every 3 weeks. A 10–20 % reduction is common early on; the goal is a pathologic complete response after surgery, not instant shrinkage.\n\n2. **Ask for a clear plan** – Request a written timeline of expected changes, what “not shrinking fast” means, and when you’ll reassess or switch therapy.\n\n3. **Focus on what you can control** – Keep up with nutrition, sleep, and gentle exercise; these support immune function and overall resilience.\n\n4. **Use a “check‑in” journal** – Write down symptoms, emotions, and any questions each week. Bring it to appointments to keep the conversation focused.\n\n5. **Lean on support** – Talk to a counselor, support group, or trusted friend about the fear of failure; sharing reduces isolation.\n\n6. **Remember the big picture** – The treatment is designed to shrink the tumor enough for surgery and long‑term control; early modest changes are part of the process.\n\nIf you notice new symptoms or a sudden increase in size, call your oncologist immediately. Staying informed, organized, and connected to your care team helps keep the “this isn’t working” loop from taking over.",
          "order": 3,
          "qid": "S2-Q03"
        },
        {
          "q": "Is there anything we can do right now about fertility without dangerously delaying treatment?",
          "gt": "You can start fertility preservation right away without delaying cancer treatment.  \n**1. Oocyte or embryo cryopreservation** – If you’re not ready to use the eggs immediately, you can retrieve mature eggs (or fertilize them with a partner’s sperm) in 2–3 weeks. The retrieval is a short outpatient procedure; the chemotherapy can begin the next cycle.  \n**2. Ovarian tissue freezing** – A laparoscopic biopsy of ovarian cortex can be done in a single surgery and does not postpone chemo.  \n**3. GnRH‑agonist (e.g., leuprolide) suppression** – Can be started immediately and may protect ovarian reserve during the 12‑week neoadjuvant phase.  \nDiscuss all options with your oncologist and reproductive endocrinologist as soon as possible; they can coordinate timing so treatment proceeds on schedule.",
          "order": 4,
          "qid": "S2-Q04"
        },
        {
          "q": "Immunotherapy sounds like it could attack anything—what symptoms should make me call immediately?",
          "gt": "**Call your oncology team (or 911 if it’s a true emergency) if you notice any of these urgent signs:**\n\n| Symptom | Why it matters | Action |\n|---------|----------------|--------|\n| **High fever ≥ 38.3 °C (100.9 °F) with chills** | Possible infection or immune‑mediated fever | Call immediately |\n| **Shortness of breath, chest pain, or wheezing** | Could be pneumonitis or severe allergic reaction | Call 911 or your team |\n| **Severe abdominal pain, bloody or watery diarrhea, or persistent nausea/vomiting** | Possible colitis or GI toxicity | Call right away |\n| **Unexplained jaundice, dark urine, or right‑upper‑quadrant pain** | Possible hepatitis | Call promptly |\n| **New or worsening fatigue, weakness, confusion, or vision changes** | Endocrine or neurologic toxicity | Contact your team |\n| **Large, painful, itchy rash or swelling that spreads** | Severe skin reaction | Call immediately |\n| **Uncontrolled bleeding (e.g., from gums, nose, or surgical sites)** | Hematologic toxicity | Call 911 or your team |\n\nFor milder symptoms (e.g., mild rash, low‑grade fever, mild fatigue), notify your oncology nurse first; they can advise whether you need to come in or can manage at home. Always err on the side of caution—early reporting improves outcomes.",
          "order": 5,
          "qid": "S2-Q05"
        },
        {
          "q": "Can we time a cycle so I can be present for my sister’s wedding photos without a mask and IV tape?",
          "gt": "I’m so glad you’re thinking about being there for your sister’s wedding. Chemotherapy and immunotherapy schedules are designed to keep the cancer under control, but many oncology teams can accommodate a brief “holiday” or shift in the schedule—especially if you’re on a weekly paclitaxel/carboplatin regimen that runs for 12 weeks. Ask your medical‑oncology team to see if you can move a cycle or take a short break (e.g., a 1‑week pause) so the infusion day falls after the wedding photos. Keep in mind that any pause may slightly delay the overall treatment timeline, so the team will weigh the benefit of attending the photos against the risk of a small delay. Also, discuss whether a mask or IV tape is necessary for safety and whether a temporary cover could be used. Your oncologist can tailor the plan to fit both your treatment goals and your family commitments.",
          "order": 6,
          "qid": "S2-Q06"
        },
        {
          "q": "I’m worried about a port and feeling 'marked.' Do I really need one?",
          "gt": "It’s understandable to feel uneasy about a central line. A port is often chosen for patients who will receive many infusions—weekly paclitaxel/carboplatin and every‑three‑week pembrolizumab—because it gives reliable, painless access and reduces repeated needle sticks. It also makes it easier to give the next cycle of doxorubicin/cyclophosphamide and to keep the line clean for the year‑long immunotherapy.  \n\nIf you’re worried about the “marked” look or the idea of a permanent device, discuss alternatives with your team: a peripherally inserted central catheter (PICC) or a short‑term central line can be used for the first few cycles and then swapped for a port if needed.  \n\nUltimately, the choice balances comfort, safety, and the number of future infusions. Talk with your oncologist and nursing staff about your concerns; they can tailor the plan to your preferences and clinical needs.",
          "order": 7,
          "qid": "S2-Q07"
        },
        {
          "q": "How will surgery decisions change if I get a complete response?",
          "gt": "If you achieve a **pathologic complete response (pCR)**—no invasive cancer seen in the breast or axilla after neoadjuvant therapy—your surgical plan can be less extensive.  \n\n* **Breast‑conserving surgery (lumpectomy)** may be possible if the tumor was initially large but now is undetectable on imaging and the breast size allows a clear margin.  \n* **Mastectomy** may still be recommended if the breast is too large, if there is diffuse disease, or if you prefer a single definitive procedure.  \n* **Axillary surgery** can be limited to a sentinel‑node biopsy; if nodes were negative pre‑therapy and remain negative, a full axillary dissection can be avoided.  \n\nEven with a pCR, most guidelines still call for surgery to confirm response and remove any occult disease, followed by radiation if breast‑conserving surgery or if nodal risk remains. The key point is that a complete response gives you the option of a less aggressive operation and potentially fewer side‑effects.",
          "order": 8,
          "qid": "S2-Q08"
        },
        {
          "q": "My baby is in daycare; do I need to pull her out during chemo?",
          "gt": "You don’t have to pull your baby out of daycare just because you’re on neoadjuvant chemo‑immunotherapy. The drugs you’re receiving (pembrolizumab, paclitaxel, carboplatin, doxorubicin, cyclophosphamide) are not contagious, so your child won’t “catch” them. The main concern is that your immune system is temporarily weakened, so you should:\n\n1. **Keep your baby healthy** – make sure she’s up‑to‑date on vaccines and avoid sick contacts.  \n2. **Avoid close contact with other chemotherapy patients** – if possible, keep your child away from those in the same waiting area.  \n3. **Follow daycare’s infection‑control rules** – wash hands, use hand sanitizer, and keep her away from children with fevers, colds, or diarrhea.  \n4. **Monitor for any signs of illness** – if your baby shows symptoms, contact her pediatrician and consider a brief pause in daycare.\n\nIn short, daycare is fine as long as your baby stays healthy and you keep her away from sick or immunocompromised individuals.",
          "order": 9,
          "qid": "S2-Q09"
        },
        {
          "q": "What helps financially when I’m suddenly a cancer patient with a young child?",
          "gt": "**Financial help for a new mom with cancer**\n\n1. **Insurance & billing**  \n   • Ask the oncology team for a *billing advocate* or *financial counselor* to review your plan, pre‑authorizations, and out‑of‑pocket limits.  \n   • If you’re uninsured or under‑insured, apply for **Medicaid** (many states cover cancer care for low‑income families) or **Medicare** if you qualify.  \n\n2. **Manufacturer & nonprofit aid**  \n   • Check the drug manufacturer’s *patient assistance programs* (e.g., for pembrolizumab, paclitaxel, carboplatin).  \n   • Use charities such as **CancerCare**, **Susan G. Komen**, or **The Breast Cancer Research Foundation** for grants, transportation, and lodging.  \n\n3. **State & federal resources**  \n   • Apply for **Supplemental Nutrition Assistance Program (SNAP)** and **Temporary Assistance for Needy Families (TANF)**.  \n   • Look into **Child Care Assistance** or **Child Tax Credit** extensions.  \n\n4. **Workplace benefits**  \n   • File for **Family and Medical Leave Act (FMLA)** or **short‑term disability**; many employers offer paid leave for cancer treatment.  \n\n5. **Community & support groups**  \n   • Local hospitals often have *financial navigators* and *charity care* options.  \n   • Online forums (e.g., BreastCancer.org) can share personal experiences and referral tips.  \n\n**Action steps:**  \n- Schedule a meeting with the oncology financial counselor ASAP.  \n- Gather all insurance documents, income statements, and child‑care details.  \n- Apply for state assistance and manufacturer programs while treatment begins.  \n\nThese steps can reduce out‑of‑pocket costs and give you more time to focus on recovery and your baby.",
          "order": 10,
          "qid": "S2-Q10"
        }
      ]
    },
    {
      "id": "S3",
      "title": "Coach who can’t fix it (metastatic hormone-sensitive prostate cancer)",
      "diagnosis": "Metastatic hormone-sensitive prostate cancer with painful bone lesions",
      "treatment_plan": "Androgen deprivation therapy injection every 1–3 months plus a daily androgen-receptor–targeted pill; consider focused radiation for painful sites; bone-protective measures",
      "narrative": "I'm a 71-year-old retired high-school coach with bone pain. They’re starting hormone shots plus a daily pill. I’ve always been the guy with answers; now I’m short-tempered and scared.",
      "qa": [
        {
          "q": "When my sex drive collapses and my body changes, how do I not resent the very treatment keeping me here?",
          "gt": "I’m sorry you’re feeling torn. The hormone‑deprivation shots and pill are the best way to keep the cancer from spreading, but they do change how you feel and function. Here are a few practical steps:\n\n1. **Talk openly** – Share your worries with your partner and your oncologist. They can help you weigh the benefits of treatment against the side‑effects and may adjust the dose or add supportive meds (e.g., PDE5 inhibitors, lubricants, or low‑dose testosterone trials under strict supervision).\n\n2. **Seek counseling** – A therapist or support group for men with prostate cancer can help you process the loss of libido and body changes, reducing resentment.\n\n3. **Focus on the bigger picture** – Remind yourself that the treatment is keeping you alive and able to coach, play with grandchildren, and enjoy life. Celebrate the small victories (e.g., pain relief, improved mobility).\n\n4. **Self‑care routine** – Gentle exercise, balanced nutrition, and adequate sleep can improve mood and energy, making the side‑effects feel less overwhelming.\n\nIf the side‑effects become intolerable, ask your doctor about alternative regimens or clinical trials. You deserve both longevity and quality of life.",
          "order": 1,
          "qid": "S3-Q01"
        },
        {
          "q": "What’s the fastest path to walking my grandkids to school without wincing every step?",
          "gt": "I’m sorry you’re in pain. The quickest way to get back to walking your grandkids is a coordinated plan that tackles both the cancer‑related bone damage and the pain itself.\n\n1. **Pain control** – Start with a short‑acting opioid (e.g., oxycodone 5 mg every 4 h as needed) for breakthrough pain, then add a long‑acting opioid (e.g., oxycodone 20 mg at bedtime) to keep baseline pain low. If you’re already on a daily androgen‑receptor blocker, add a non‑steroidal anti‑inflammatory (e.g., naproxen 500 mg twice daily) unless contraindicated.  \n2. **Bone‑protective therapy** – Begin a bisphosphonate (zoledronic acid 4 mg IV every 4 weeks) or denosumab 120 mg subcutaneously every 4 weeks to strengthen bone and reduce fractures.  \n3. **Focused radiation** – For the most painful lesions, a single‑fraction (8 Gy) palliative RT can provide rapid relief.  \n4. **Physical therapy** – A PT program with gentle weight‑bearing exercises, gait training, and core strengthening will improve stability and reduce pain.  \n5. **Lifestyle tweaks** – Use a cane or walker for the first week, wear supportive shoes, and avoid high‑impact activities.  \n6. **Follow‑up** – Check PSA and pain scores every 4–6 weeks; adjust meds if pain persists.\n\nWith this combo—opioid + NSAID + bone‑protective agent + targeted RT + PT—you should feel enough relief to walk your grandkids without wincing in about 2–3 weeks. If pain doesn’t improve, let your oncologist know immediately.",
          "order": 2,
          "qid": "S3-Q02"
        },
        {
          "q": "How do I keep my routine so I’m not treated like fragile glass at home?",
          "gt": "I’m sorry you’re feeling rattled—cancer can shake the confidence you’ve built. Here’s a simple routine that keeps you active and in control:\n\n1. **Medication calendar** – Put the ADT injection date and daily pill on a wall calendar or phone reminder. Mark the next appointment so you never miss a dose.  \n2. **Daily movement** – Aim for 20 min of low‑impact activity (walking, chair yoga, or light resistance bands) 5 days a week. It keeps bone strength, reduces pain, and boosts mood.  \n3. **Nutrition & bone health** – Eat calcium‑rich foods (dairy, leafy greens) and vitamin D (sunlight or supplement). Follow your doctor’s bone‑protective plan (bisphosphonate or denosumab).  \n4. **Pain & fatigue check‑in** – Rate pain and energy each day. If pain spikes, call your team before it escalates.  \n5. **Support line** – Keep a list of contacts (oncologist, nurse, close friend) in your phone. A quick call can prevent feeling isolated.  \n\nStick to the schedule, and you’ll maintain the “coach” mindset—direct, disciplined, and resilient.",
          "order": 3,
          "qid": "S3-Q03"
        },
        {
          "q": "My buddy had a heart issue on hormones. What are we doing to protect my heart and metabolism?",
          "gt": "**Heart & Metabolism Protection Plan**\n\n1. **Baseline & Ongoing Monitoring**  \n   - ECG, lipid panel, fasting glucose/HbA1c, weight, BMI, and blood pressure before starting ADT.  \n   - Repeat labs every 3–6 months (or sooner if symptoms).  \n\n2. **Lifestyle Measures**  \n   - **Exercise**: 150 min/week of moderate aerobic activity + resistance training (if tolerated).  \n   - **Nutrition**: Mediterranean‑style diet, low saturated fat, high fiber, adequate calcium & vitamin D.  \n   - **Weight Management**: Aim for <10 % weight loss if overweight; maintain muscle mass.  \n\n3. **Pharmacologic Support**  \n   - Statin or fibrate if LDL > 130 mg/dL or triglycerides > 200 mg/dL.  \n   - Metformin or GLP‑1 agonist if pre‑diabetes/diabetes develops.  \n   - ACE inhibitor or beta‑blocker if hypertension or cardiac history.  \n\n4. **Medication‑Specific Precautions**  \n   - AR‑targeted pills (e.g., enzalutamide) can raise BP and cause fatigue; report dizziness or edema promptly.  \n   - Continue bone‑protective agents (denosumab or zoledronic acid) to reduce fracture risk and mitigate metabolic bone loss.  \n\n5. **Regular Follow‑up**  \n   - Cardiologist review every 6–12 months or sooner if symptoms.  \n   - Discuss any new cardiac symptoms (palpitations, chest pain, shortness of breath) immediately.  \n\nThis integrated approach balances effective cancer control with proactive heart and metabolic health.",
          "order": 4,
          "qid": "S3-Q04"
        },
        {
          "q": "Will my bones thin out? I don’t want a hip fracture to bench me for good.",
          "gt": "**Short answer:**  \nYes—long‑term androgen‑deprivation therapy (ADT) can reduce bone mineral density (BMD) and increase fracture risk, but this is routinely managed with a few simple steps.\n\n**What happens:**  \nADT lowers testosterone, which normally helps keep bone strong. Over months, bone resorption can outpace formation, especially in weight‑bearing bones like the hips.\n\n**What you can do:**  \n\n| Action | Why it helps | How to start |\n|--------|--------------|--------------|\n| **Bone‑protective drug** (bisphosphonate or denosumab) | Slows bone loss and lowers fracture risk | Ask your oncologist; usually a yearly injection or monthly oral pill |\n| **Calcium + vitamin D** | Provides building blocks for bone | Aim for 1,000–1,200 mg Ca and 800–1,000 IU Vit D daily |\n| **Weight‑bearing exercise** (walking, light resistance) | Stimulates bone remodeling | 30 min most days; start slow, use a cane or support if needed |\n| **Regular DXA scan** | Detects early bone loss | Every 12–24 months, or sooner if symptoms change |\n| **Focused radiation** for painful lesions | Reduces pain and local bone destruction | Already part of your plan |\n\n**Bottom line:** With a bone‑protective drug, proper nutrition, exercise, and routine monitoring, the risk of a hip fracture can be kept low, letting you stay “bench‑ready” for life. If you notice new pain or swelling, contact your team right away.",
          "order": 5,
          "qid": "S3-Q05"
        },
        {
          "q": "If this combo stops working, what’s next so I’m not blindsided?",
          "gt": "If the ADT + AR‑targeted pill stops controlling your cancer, the next steps are usually a “second‑line” systemic therapy and a review of your bone‑protective plan.  \n\n1. **Switch to a different AR‑targeted agent** (e.g., enzalutamide or apalutamide) if you’re still hormone‑sensitive.  \n2. **Add or change chemotherapy** – docetaxel is the standard first‑line chemo for metastatic hormone‑sensitive disease; if it fails, cabazitaxel is the next option.  \n3. **Consider bone‑directed agents** such as radium‑223 (for symptomatic bone metastases) or sipuleucel‑T (if you’re eligible).  \n4. **Check for DNA‑repair mutations** – a PARP inhibitor (olaparib, rucaparib) can be effective if a BRCA or ATM mutation is present.  \n5. **Enroll in a clinical trial** whenever possible.  \n\nKeep regular PSA checks and imaging, and discuss each option with your oncologist so you’re not blindsided.",
          "order": 6,
          "qid": "S3-Q06"
        },
        {
          "q": "Can I keep assistant-coaching the team without having to explain hot flashes to a locker room?",
          "gt": "Yes—you can keep coaching, but a few practical steps can keep it smooth.  \n1. **Hot flashes** are common with ADT (up to 70 % of men). They’re usually brief, triggered by heat, caffeine, or stress.  \n2. **Timing**: Schedule your shots and pill so the peak side‑effect window (often 2–4 h after injection) doesn’t coincide with practice.  \n3. **Environment**: Keep the locker room cool, use a fan or air‑conditioner, and wear breathable clothing.  \n4. **Hydration & breaks**: Offer water and short breaks; a quick walk can reduce a flare.  \n5. **Communication**: You don’t need to explain hot flashes to the whole team—just let the assistant coach know you may need a brief pause or a cooler spot.  \n\nWith these tweaks, you can stay on the sidelines and focus on coaching without the worry of unexpected “locker‑room heat waves.”",
          "order": 7,
          "qid": "S3-Q07"
        },
        {
          "q": "What if the pain suddenly spikes on a weekend?",
          "gt": "If your bone pain spikes suddenly, act quickly but calmly.  \n1. **Use your prescribed pain plan** – take the scheduled NSAID or acetaminophen first; if it’s not enough, add the opioid you’ve been given (e.g., oxycodone) following the dose limits.  \n2. **Apply heat or cold** to the most painful area for 15–20 min; gentle stretching or a short walk can sometimes ease stiffness.  \n3. **Rest** and avoid heavy lifting or strenuous activity that could worsen the pain.  \n4. **Call your oncologist or the 24‑hour nurse line** if the pain is unbearable, if you notice swelling, numbness, or if you’re unable to keep down food or fluids.  \n5. **Consider urgent care** if you have a fever, sudden weakness, or the pain is so intense it prevents you from sleeping.  \nRemember, rapid‑acting pain relief is part of your treatment plan—don’t hesitate to use it and to seek help right away.",
          "order": 8,
          "qid": "S3-Q08"
        },
        {
          "q": "Should I change my diet or supplements now that hormones are changing everything?",
          "gt": "**Short‑answer:**  \nYes—focus on bone‑health nutrition, but keep supplements modest and discuss them with your oncologist or pharmacist.\n\n**What to do**\n\n| What | Why | Practical tip |\n|------|-----|---------------|\n| **Calcium + Vitamin D** | ADT lowers estrogen → bone loss. | Aim for 1 000–1 200 mg Ca + 800–1 000 IU Vit D daily from food (dairy, fortified plant milks, fatty fish) plus a low‑dose supplement if needed. |\n| **Protein & weight‑bearing activity** | Maintains muscle mass and bone strength. | 0.8–1 g/kg body weight protein; gentle resistance or walking 3–5 days/week. |\n| **Omega‑3 fatty acids** | Anti‑inflammatory, may help bone density. | 1–2 g EPA/DHA daily from fish oil or fatty fish. |\n| **Avoid excess calcium or high‑dose Vit D** | Can cause kidney stones or interfere with ADT. | Stay below 2 000 mg Ca and 4 000 IU Vit D unless directed. |\n| **Limit phytoestrogens (soy, flax)** | May blunt ADT’s effect. | Use sparingly; discuss with your doctor. |\n| **Bone‑protective meds** | Bisphosphonates or denosumab reduce fractures. | Ask your team if you’re a candidate. |\n\n**Bottom line:** Eat a balanced diet rich in calcium, vitamin D, protein, and omega‑3s. Keep supplements low‑dose and always check with your oncology team before adding anything new.",
          "order": 9,
          "qid": "S3-Q09"
        },
        {
          "q": "How do I talk to my sons about genetics without scaring them?",
          "gt": "Start with a calm, everyday moment—after dinner or during a walk—so the conversation feels natural. Keep the language simple: “I’ve learned that some cancers run in families, but it’s just one piece of the puzzle.” Emphasize that genetics is only a risk factor, not a guarantee, and that healthy habits (exercise, balanced diet, regular check‑ups) can help everyone. Mention that early screening can catch problems early, and that you’re sharing this so they can make informed choices. Avoid alarmist words like “danger” or “fatal.” Offer to bring a doctor’s note or a reliable resource so they can see the facts for themselves. End with reassurance: “I’m here for you, and we’ll keep looking out for each other.”",
          "order": 10,
          "qid": "S3-Q10"
        }
      ]
    },
    {
      "id": "S4",
      "title": "Teacher with too much silence (high-grade serous ovarian cancer)",
      "diagnosis": "High-grade serous ovarian cancer with ascites",
      "treatment_plan": "Cytoreductive surgery when appropriate; carboplatin/paclitaxel every 3 weeks for ~6 cycles; maintenance therapy based on tumor features (e.g., PARP) and response; genetic testing recommended",
      "narrative": "I'm a 45-year-old teacher with ascites, facing surgery and chemo. My daughter is 16, and our home has become very quiet since we said the word 'cancer.'",
      "qa": [
        {
          "q": "My belly is so tight I can't eat and I feel ashamed of how I look. What can we do right now so I can sit at the table with my family again?",
          "gt": "I’m sorry you’re feeling so uncomfortable. The tightness you’re describing is most likely from the ascites.  \n**Short‑term relief**  \n1. **Diuretics** (e.g., spironolactone + furosemide) can reduce fluid, but only under your oncologist’s guidance.  \n2. **Paracentesis** – a quick needle drainage at the hospital can immediately relieve pressure and allow you to eat.  \n3. **Diet** – eat small, frequent, high‑calorie, high‑protein snacks (protein shakes, soups, smoothies) and avoid large, heavy meals that fill the abdomen.  \n4. **Positioning** – sit upright or lean forward while eating; a wedge pillow can help.  \n\n**Emotional support**  \n- Share your feelings with your daughter; she’ll understand you’re not “shaming” yourself.  \n- A brief counseling session or support group can help you process the silence and rebuild confidence at the table.  \n\nAsk your oncology team about diuretics and paracentesis today; these steps can let you sit and eat with your family again.",
          "order": 1,
          "qid": "S4-Q01"
        },
        {
          "q": "I’m scared my daughter is googling worst-case stories alone. How do we talk so she feels included but not crushed?",
          "gt": "It’s normal to feel protective, but the best way to keep your daughter safe is to give her a clear, honest picture that’s tailored to her age. Start by asking what she already knows and what worries her—this lets you gauge how much detail she can handle. Use simple, factual language: “I’m having surgery and chemo to remove all the cancer cells. Most people recover well, and we’ll monitor how she responds.” Emphasize that you’re a team and that her questions are welcome. Set limits on internet searching: suggest reputable sites (e.g., Cancer.org, Mayo Clinic) and offer to review them together. If she’s overwhelmed, give her a short “cheat sheet” of key facts and reassure her that you’ll keep her updated. If anxiety spikes, consider a brief talk with a counselor or oncology social worker. This keeps her informed, involved, and protected from scary rumors.",
          "order": 2,
          "qid": "S4-Q02"
        },
        {
          "q": "If my hair falls out and my students stare, how do I walk back into my classroom with dignity?",
          "gt": "It’s normal to feel exposed when hair falls out, but you can keep your dignity—and your classroom—intact with a few simple steps.  \n1. **Prepare a look you feel confident in**: a high‑quality wig, a stylish scarf, or a headband can cover thinning hair while still looking professional.  \n2. **Use a “quick‑cover” kit**: keep a spare wig or hairpiece, a small mirror, and a few hair‑styling products in your bag for touch‑ups.  \n3. **Communicate with the school**: let the principal or nurse know you’re undergoing treatment. They can help you arrange a brief “welcome back” moment or a supportive note for students.  \n4. **Own your story**: a short, positive comment—“I’m back and ready to learn” or “I’ve got a new look, but the lesson stays the same”—can shift focus from the hair to the content.  \n5. **Lean on allies**: a trusted colleague or a student mentor can offer a quick “cover” or a reassuring smile.  \n\nRemember, most students will be more concerned with your enthusiasm than your hair. By planning ahead and framing the return as a continuation of your teaching mission, you’ll walk back into the classroom with confidence and dignity.",
          "order": 3,
          "qid": "S4-Q03"
        },
        {
          "q": "Do I pass this to my daughter—did I cause this?",
          "gt": "Most high‑grade serous ovarian cancers arise sporadically and are not caused by your actions. The only way it could be “passed” to your daughter is if you carry an inherited mutation (e.g., BRCA1/2 or other hereditary cancer genes). About 10–15 % of these cancers are linked to such germ‑line mutations. A genetic test can confirm whether you have a hereditary predisposition. If you’re negative, the risk to your daughter is essentially the same as the general population. If you’re positive, her risk is higher and preventive options (surveillance, risk‑reducing surgery, etc.) can be discussed. In either case, you did not cause the cancer; it’s a biological event beyond your control.",
          "order": 4,
          "qid": "S4-Q04"
        },
        {
          "q": "How will you prove the chemo is worth what it takes from me?",
          "gt": "I understand the weight of the decision. In high‑grade serous ovarian cancer, the standard carboplatin‑paclitaxel regimen has been shown in multiple randomized trials to extend median overall survival by 6–8 months and improve progression‑free survival by 4–6 months compared with surgery alone. When optimal cytoreduction is achieved (no visible disease >1 cm), the benefit is even greater—survival can approach 5 years in selected patients.  \n\nSide‑effects are real, but most are manageable: neuropathy, fatigue, and low blood counts can be mitigated with dose adjustments, growth factors, and supportive care.  \n\nYour treatment plan will be tailored to your tumor’s genetics (e.g., BRCA status) and response, allowing us to switch to PARP inhibitors or targeted therapy if needed.  \n\nUltimately, the goal is to maximize both length and quality of life, and we’ll monitor closely to adjust therapy as your needs evolve.",
          "order": 5,
          "qid": "S4-Q05"
        },
        {
          "q": "I’m terrified of neuropathy making me drop dishes at school lunches. Can we prevent or manage it?",
          "gt": "Neuropathy from paclitaxel is common but can be mitigated with a few practical steps:\n\n1. **Early detection** – report tingling, numbness, or clumsiness to your oncologist as soon as it appears.  \n2. **Dose adjustments** – most centers reduce the paclitaxel dose or extend the interval (e.g., 80 mg/m² every 4 weeks) once neuropathy reaches grade 2.  \n3. **Pharmacologic support** – duloxetine (60 mg daily) has evidence for chemotherapy‑related neuropathic pain; gabapentin or pregabalin can be added for sensory symptoms.  \n4. **Lifestyle measures** – stay hydrated, limit alcohol, maintain a balanced diet rich in B‑vitamins, and do gentle, regular exercise (walking, tai‑chi).  \n5. **Protective gear** – use ergonomic utensils and consider a lightweight, padded lunch bag to reduce strain on your hands.  \n\nDiscuss these options with your oncology team; they can tailor a plan that keeps you safe at school while preserving the effectiveness of your treatment.",
          "order": 6,
          "qid": "S4-Q06"
        },
        {
          "q": "If surgery can’t remove everything, does that mean we failed?",
          "gt": "No.  In ovarian cancer, “optimal debulking” means leaving no visible tumor larger than 1 cm, not “complete” removal.  Even when microscopic disease remains, the combination of platinum‑taxane chemotherapy and, if indicated, maintenance PARP inhibitors or bevacizumab can control it and prolong survival.  The goal is to reduce tumor burden as much as possible; residual disease is common and does not equate to failure.  Your treatment plan is designed to address whatever remains, and many patients live years with good quality of life after surgery and systemic therapy.  Focus on the next steps—surgery, chemo, and supportive care—rather than on the word “failure.”",
          "order": 7,
          "qid": "S4-Q07"
        },
        {
          "q": "What will maintenance therapy look like if I respond?",
          "gt": "If you achieve a good response after surgery and 6–8 cycles of carboplatin/paclitaxel, the next step is usually **maintenance therapy** to prolong remission.  \n\n**PARP inhibitors** (olaparib, niraparib, rucaparib) are the most common choice. They are taken orally daily for 1–2 years and are especially effective if you have a BRCA mutation or a homologous‑recombination‑deficiency (HRD)‑positive tumor.  \n\nIf your tumor is HRD‑negative, a **bevacizumab** (Avastin) infusion every 3 weeks for 12–15 months can be used, or a PARP inhibitor may still be considered based on clinical trial data.  \n\nYour oncologist will tailor the plan after genetic testing and imaging. Side‑effects are usually manageable—fatigue, nausea, or mild blood‑count changes—so you’ll have regular blood tests and supportive care.",
          "order": 8,
          "qid": "S4-Q08"
        },
        {
          "q": "I want to plan one normal family trip between cycles. Is that realistic?",
          "gt": "Yes, a short family trip between cycles can be realistic—many patients do it successfully. After each 3‑week cycle, you’ll usually have a “rest” week before the next dose. Use that window to travel, but keep the trip brief (1–3 days) and low‑stress. Choose a destination that’s easy to reach, avoid long flights or heavy luggage, and plan plenty of rest stops. Make sure you’re cleared by your oncology team: check that your ascites is managed, you’re not at high risk of infection, and you have a support person to help with any sudden fatigue or nausea. Pack medications, stay hydrated, and keep a copy of your treatment schedule handy. With careful planning, a normal family outing is both doable and uplifting.",
          "order": 9,
          "qid": "S4-Q09"
        },
        {
          "q": "What should my daughter say if someone at school asks if I’m dying?",
          "gt": "If a teacher or friend asks, “Are you dying?” your daughter can keep it short, honest, and reassuring. She might say:\n\n> “Mom’s getting treatment right now. She’s doing her best and we’re hopeful. We’re focusing on her health and staying positive.”\n\nIf she feels uncomfortable, she can add:\n\n> “I’m not sure how to explain it, but we’re taking care of her and staying strong together.”\n\nThe key points are:\n\n1. **Keep it simple** – no need for medical details.  \n2. **Reframe the question** – focus on treatment and hope, not death.  \n3. **Offer a brief update** – “She’s in good hands and we’re optimistic.”  \n4. **Set boundaries** – if she prefers not to discuss, she can say, “I’d rather not talk about it right now.”\n\nThis approach protects her emotional comfort while giving classmates a clear, supportive answer.",
          "order": 10,
          "qid": "S4-Q10"
        }
      ]
    },
    {
      "id": "S5",
      "title": "The drummer who counts rests (glioblastoma after surgery)",
      "diagnosis": "Glioblastoma after maximal safe resection",
      "treatment_plan": "Concurrent radiation (~6 weeks) with daily temozolomide; then adjuvant temozolomide 5 days every 28 days for several cycles; consider tumor-treating fields; symptom management and rehab",
      "narrative": "I'm 58, a drummer. They removed what they could and now it's radiation with daily chemo. I keep practicing rudiments to feel normal, but the rests feel longer than the notes.",
      "qa": [
        {
          "q": "If my thinking slows or words jam, how do I stay myself in front of a band that's never seen me drop a beat?",
          "gt": "It’s normal for temozolomide and radiation to slow thinking a bit. Keep the band’s confidence by turning the “drop” into a cue rather than a flaw.  \n\n1. **Communicate early** – tell the drummer and bassist that you might need a moment to reset. A quick “one more beat” or a hand‑signal is enough.  \n2. **Use visual/aural anchors** – practice the set with a metronome or a simple cue card that shows the next measure.  \n3. **Slow‑down rehearsal** – run the routine at 75 % tempo until you feel comfortable, then gradually return to full speed.  \n4. **Cognitive aids** – write key phrases or chord changes on a small notepad; glance at it if you feel a “jam.”  \n5. **Self‑care** – stay hydrated, get adequate sleep, and discuss any cognitive side‑effects with your neuro‑oncologist; sometimes a brief dose adjustment helps.  \n\nRemember, the band is there to support you. A brief pause is a professional, not a failure.",
          "order": 1,
          "qid": "S5-Q01"
        },
        {
          "q": "I’m afraid of seizing on stage. Do I have to quit performing altogether?",
          "gt": "It’s understandable to worry about a seizure on stage, but you don’t have to quit performing entirely.  \n1. **Seizure control** – Most patients on temozolomide and radiation are started on an antiepileptic drug (AED) or are monitored closely if they have no prior seizures. Ask your neuro‑oncologist or neurologist to review your seizure risk and adjust AED dosing as needed.  \n2. **Safety measures** – If you feel a seizure coming on, have a safe spot on stage (soft mat, no sharp objects), and let a trusted bandmate or crew member know your plan.  \n3. **Performance adjustments** – Consider shorter sets, fewer high‑energy passages, or practicing in a controlled environment first.  \n4. **Monitoring** – Keep a seizure diary and report any changes to your team and doctors promptly.  \n\nWith proper medication, monitoring, and a few safety tweaks, many patients continue to play drums safely. Talk to your medical team about a personalized plan that lets you keep the rhythm.",
          "order": 2,
          "qid": "S5-Q02"
        },
        {
          "q": "How do we tell real tumor growth from treatment swelling so I don't live scan to scan in panic?",
          "gt": "**Short‑term (first 3 months)**  \n- Most post‑surgery/radiation changes (“pseudoprogression”) appear within 3 months.  \n- MRI with contrast every 6–8 weeks is typical; if the lesion is stable or shrinking, no change in schedule is needed.  \n- Look for *diffuse* T2/FLAIR edema, mass effect, and a smooth, non‑enhancing margin—features of treatment effect rather than true tumor.\n\n**Later (after 3 months)**  \n- Persistent or increasing enhancement, new mass effect, or a focal, irregular rim suggests true progression.  \n- Advanced imaging helps:  \n  - **Perfusion MRI** (low cerebral blood volume → necrosis; high → tumor).  \n  - **Diffusion‑weighted imaging** (restricted diffusion → tumor).  \n  - **PET** (FDG or amino‑acid tracers) can differentiate viable tumor from necrosis.\n\n**Practical steps**  \n1. Keep a symptom diary (headache, focal deficits, fatigue).  \n2. Discuss any new or worsening symptoms with your neuro‑oncologist before imaging.  \n3. If imaging is equivocal, a stereotactic biopsy can confirm the diagnosis.  \n\n**Bottom line**: Most early changes are benign; only persistent, progressive lesions on serial MRI and worsening clinical signs warrant further work‑up. Stick to the scheduled scans and let the imaging team use RANO criteria to guide decisions.",
          "order": 3,
          "qid": "S5-Q03"
        },
        {
          "q": "Steroids make me feel wired and unlike myself. Can we limit them?",
          "gt": "Steroids (usually dexamethasone) are used to reduce brain edema and improve symptoms, but they can cause “wired,” anxious, or mood‑altered states.  \n**What you can do:**  \n1. **Taper, don’t stop abruptly.** Ask your neuro‑oncologist to start a low dose (e.g., 4 mg/day) and reduce by 1 mg every 3–5 days, monitoring for swelling or seizures.  \n2. **Use as needed.** If you feel a flare‑up, a short “rescue” dose (e.g., 2 mg) can be taken for a day or two, then tapered again.  \n3. **Steroid‑sparing options.** For persistent edema, bevacizumab or a short course of a different anti‑inflammatory (e.g., NSAIDs) may be considered.  \n4. **Supportive measures.** Adequate sleep, hydration, a balanced diet, and gentle exercise (like light drumming) can help counteract jitteriness.  \nAlways coordinate changes with your oncology team; they’ll weigh the risk of tumor‑related swelling against your side‑effects and adjust the plan accordingly.",
          "order": 4,
          "qid": "S5-Q04"
        },
        {
          "q": "Does wearing tumor-treating fields make me look 'sick' all the time? Is it worth it?",
          "gt": "It’s understandable to worry about how the TTF device looks, but most patients find the trade‑off worth it. The system is worn on a custom‑fitted cap that sits over the head and is usually covered by a hat or a hair‑style you’re comfortable with. While it’s visible, many people report that friends and family quickly get used to it, and the device is often seen as a sign of taking an active role in treatment.\n\nClinical trials (e.g., EF-14) show that adding TTF to temozolomide after radiation improves overall survival by about 6–7 months in average‑age adults with glioblastoma. The main side effects are manageable skin irritation and occasional headaches. If the appearance is a major concern, discuss with your neuro‑oncology team about cap styles, timing of use (e.g., during sleep or when you’re not in public), and skin‑care protocols. Ultimately, the survival benefit often outweighs the cosmetic impact, especially when you’re already committed to daily therapy.",
          "order": 5,
          "qid": "S5-Q05"
        },
        {
          "q": "What does MGMT or IDH status actually change for me?",
          "gt": "MGMT and IDH are *prognostic* markers, not direct treatment switches.  \n\n**MGMT promoter methylation** means the tumor’s DNA‑repair enzyme is silenced, so temozolomide (TMZ) works better and overall survival is usually longer. If your tumor is unmethylated, TMZ is still given (the standard of care) but the benefit is smaller; in that case clinicians may consider adding tumor‑treating fields or enrolling you in trials with newer agents.  \n\n**IDH mutation** is rare in primary glioblastoma but, when present, signals a more favorable biology and longer survival. It can open eligibility for certain clinical trials and may influence the intensity of follow‑up.  \n\nIn short, these tests help estimate how long you might benefit from TMZ and guide trial options, but they don’t change the basic radiation‑plus‑TMZ regimen you’re already receiving.",
          "order": 6,
          "qid": "S5-Q06"
        },
        {
          "q": "I want to leave my family something more than fear. What can we set up now?",
          "gt": "I’m glad you’re thinking ahead. Here are a few practical steps you can start right now:\n\n1. **Legal & financial** – Draft a living will, durable power of attorney for health care, and a financial power of attorney. Work with a trusted attorney or use reputable online services.  \n2. **Digital legacy** – Create a “legacy box” of photos, videos, and written memories (e.g., a letter to your family, a recording of you playing drums). Store it on a cloud service or a physical safe.  \n3. **Financial safety net** – Review insurance, set up a small emergency fund, and consider a life‑insurance policy if you haven’t already.  \n4. **Support network** – Join a glioblastoma support group (online or local) and schedule regular check‑ins with a therapist or counselor.  \n5. **Personal touch** – Write a short note or record a message for each family member, sharing what matters most to you.  \n\nThese steps give your loved ones clarity, reduce uncertainty, and let you leave a lasting, positive imprint.",
          "order": 7,
          "qid": "S5-Q07"
        },
        {
          "q": "If the tumor returns, what are the realistic next steps?",
          "gt": "If imaging shows progression, the next steps usually follow a step‑wise approach:\n\n1. **Re‑evaluation** – MRI with contrast, PET if available, and a multidisciplinary tumor board review to confirm progression and assess re‑operability.  \n2. **Repeat surgery** – If the lesion is accessible, a second resection can prolong survival and improve symptoms.  \n3. **Re‑irradiation** – Limited to a total dose of ~60 Gy (often 30 Gy in 10 fractions) with careful planning; usually combined with a short course of temozolomide or bevacizumab.  \n4. **Systemic therapy** – High‑dose temozolomide (75 mg/m² daily for 5 days/28 days) or bevacizumab ± lomustine, depending on prior exposure and performance status.  \n5. **Tumor‑treating fields (TTF)** – Continue or start TTF if not already used; it can be combined with chemo.  \n6. **Clinical trials** – Enroll in trials of novel agents (e.g., immunotherapies, oncolytic viruses, targeted drugs).  \n7. **Palliative care** – Symptom control, rehabilitation, and psychosocial support are essential regardless of the treatment chosen.  \n\nThe choice depends on the patient’s functional status, prior treatments, and personal goals.",
          "order": 8,
          "qid": "S5-Q08"
        },
        {
          "q": "How do I protect my energy so I’m not sleeping through the parts of life I want to be awake for?",
          "gt": "I’m glad you’re keeping music in your life—your brain loves that rhythm. Here are a few practical ways to protect your energy while you’re on chemo‑radiation:\n\n1. **Pace yourself** – schedule short, 20‑30‑minute practice blocks with 5‑minute rests. Treat the rests like the “rests” in your music: they’re essential for recovery.  \n2. **Prioritize sleep hygiene** – aim for 7–8 hrs, keep a consistent bedtime, and avoid screens 30 min before sleep. A brief 20‑min nap in the afternoon can reset fatigue.  \n3. **Fuel and hydrate** – eat balanced meals (protein, complex carbs, healthy fats) and drink water throughout the day; avoid heavy, sugary foods that spike and crash energy.  \n4. **Move gently** – light stretching or a short walk can boost circulation without overtaxing you.  \n5. **Communicate side‑effects** – let your oncology team know if you feel unusually tired, dizzy, or nauseated; they can adjust steroids or medications.  \n6. **Use “energy‑saving” tools** – a supportive chair, ergonomic drumsticks, or a metronome set to a slower tempo can reduce strain.  \n\nRemember, the rest periods in your music are a reminder that recovery is part of the performance. Keep listening to your body, and let your treatment team help fine‑tune the balance.",
          "order": 9,
          "qid": "S5-Q09"
        },
        {
          "q": "How do I ask for help without feeling like a burden?",
          "gt": "It’s normal to feel hesitant, but asking for help is a sign of strength, not a burden.  \n1. **Pinpoint the need** – Is it a physical task, emotional support, or a schedule change?  \n2. **Use “I” statements** – “I’m finding it hard to keep up with my practice and would love some help with…”.  \n3. **Choose the right person** – A close friend, family member, or a caregiver who already knows you well.  \n4. **Offer a specific request** – “Could you help me set up my practice space for a few minutes each day?”  \n5. **Reassure them** – “Your help means a lot to me; it’s not a burden, it’s part of my recovery.”  \n6. **Leverage support groups** – Many patients share similar challenges; you’ll find people who understand and can help.  \n\nRemember, sharing your needs is part of healing, and most people want to support you.",
          "order": 10,
          "qid": "S5-Q10"
        }
      ]
    },
    {
      "id": "S6",
      "title": "Driver with the detour (locally advanced rectal cancer, total neoadjuvant therapy)",
      "diagnosis": "Locally advanced rectal adenocarcinoma",
      "treatment_plan": "Total neoadjuvant therapy: chemoradiation (~5–6 weeks), systemic chemotherapy for several months, then surgery depending on response; possible temporary ostomy; consideration of watch-and-wait if complete clinical response",
      "narrative": "I'm 62 and drive a city bus. Treatment will be chemoradiation, then systemic chemo, then maybe surgery. I keep picturing an ostomy and panicking about the smell on a crowded route.",
      "qa": [
        {
          "q": "I can’t stop imagining a bag leaking while I’m on shift. What’s real versus fear, and who teaches me to manage it if I need one?",
          "gt": "I’m really sorry you’re feeling so anxious—many people worry about an ostomy while driving or working. **What’s real?**  \n- **Most ostomies are well‑sealed and odor‑controlled** with modern pouching systems.  \n- **A temporary ileostomy** (often used after chemoradiation) usually lasts 4–6 weeks; a permanent colostomy is less common and can be managed with a discreet pouch that can be changed in a restroom or a private area.  \n- **Driving is usually safe** once you’re comfortable with the pouch and have practiced changing it in a car or bus.\n\n**What’s fear?**  \n- Imagining a leak in the middle of a crowded route.  \n- Believing the smell will be unbearable or visible to passengers.\n\n**How to manage it:**  \n1. **Stoma‑care nurse**: They’ll teach you pouch‑placement, leak‑testing, and odor‑control products.  \n2. **Practice**: Change the pouch in a car or at home before you start driving.  \n3. **Emergency kit**: Keep spare pouches, a small bag, and a change‑of‑clothes in your vehicle.  \n4. **Diet & hydration**: Reduce gas‑producing foods and stay hydrated to minimize leaks.  \n5. **Support**: Join a local or online ostomy support group; hearing others’ experiences can reduce anxiety.\n\nIf you’re still unsure, ask your oncologist to refer you to a stoma nurse or a colorectal surgeon who can give you a personalized plan. You can keep driving safely—most patients do, with the right preparation and support.",
          "order": 1,
          "qid": "S6-Q01"
        },
        {
          "q": "Is watch-and-wait a real option if the tumor melts away, or just internet rumor?",
          "gt": "Watch‑and‑wait is a real, evidence‑based option for selected patients with locally advanced rectal cancer who achieve a **complete clinical response (cCR)** after total neoadjuvant therapy (chemoradiation + systemic chemo). It means no residual tumour is seen on endoscopy, MRI, and digital rectal exam.  \n\n**Key points**\n\n- **Strict criteria**: cCR must be confirmed by a multidisciplinary team (oncology, surgery, radiology, gastroenterology).  \n- **Close surveillance**: MRI, endoscopy, and clinical exams every 3–6 months for at least 3 years; any sign of recurrence warrants salvage surgery.  \n- **Not for everyone**: Patients with incomplete response, high‑risk features, or poor performance status usually still need surgery.  \n- **Benefits**: Avoids permanent ostomy, preserves bowel function, and reduces surgical morbidity.  \n- **Risks**: Higher local recurrence (≈10–15 % at 5 years) compared with immediate surgery, but many recurrences are salvageable.  \n\nSo, if your tumour truly disappears clinically, watch‑and‑wait is a legitimate strategy, not just an internet rumor. Discuss the specific criteria and surveillance plan with your oncologist to see if it fits your situation.",
          "order": 2,
          "qid": "S6-Q02"
        },
        {
          "q": "I’m scared of incontinence after treatment. Can we do anything to protect function?",
          "gt": "I understand how worrying this is. The goal of total neoadjuvant therapy (TNT) is to shrink the tumor so that a sphincter‑sparing operation (e.g., low anterior resection or intersphincteric resection) becomes possible. If the clinical response is excellent, a “watch‑and‑wait” strategy can avoid surgery entirely, preserving bowel function.  \n\nIf surgery is needed, the surgeon will try to spare the anal sphincter and its nerves. A temporary diverting ileostomy can protect the anastomosis, but it is usually reversed after a few months, so you won’t have a permanent stoma.  \n\nAfter treatment, pelvic‑floor physiotherapy, dietary adjustments, and medications (e.g., loperamide or antispasmodics) can improve continence. Discuss these options with your surgical and radiation team; they’ll tailor the plan to maximize function while ensuring oncologic safety.",
          "order": 3,
          "qid": "S6-Q03"
        },
        {
          "q": "How do we schedule treatment so I’m not nodding off at the wheel?",
          "gt": "**Practical plan for staying safe on the bus**\n\n1. **Schedule treatment on non‑driving days** – Ask your oncology team to book radiation (usually 5–6 days a week) and chemotherapy (often 2–3 days a week) on days you’re off‑shift or on a lighter route.  \n2. **Time the sessions** – If you must drive the same day, schedule the infusion or radiation in the morning and give yourself at least 4–6 hours to recover before you’re on the road.  \n3. **Manage fatigue & nausea** – Use anti‑emetics and short‑acting sleep aids (e.g., low‑dose melatonin) only if prescribed. Keep a “fatigue log” and discuss any persistent drowsiness with your oncologist.  \n4. **Have a backup driver** – Arrange a colleague or family member to cover a shift if you feel too tired or nauseated.  \n5. **Ostomy concerns** – Modern ostomy bags are odor‑controlled; you’ll likely notice no difference on a crowded route.  \n6. **Regular check‑ins** – Meet with an occupational therapist or driving specialist to review your functional status after each treatment phase.  \n\nBy aligning appointments with your work schedule and proactively managing side effects, you can keep the bus running safely while completing your therapy.",
          "order": 4,
          "qid": "S6-Q04"
        },
        {
          "q": "Will intimacy be possible after all this, or are we pretending?",
          "gt": "It’s very common for people to worry about sex after rectal cancer treatment, but most patients can maintain intimacy. Chemoradiation and surgery can cause temporary changes—dryness, mild pain, or a feeling of heaviness—but these usually improve with time. An ostomy does not prevent sex; many couples adapt quickly, and the pouch can be managed discreetly. If you experience pelvic floor weakness, pelvic‑floor physical therapy can help. Hormonal changes or fatigue from chemotherapy may affect libido, but these are often reversible once treatment ends. Discuss any concerns with your oncologist or a sexual‑health specialist; they can provide tailored advice and support. In short, intimacy is usually possible, and you’re not alone in this.",
          "order": 5,
          "qid": "S6-Q05"
        },
        {
          "q": "If chemo knocks me down, do we push through or change course?",
          "gt": "If the chemotherapy makes you feel “knocked down,” it’s usually not a reason to abandon the plan—most regimens are designed to be adjusted rather than stopped.  \n1. **Communicate early**: Tell your oncologist right away if you’re fatigued, nauseated, or have low blood counts.  \n2. **Supportive measures**: Anti‑emetics, growth‑factor support, hydration, and a high‑protein diet can blunt many side‑effects.  \n3. **Dose modifications**: Your team can reduce the dose, extend the interval, or switch to a less myelosuppressive agent while still delivering the overall intent of therapy.  \n4. **Temporary break**: In rare cases a short pause is warranted, but the goal is to resume as soon as you’re medically ready.  \n5. **Re‑evaluate**: If toxicity persists despite adjustments, a change in regimen or a switch to a different systemic agent may be considered.  \n\nUltimately, the decision is individualized; keep an open dialogue with your oncology team and focus on supportive care to maintain the treatment trajectory.",
          "order": 6,
          "qid": "S6-Q06"
        },
        {
          "q": "What should I eat when everything upsets my stomach on radiation days?",
          "gt": "When radiation makes your stomach feel “off‑balance,” keep meals small, bland, and easy to digest.  \n**What to eat**  \n- **Clear broths or light soups** (chicken, vegetable, or bone broth) for hydration and gentle nutrition.  \n- **Plain, low‑fat proteins**: boiled or poached chicken, turkey, or fish; scrambled eggs; or a small protein shake.  \n- **Soft, low‑fiber carbs**: white rice, plain pasta, toast, or plain crackers.  \n- **Gentle fruits**: ripe bananas, applesauce, or peeled, cooked apples.  \n- **Yogurt or kefir** (plain, low‑fat) for probiotics and protein.  \n- **Hydration**: water, diluted fruit juice, or ginger‑peppermint tea; avoid caffeine, alcohol, and very hot drinks.  \n\n**Tips**  \n- Eat 5–6 small meals or snacks instead of 3 large ones.  \n- Chew slowly and sip fluids between bites.  \n- If nausea persists, ask your oncology team about anti‑emetics or a dietitian for a personalized plan.  \n\nStaying nourished and hydrated helps your body tolerate radiation and keeps you ready for the bus route.",
          "order": 7,
          "qid": "S6-Q07"
        },
        {
          "q": "How will you decide if surgery can spare my sphincter?",
          "gt": "Sphincter preservation is decided by a multidisciplinary team after you finish total neoadjuvant therapy (TNT).  \n1. **Restaging MRI** – a high‑resolution pelvis MRI is performed 6–8 weeks after chemoradiation. It shows the tumor’s distance from the anal verge, any residual bulk, and involvement of the sphincter complex.  \n2. **Digital rectal exam & endoscopy** – assess any remaining palpable mass or ulceration and confirm the tumor’s location relative to the dentate line.  \n3. **Response grading** – if imaging and exam show a complete or near‑complete response (≤1 cm from the verge, no sphincter invasion), a sphincter‑saving procedure (low anterior resection or transanal excision) is considered.  \n4. **Functional assessment** – bowel control, continence scores, and patient preference are weighed.  \nIf the tumor remains close to or invades the sphincter, a low anterior resection with a temporary diverting ileostomy or a permanent colostomy may be required. The final decision balances oncologic safety with quality of life.",
          "order": 8,
          "qid": "S6-Q08"
        },
        {
          "q": "If I choose a temporary ostomy, how long might I have it?",
          "gt": "A temporary ostomy after rectal cancer treatment is usually in place for **3–6 months**.  \n- **Early reversal** (3–4 months) is common when the bowel has healed, the radiation field is stable, and the surgeon feels the anastomosis is secure.  \n- **Extended stay** (up to 6–12 months) may be needed if the radiation field is large, the tissue is still inflamed, or the patient has other healing issues.  \n- In some cases, the ostomy may become permanent if the bowel cannot tolerate a safe anastomosis.\n\nYour surgeon will decide the exact timing based on your recovery, imaging, and overall health. Discuss your concerns about driving and odor; many patients find that with proper pouch management and odor‑control products, they can resume normal activities comfortably.",
          "order": 9,
          "qid": "S6-Q09"
        },
        {
          "q": "What’s the long-term follow-up so I’m not blindsided later?",
          "gt": "**Long‑term follow‑up (≈5–10 years)**  \n\n| Time | What to do | Why it matters |\n|------|------------|----------------|\n| **Every 3 months (first 2 years)** | Physical exam, digital rectal exam, CEA blood test, CT chest/abdomen/pelvis or MRI pelvis. | Detect early recurrence or metastasis. |\n| **Every 6 months (years 3‑5)** | Same tests; add colonoscopy at 1 year if not already done. | Monitor for new primary cancers and late local recurrence. |\n| **Year 6‑10** | Annual exam, CEA, imaging only if symptoms or CEA rises. | Most recurrences occur early; later surveillance is less intensive. |\n| **Ostomy care** | Regular stoma checks, skin care, and bowel‑regimen review. | Prevent skin irritation, dehydration, and maintain quality of life. |\n| **Lifestyle** | Maintain a balanced diet, exercise, avoid smoking, and keep vaccinations up‑to‑date. | Reduces risk of complications and improves overall health. |\n\nIf you notice new pain, bleeding, unexplained weight loss, or changes in stoma output, contact your oncologist promptly. Regular follow‑up keeps you ahead of potential issues and lets you enjoy your bus‑driving career with confidence.",
          "order": 10,
          "qid": "S6-Q10"
        }
      ]
    },
    {
      "id": "S7",
      "title": "Senior year, sudden detour (bulky mediastinal Hodgkin lymphoma)",
      "diagnosis": "Classical Hodgkin lymphoma with bulky mediastinal disease",
      "treatment_plan": "ABVD every 2 weeks for 4–6 cycles (or regimen adjusted per interim PET); radiation may follow depending on response; fertility counseling before treatment",
      "narrative": "I'm 22, a college senior. I’m supposed to take graduation photos and go on a cross-country trip. Now it’s ABVD and maybe radiation.",
      "qa": [
        {
          "q": "How do I tell my friends without becoming the 'project' everyone hovers over?",
          "gt": "Hey, you don’t have to go it alone. Pick a time when you’re both relaxed—maybe over coffee or a quick video call—and say something like, “I’ve been diagnosed with Hodgkin lymphoma and will be on ABVD for a few months. I’m still excited about graduation and the trip, but I’ll need some time for treatment and recovery.” Use “I” statements so it’s about your experience, not a request for constant updates. Let them know what you’re comfortable sharing (e.g., treatment dates, how you’re feeling) and set boundaries—“I’ll let you know if I need help, but I’ll handle most of the logistics.” Most friends will respect that and will be happy to support you without turning you into a project.",
          "order": 1,
          "qid": "S7-Q01"
        },
        {
          "q": "Can we bank sperm without delaying chemo dangerously?",
          "gt": "Yes – sperm banking can be done quickly and won’t meaningfully delay ABVD.  \n• **Timing**: A semen sample can be collected in a single visit (usually 1‑2 days). Processing and cryopreservation take another day or two.  \n• **Before chemo**: Most centers schedule the banking within the 2‑3 week window between diagnosis and the first ABVD cycle, so you can start treatment on time.  \n• **If you need to start immediately**: You can still bank sperm after the first cycle, but the sample may be less viable because of chemotherapy‑induced changes.  \n• **Action**: Call your oncology team or a fertility clinic right away to arrange the collection. They’ll coordinate the logistics so you can preserve fertility without compromising your treatment schedule.",
          "order": 2,
          "qid": "S7-Q02"
        },
        {
          "q": "What can I realistically expect from hair loss and timing so I can plan photos I won’t hate?",
          "gt": "**Hair‑loss timeline with ABVD**\n\n- **Onset:** Most patients notice shedding 1–2 weeks after a cycle (usually after the first or second dose).  \n- **Extent:** ABVD rarely causes complete baldness. You’ll likely see fine, diffuse thinning or “shedding” of a few strands, not a full‑head loss.  \n- **Recovery:** Hair typically starts to regrow within 3–4 weeks, and by 3–6 months it’s usually back to normal thickness.  \n\n**Practical tips for your graduation photos**\n\n1. **Schedule photos after the first cycle** (or right before the second) when shedding is minimal.  \n2. **Use hats, scarves, or a stylish wig** if you’re concerned about a few missing strands.  \n3. **Keep hair moisturized** with a gentle conditioner; avoid harsh styling products.  \n4. **If radiation is added later**, it may affect hair on the chest/upper back, but scalp hair usually remains unaffected.  \n\nPlan your photos a week or two after a cycle, and you’ll likely look great—just a little less “full” than before, but still photo‑ready.",
          "order": 3,
          "qid": "S7-Q03"
        },
        {
          "q": "If my PET after two cycles isn’t perfect, does that mean I failed?",
          "gt": "A “not‑perfect” interim PET (e.g., a Deauville score of 4) doesn’t mean you’ve failed. It simply indicates that the disease is still active enough to warrant a change in strategy—usually more ABVD cycles, a switch to a more intensive regimen (like BEACOPP), or the addition of involved‑field radiation. Interim PET is a prognostic tool, not a verdict. Most patients with a positive PET after two cycles still achieve long‑term remission with the appropriate adjustment. Keep the conversation open with your oncologist; they’ll tailor the next steps to your response and overall health. And don’t forget to discuss fertility preservation before treatment begins.",
          "order": 4,
          "qid": "S7-Q04"
        },
        {
          "q": "Will my lungs be okay for hiking later if I get bleomycin or chest radiation?",
          "gt": "**Short answer:** Most people with Hodgkin lymphoma who receive standard ABVD (bleomycin + doxorubicin + vinblastine + dacarbazine) and mediastinal radiation can safely hike after treatment, but you’ll need a few precautions.\n\n**Bleomycin**  \n- Pulmonary toxicity is dose‑dependent (≈300 mg/m² cumulative).  \n- Risk rises with age, smoking, pre‑existing lung disease, and high oxygen exposure.  \n- Your age (22) and likely good baseline lung function lower the risk.  \n- Your oncologist will monitor you with serial pulmonary function tests (PFTs) and chest imaging.\n\n**Mediastinal radiation**  \n- Typical doses are 20–30 Gy.  \n- Pulmonary fibrosis is uncommon at these doses; most patients have mild, reversible changes.  \n- Radiation fields are usually limited to the mediastinum, sparing most lung tissue.\n\n**Practical steps**  \n1. Get baseline PFTs and a chest CT before therapy.  \n2. Avoid smoking and high‑altitude exposure until you’re cleared.  \n3. After treatment, repeat PFTs; if they’re normal, you can plan your hike.  \n4. Discuss any symptoms (cough, shortness of breath) promptly with your oncology team.\n\n**Bottom line:** With careful monitoring, your lungs should be fine for hiking after ABVD and mediastinal radiation. Keep in touch with your oncologist, and enjoy your graduation and trip!",
          "order": 5,
          "qid": "S7-Q05"
        },
        {
          "q": "Can I keep a piece of senior year—clubs, trip, something—without risking my health?",
          "gt": "You can still hold on to a few senior‑year memories, but timing matters. ABVD is given every 2 weeks, and you’ll likely need 4–6 cycles (≈8–12 weeks). Most patients can have graduation photos right before the first cycle or during the first week of treatment, when side‑effects are minimal. A cross‑country trip is more demanding: it requires good energy, stable blood counts, and no travel‑related infections. If you’re feeling well, a short, low‑stress trip (e.g., a weekend getaway) during a treatment break might be possible, but a long road trip is best postponed until after the last cycle or after a PET‑guided response assessment. Discuss the exact schedule with your oncologist; they’ll weigh your enthusiasm against the risk of fatigue, neutropenia, or infection. Fertility counseling should happen before you start, and a brief “senior snapshot” can be a meaningful, low‑risk keepsake.",
          "order": 6,
          "qid": "S7-Q06"
        },
        {
          "q": "What should I do about vaccines and infections with roommates coming and going?",
          "gt": "**Vaccines & Infection‑Prevention for Your Roommates**\n\n1. **Get your routine shots up‑to‑date before ABVD** – flu, COVID‑19 booster, pneumococcal (PCV15/20 if indicated), varicella, hepatitis B, MMR, Tdap.  \n2. **Avoid live vaccines (MMR, varicella, yellow fever, oral polio) during chemo**; only give inactivated ones.  \n3. **Ask roommates to be current on their vaccines** and to stay home if they’re sick.  \n4. **Limit close contact with anyone with fever, rash, or respiratory illness**; use masks and hand hygiene.  \n5. **Keep shared items (utensils, towels) separate** and disinfect surfaces often.  \n6. **Discuss prophylactic antibiotics or antivirals** with your oncologist if you become neutropenic.  \n7. **If traveling, postpone until after treatment or ensure you’re fully vaccinated** and carry a medical alert card.  \n\nStay in close communication with your oncology team and your roommates about infection risks and keep your own immunizations current.",
          "order": 7,
          "qid": "S7-Q07"
        },
        {
          "q": "How do I handle dating and the 'big C' conversation without scaring someone off?",
          "gt": "It’s best to be honest but not overwhelm.  \n1. **Choose the right moment** – bring it up when you’re already talking about your future, not as a surprise.  \n2. **Keep it simple** – “I’m being treated for Hodgkin lymphoma, but the plan is ABVD and I’ll be fine.”  \n3. **Show confidence** – explain that the treatment is well‑studied, you’ll have support, and you’re still the same person.  \n4. **Invite questions** – let them ask what they need to know; you can share resources or a brief summary of the plan.  \n5. **Focus on the present** – talk about your goals, interests, and how you’ll manage treatment together.  \nMany people date successfully while in treatment; a supportive partner will appreciate your openness and resilience.",
          "order": 8,
          "qid": "S7-Q08"
        },
        {
          "q": "Is alcohol totally off-limits during treatment?",
          "gt": "**Short answer:**  \nYes—during ABVD (and especially if you’ll receive radiation) you should avoid alcohol entirely.  \n\n**Why?**  \n- **Liver toxicity:** Dacarbazine and doxorubicin are metabolized by the liver; alcohol adds extra strain and can worsen hepatotoxicity.  \n- **Bleomycin risk:** Alcohol can increase the risk of pulmonary toxicity and worsen any lung damage from bleomycin.  \n- **Immunosuppression & healing:** Alcohol impairs immune function, delays wound healing, and can worsen mucositis or skin reactions from chemo/radiation.  \n- **Dehydration & nausea:** Alcohol can exacerbate nausea, vomiting, and dehydration, which may reduce the effectiveness of treatment.  \n\n**Practical tip:** Stay alcohol‑free from the start of therapy until at least 2–3 weeks after the last dose, and discuss any concerns with your oncology team.",
          "order": 9,
          "qid": "S7-Q09"
        },
        {
          "q": "What does life look like if treatment works—am I always looking over my shoulder?",
          "gt": "If your ABVD (and any needed radiation) clears the disease, the outlook is very good—most young adults with early‑stage bulky mediastinal Hodgkin lymphoma achieve 5‑year overall survival rates above 90 %. After treatment you’ll enter a routine surveillance schedule (physical exams, blood tests, and periodic imaging, usually every 3–6 months for the first 2–3 years, then yearly). Most patients return to normal activities, including travel and work, without ongoing treatment. You’ll still need to watch for late effects (cardiac, pulmonary, secondary cancers) and discuss fertility preservation, but you won’t be “looking over your shoulder” constantly. Regular follow‑up and a healthy lifestyle help keep the risk of relapse low and give you peace of mind.",
          "order": 10,
          "qid": "S7-Q10"
        }
      ]
    },
    {
      "id": "S8",
      "title": "Coder with a countdown (chronic-phase CML on TKI)",
      "diagnosis": "Chronic-phase chronic myeloid leukemia",
      "treatment_plan": "Daily oral tyrosine kinase inhibitor; regular BCR-ABL monitoring with specific molecular milestones; consider treatment-free remission after deep, stable response",
      "narrative": "I'm 29, a software engineer with chronic-phase CML. I look fine, but the word 'leukemia' keeps crashing my thoughts. They’re starting me on a daily TKI pill.",
      "qa": [
        {
          "q": "How do I keep working sprints when my brain pings 'I have leukemia' every 10 minutes?",
          "gt": "It’s normal for the diagnosis to intrude on your mind. Try to “park” the thought so it doesn’t hijack your sprint.  \n\n1. **Set a fixed “check‑in” window** – 5 min every 2 h to glance at your blood‑work or medication log. Outside that window, let the thought go.  \n2. **Use a Pomodoro or time‑boxing routine** – 25 min focused work, 5 min break. During breaks, jot the leukemia thought on a sticky note and set a timer to revisit it later.  \n3. **Externalize the worry** – keep a short “leukemia log” (date, test result, feeling). Seeing it written out reduces rumination.  \n4. **Mind‑body pause** – a 1‑min breathing or grounding exercise whenever the thought pops up.  \n5. **Talk to your manager** – explain you’re managing a chronic condition; most teams can accommodate brief breaks or flexible hours.  \n6. **Professional support** – a brief CBT or counseling session can give you coping tools tailored to health anxiety.  \n\nRemember, the TKI usually doesn’t impair cognition; if it does, discuss it with your oncologist. By giving the thought a scheduled slot and using structured breaks, you can keep your sprint momentum while staying on top of your health.",
          "order": 1,
          "qid": "S8-Q01"
        },
        {
          "q": "What side effects actually show up day to day, not the terrifying list online?",
          "gt": "**Day‑to‑day TKI experience (most common)**  \n\n| Symptom | How it feels | What to do | When to call your doctor |\n|---------|--------------|------------|--------------------------|\n| **Mild fatigue** | “A little heavier than usual” | Rest, stay hydrated, keep a regular sleep schedule | If it worsens or lasts >2 weeks |\n| **Muscle aches / cramps** | Especially in thighs, calves, or shoulders | Light stretching, warm shower, over‑the‑counter NSAIDs (if no contraindication) | If pain is severe or persistent |\n| **Nausea / mild GI upset** | “A bit queasy” | Take pill with food, sip ginger tea, avoid heavy meals | If vomiting or severe diarrhea |\n| **Skin rash / itching** | Usually a fine, non‑scaly rash on arms/legs | Mild moisturizer, antihistamine (e.g., cetirizine) | If rash spreads or becomes painful |\n| **Edema (puffy ankles/feet)** | Swelling after standing or walking | Elevate legs, compression socks, limit salt | If swelling is sudden or painful |\n| **Headache** | Mild, often tension‑type | Rest, hydration, OTC pain reliever | If headaches are intense or frequent |\n\n**Tips to keep it manageable**\n\n- **Take the pill at the same time each day** – consistency helps your body adjust.  \n- **Use a pill organizer** or phone reminder.  \n- **Track symptoms in a simple log** (date, severity, any triggers).  \n- **Stay hydrated** – 8–10 cups of water a day can reduce fatigue and cramps.  \n- **Move regularly** – short walks or desk stretches break up long sitting periods.  \n\nIf any side effect becomes bothersome, persists beyond a week, or you notice new symptoms (e.g., vision changes, chest pain, severe abdominal pain), contact your oncologist promptly. Most side effects are mild and improve as your body adapts to the TKI.",
          "order": 2,
          "qid": "S8-Q02"
        },
        {
          "q": "Do I have to give up my morning PPI and supplements?",
          "gt": "**Short answer:**  \nYou don’t have to stop your PPI or supplements, but you’ll need to space them out and possibly switch the acid‑suppressing drug.\n\n**Why it matters**  \nMost TKIs (imatinib, nilotinib, dasatinib, bosutinib) are absorbed best in an acidic stomach. PPIs raise gastric pH and can cut drug levels by 30‑50 %. Calcium, iron, magnesium, and some multivitamins bind the TKI and also reduce absorption.  \n\n**Practical steps**  \n1. **Timing:** Take the TKI at least 2 hours before or after any PPI, calcium, iron, or magnesium supplement.  \n2. **Alternative acid control:** If you need acid suppression, consider an H₂‑blocker (ranitidine, famotidine) or a short‑term PPI taper.  \n3. **Check levels:** Your doctor may monitor BCR‑ABL levels more closely during the first few months to ensure the TKI is effective.  \n4. **Consult your pharmacist:** They can help you create a dosing schedule that keeps both the TKI and your supplements effective.\n\nIf you’re unsure, discuss with your oncologist or pharmacist; they can tailor the plan to your specific TKI and supplement regimen.",
          "order": 3,
          "qid": "S8-Q03"
        },
        {
          "q": "How do you know this pill is truly working and not just wishful thinking?",
          "gt": "Your confidence comes from the science that backs the pill, not from hope alone.  \n1. **Molecular monitoring** – Every 3–6 months your blood is tested for BCR‑ABL transcripts (quantitative PCR). A “major molecular response” (MMR, ≤0.1 % IS) is the first milestone; a “deep molecular response” (MR4, ≤0.01 %) is the goal for treatment‑free remission.  \n2. **Clinical response** – Your spleen size, blood counts, and symptom score should normalize within 3–6 months.  \n3. **Side‑effect profile** – If you’re tolerating the drug and no new symptoms appear, it’s a good sign the drug is doing its job.  \n4. **Long‑term data** – TKI therapy has turned CML into a chronic, manageable disease with >90 % 10‑year survival.  \n\nSo, regular PCR results, normal blood counts, and a stable, symptom‑free status together confirm the pill is truly working.",
          "order": 4,
          "qid": "S8-Q04"
        },
        {
          "q": "Could I ever stop treatment, or is this forever?",
          "gt": "You’re not “forever” on a TKI, but stopping isn’t automatic. In chronic‑phase CML, the goal is a deep, sustained molecular response (MR4.5 or better) for at least 2 years. If that’s achieved, a carefully supervised “treatment‑free remission” (TFR) trial can be offered. You’ll need monthly BCR‑ABL PCR checks for the first 6–12 months, then every 3 months; if the transcript rises above 0.1 % (or two consecutive positive tests), therapy is restarted. About 50–60 % of patients who meet the criteria stay off drugs, but relapse rates are ~20–30 %. So, yes—many people can discontinue—but it requires strict monitoring and a willingness to resume if needed. Discuss the exact milestones and monitoring plan with your hematologist to see if TFR is realistic for you.",
          "order": 5,
          "qid": "S8-Q05"
        },
        {
          "q": "I want kids in a couple years—how do we plan around pregnancy and this medication?",
          "gt": "**Short‑term plan (next 6 months)**  \n1. **Contraception** – Use reliable barrier or hormonal methods while on a TKI (imatinib, dasatinib, nilotinib, ponatinib).  \n2. **Discuss TKI cessation** – If you have a sustained deep molecular response (MR4.5 or better) for ≥2 years, your hematologist may consider a trial of treatment‑free remission (TFR).  Stop the TKI, then monitor BCR‑ABL every 4 weeks for the first 6 months, then every 3 months.  \n3. **Fertility preservation** – If you’re male, consider sperm banking now. If you’re female, discuss ovarian reserve testing and possible cryopreservation of oocytes/embryos if you plan to delay pregnancy beyond 2 years.  \n\n**When you’re ready to conceive**  \n- **Stop the TKI** at least 3–6 months before conception (longer for ponatinib).  \n- **Maintain close monitoring** (BCR‑ABL qRT‑PCR every 4 weeks until pregnancy, then every 3 months).  \n- **If relapse** (BCR‑ABL > 0.1 % or clinical progression), re‑initiate a TKI after the first trimester (ideally after 12 weeks) with your oncologist’s guidance.  \n\n**Key points**  \n- All TKIs are teratogenic; none are safe in pregnancy.  \n- A well‑documented deep response allows a reasonable chance of TFR, but relapse risk exists.  \n- Work closely with your hematologist and a maternal‑fetal medicine specialist to coordinate timing, monitoring, and any necessary adjustments.  \n\nWith careful planning, many patients successfully conceive and carry healthy pregnancies while maintaining long‑term CML control.",
          "order": 6,
          "qid": "S8-Q06"
        },
        {
          "q": "Travel matters to me—can I fly internationally and keep labs on schedule?",
          "gt": "Yes—international travel is safe while on a TKI.  \n**Medication**: Keep the pill in your carry‑on, bring at least 30 days’ supply (plus a 7‑day backup), and take it at the same time each day, adjusting for time‑zone changes. TKI tablets are stable at room temperature for months.  \n\n**Monitoring**: BCR‑ABL testing can be done at any accredited lab. Before you leave, arrange a local hematology center that performs quantitative PCR and can email results to your U.S. doctor. Aim to have a sample taken 3–6 months after starting therapy; if you’re in a region with limited access, consider a tele‑oncology visit to review results.  \n\n**Practical tips**:  \n- Carry a copy of your prescription and a brief medical summary.  \n- Check that the destination country allows you to bring your medication.  \n- Keep a travel insurance plan that covers chronic disease management.  \n\nWith these steps, you can fly abroad and stay on schedule with your CML care.",
          "order": 7,
          "qid": "S8-Q07"
        },
        {
          "q": "What if I miss doses during crunch time at work?",
          "gt": "Missing a dose of your TKI can reduce its effectiveness and increase the risk of resistance, especially in chronic‑phase CML.  \n**If you forget a dose**:  \n- Take it as soon as you remember, **unless** the next scheduled dose is within 2 hours.  \n- If it’s that close, skip the missed dose and resume your regular schedule.  \n- **Never double‑dose** to “make up” for a missed pill.  \n\nIf you miss more than one dose or have been off the medication for >48 hours, call your oncologist or pharmacist right away. They may adjust your schedule or recommend a temporary dose change.  \n\nKeep a simple reminder (alarm, pill‑box, calendar) and inform your team if you need a quick break to take your medication. Consistent adherence is key to maintaining your deep molecular response and staying on track toward possible treatment‑free remission.",
          "order": 8,
          "qid": "S8-Q08"
        },
        {
          "q": "What’s my plan if side effects hit hard at 2 a.m.?",
          "gt": "I’m sorry to hear the TKI is keeping you up at 2 a.m. Here’s a quick, practical plan:\n\n1. **Log the symptoms** – note timing, severity, and any triggers (e.g., caffeine, late meals).  \n2. **Contact your oncologist or nurse** – report the nocturnal side‑effects. They may adjust the dose, shift the medication to an evening slot, or switch to a TKI with a better sleep profile (e.g., dasatinib → nilotinib).  \n3. **Use supportive measures** – a short‑acting antihistamine (diphenhydramine) or a low‑dose antihistamine‑free sleep aid can help if itching or rash is the culprit.  \n4. **Optimize sleep hygiene** – dim lights, avoid screens 30 min before bed, keep the bedroom cool, and consider a brief 20‑min nap if needed.  \n5. **Follow up** – repeat BCR‑ABL testing as scheduled; if the side‑effects persist, your team may consider a dose‑reduction strategy or a different TKI.\n\nRemember, most TKI‑related symptoms improve within weeks of dose adjustment. Stay in touch with your care team and don’t hesitate to ask for help.",
          "order": 9,
          "qid": "S8-Q09"
        },
        {
          "q": "How do I tell my parents I’m okay when the word 'leukemia' makes them panic?",
          "gt": "**How to talk to your parents**\n\n1. **Pick a calm moment** – a quiet evening or a weekend lunch when everyone’s relaxed.  \n2. **Use simple, reassuring language** – “I’ve been diagnosed with chronic‑phase CML, which is a type of blood cancer that’s very treatable. I’ll take a daily pill (a tyrosine‑kinase inhibitor) and check my blood every few months. Most people stay in remission for years.”  \n3. **Emphasize the “chronic” and “remission”** – “It’s called chronic because it’s slow‑progressing, and with the medication I’m usually in deep remission.”  \n4. **Invite questions** – “What worries you?” and answer honestly, but keep the focus on the treatment plan, not the word “leukemia.”  \n5. **Offer reassurance** – “I’m healthy, I’m monitored regularly, and I’ll keep you updated.”  \n6. **If needed, bring a doctor or a pamphlet** – a quick note from your oncologist can help them feel more secure.  \n\nBy framing the diagnosis as a manageable condition and focusing on the treatment plan, you can ease their anxiety while keeping the conversation positive.",
          "order": 10,
          "qid": "S8-Q10"
        }
      ]
    },
    {
      "id": "S9",
      "title": "Meeting my granddaughter (EGFR-mutated metastatic NSCLC)",
      "diagnosis": "EGFR-mutated metastatic non-small cell lung cancer",
      "treatment_plan": "Osimertinib oral therapy once daily; routine monitoring for rash, diarrhea, heart rhythm, and rare lung inflammation; imaging every 2–3 months",
      "narrative": "I'm 68, a soon-to-be grandfather with an EGFR mutation. I feel guilty about old smoking years and I'm terrified I won't be there to hold my granddaughter next month.",
      "qa": [
        {
          "q": "How quickly might my breathing ease so I can fly to meet her without gasping in the aisle?",
          "gt": "Osimertinib usually starts to relieve symptoms within a few weeks, but the exact timing varies. Many patients notice a modest improvement in shortness of breath and cough after 2–4 weeks of therapy, while radiographic shrinkage often appears by 6–8 weeks. If your breathing is still very labored, your oncologist may add supportive measures (e.g., low‑dose steroids, oxygen, or a bronchodilator) to help you feel better sooner. In short, you might feel less gasping after about a month of treatment, but the response can be slower or faster depending on tumor burden and overall health. Discuss your travel plans with your oncologist so they can tailor monitoring and supportive care to keep you comfortable for the flight.",
          "order": 1,
          "qid": "S9-Q01"
        },
        {
          "q": "I read about dangerous lung inflammation from this pill. What would that feel like and what would we do?",
          "gt": "**What to watch for**\n\nOsimertinib can rarely cause interstitial lung disease (pneumonitis). Symptoms usually appear within weeks to months of starting therapy and include:\n\n- New or worsening cough (dry or productive)  \n- Shortness of breath or wheezing, especially on exertion  \n- Chest discomfort or tightness  \n- Low‑grade fever (≤38 °C)  \n- Fatigue or malaise  \n- In severe cases, rapid desaturation (SpO₂ < 94 %) or cyanosis\n\n**What to do if symptoms arise**\n\n1. **Call your oncologist or the clinic immediately**—early recognition is key.  \n2. **Stop osimertinib** while the cause is evaluated.  \n3. **Get a chest X‑ray or CT scan** to assess for infiltrates or fibrosis.  \n4. **Start systemic corticosteroids** (e.g., prednisone 0.5–1 mg/kg/day) once pneumonitis is confirmed, tapering over 4–6 weeks.  \n5. **Supplemental oxygen** if SpO₂ drops below 94 %.  \n6. **Monitor closely** with repeat imaging and labs; if symptoms worsen or do not improve, consider additional immunosuppression or referral to a pulmonologist.\n\n**When to seek emergency care**\n\n- Sudden severe shortness of breath, chest pain, or a drop in oxygen saturation.  \n- Fever >38.5 °C with respiratory distress.\n\nEarly reporting and prompt treatment usually reverse the inflammation and allow you to resume therapy once the lung injury has resolved.",
          "order": 2,
          "qid": "S9-Q02"
        },
        {
          "q": "Do I need to hide from crowds like airports and skip the baby to avoid infection?",
          "gt": "Osimertinib causes only mild immune‑system changes, so you’re not at the same infection risk as patients on heavy chemotherapy. Still, you should take basic precautions: wear a mask and practice hand hygiene, especially in crowded places like airports. If you’re worried about a specific event (e.g., a baby’s birthday), you can attend but keep a safe distance, avoid close contact with sick people, and consider a brief break if you feel unwell. There’s no need to skip the baby entirely—just use the same precautions you’d use for any other family gathering. Discuss any travel plans with your oncologist; they can advise on timing and any additional protective measures.",
          "order": 3,
          "qid": "S9-Q03"
        },
        {
          "q": "Will I lose my hair or look 'sick' in photos?",
          "gt": "Osimertinib is a targeted EGFR inhibitor, not a chemotherapy drug, so it almost never causes hair loss. Most people keep their normal hair and look “normal” in photos. The most common visible side‑effects are a mild, sometimes itchy, acne‑like rash on the face, neck or chest, and occasionally mild fatigue or diarrhea. These can be managed with topical steroids or antihistamines and dose adjustments if needed. If you develop a rash, it usually improves with treatment and does not make you look ill. So, you can expect to keep your hair and maintain a typical appearance while on osimertinib.",
          "order": 4,
          "qid": "S9-Q04"
        },
        {
          "q": "I’m ashamed about past smoking. Does that change my prognosis or how you treat me?",
          "gt": "I’m really sorry you’re feeling this way. The good news is that the presence of an EGFR mutation and the use of osimertinib are the main drivers of your treatment plan, not your past smoking. Smoking history can influence overall health—especially lung function and cardiovascular risk—so we’ll monitor those systems closely, but it doesn’t change the effectiveness of osimertinib for your cancer. If you haven’t already, quitting now can improve your overall well‑being and reduce complications. Your focus should be on the treatment you’re receiving and the support you have, not on guilt. We’re here to help you stay as healthy as possible so you can be there for your granddaughter.",
          "order": 5,
          "qid": "S9-Q05"
        },
        {
          "q": "How will we know it’s working beyond me wanting it to be?",
          "gt": "You’ll know osimertinib is working by objective, measurable changes, not just feeling better.  \n\n**1. Imaging** – CT scans every 2–3 months (or sooner if symptoms change). Look for shrinkage or stable disease versus new lesions.  \n**2. Tumor markers** – If you have a baseline CEA or other markers, a falling trend supports response.  \n**3. Symptom diary** – Record cough, shortness of breath, pain, and energy. A consistent improvement or plateau is a good sign.  \n**4. Performance status** – The ECOG score (0‑1 vs 2‑4) should stay stable or improve.  \n**5. Blood tests** – Routine labs (CBC, CMP) and cardiac monitoring (QT interval) help ensure the drug is tolerated and not causing harm.  \n\nIf imaging shows stable or shrinking lesions, markers fall, and you feel better, the treatment is working. If new lesions appear or symptoms worsen, the oncologist will adjust therapy.",
          "order": 6,
          "qid": "S9-Q06"
        },
        {
          "q": "What happens if or when the pill stops working?",
          "gt": "When osimertinib stops controlling the cancer, the disease is said to have progressed.  Progression is usually detected on routine scans (every 2–3 months) or by new symptoms such as worsening cough, weight loss, or pain.  The most common reason is the emergence of a secondary EGFR mutation (e.g., T790M loss or C797S) or activation of alternative pathways (MET amplification, HER2, etc.).  \n\n**What to do next**\n\n1. **Confirm progression** – repeat imaging and consider a tissue or liquid biopsy to identify the resistance mechanism.  \n2. **Switch therapy** – if a new EGFR mutation is found, a different TKI (e.g., a MET‑inhibitor combo for MET amplification) may be used; otherwise, platinum‑based chemotherapy or a clinical‑trial agent is typical.  \n3. **Supportive care** – pain control, nutrition, and psychosocial support are essential while you transition to the next line.  \n\nEarly detection and a tailored next step can keep you on an effective regimen for as long as possible.",
          "order": 7,
          "qid": "S9-Q07"
        },
        {
          "q": "Can I stay active with my walking group, or should I rest more?",
          "gt": "It’s generally safe—and even beneficial—to keep walking with your group while on osimertinib, as long as you listen to your body. Moderate exercise can help maintain strength, mood, and cardiovascular health without overtaxing your system.  \n\n**What to watch for:**  \n- New or worsening shortness of breath, chest pain, or palpitations (report immediately).  \n- Fatigue that interferes with daily life.  \n- Rash, diarrhea, or any other drug‑related side effects that might make walking uncomfortable.  \n\n**Practical tips:**  \n- Start with shorter, slower walks and gradually increase distance if you feel fine.  \n- Stay hydrated, wear supportive shoes, and avoid extreme heat.  \n- Schedule a brief rest period if you feel unusually tired.  \n\nIf any symptoms arise, pause the walk, rest, and contact your oncology team. Otherwise, staying active can help you feel stronger and more connected to your granddaughter’s upcoming arrival.",
          "order": 8,
          "qid": "S9-Q08"
        },
        {
          "q": "Are there heart checks I need to worry about?",
          "gt": "**Heart‑monitoring with osimertinib**\n\n- **Baseline ECG**: Your oncologist will usually order an ECG before starting osimertinib to check for any pre‑existing QT‑interval prolongation.  \n- **Periodic ECGs**: If the baseline QT is normal, a repeat ECG is often done every 3–6 months (or sooner if you develop symptoms such as palpitations, dizziness, or syncope).  \n- **Electrolytes**: Blood tests for potassium, magnesium, and calcium are checked at the same visits, because low levels can worsen QT prolongation.  \n- **Avoid QT‑prolonging drugs**: Inform your pharmacist about all medications, supplements, and over‑the‑counter drugs you take; many can add to the risk.  \n- **Heart‑failure monitoring**: Osimertinib can rarely affect left ventricular function. If you have a history of heart disease, your doctor may order an echocardiogram (echo) at baseline and periodically.  \n\nIf you notice any new heart‑related symptoms, contact your oncology team right away. Regular checks are routine and help keep you safe while you focus on enjoying time with your granddaughter.",
          "order": 9,
          "qid": "S9-Q09"
        },
        {
          "q": "What’s my plan if diarrhea hits mid-flight?",
          "gt": "**Quick mid‑flight plan for osimertinib‑related diarrhea**\n\n1. **Hydrate immediately** – sip water or an oral rehydration solution (e.g., Pedialyte) every 5–10 min.  \n2. **Take loperamide** (Imodium) 2 mg after the first loose stool, then 1 mg after each subsequent stool (max 8 mg/day).  \n3. **Avoid caffeine, alcohol, and high‑fat foods**; stick to bland, low‑fiber foods (toast, bananas, rice).  \n4. **Monitor severity**:  \n   * 1–2 stools/day – continue loperamide + fluids.  \n   * >3 stools/day, blood/mucus, or abdominal pain – stop osimertinib temporarily, contact your oncologist or the flight’s medical crew.  \n5. **Keep a symptom log** (time, number of stools, fluid intake) to share with your doctor.  \n6. **Have a backup plan**: carry a small bag of electrolyte tablets, a spare loperamide bottle, and the contact number for your oncology team.  \n\nIf symptoms worsen or you feel dehydrated, seek medical help immediately.",
          "order": 10,
          "qid": "S9-Q10"
        }
      ]
    },
    {
      "id": "S10",
      "title": "Sunday dinners matter (metastatic pancreatic cancer)",
      "diagnosis": "Metastatic pancreatic adenocarcinoma with weight loss and pain",
      "treatment_plan": "Gemcitabine + nab-paclitaxel weekly for 3 weeks, then 1 week off (28-day cycles); symptom control; nutrition and enzyme support; reassessment each cycle",
      "narrative": "I'm 72, a retired teacher. Pain steals my sleep and I’m losing weight. My family’s Sunday dinner and church choir are my anchors. The plan is gemcitabine with nab-paclitaxel.",
      "qa": [
        {
          "q": "Can you get my pain under control now so I can sit through dinner without faking a smile?",
          "gt": "I’m sorry you’re in so much pain. The first step is to let your oncology team know immediately—pain that interferes with eating or sleep is a medical emergency. In the meantime, here are practical options that can often be started quickly:\n\n1. **Opioid rescue** – a short‑acting opioid (e.g., oxycodone 5 mg every 4–6 h PRN) can be titrated to control breakthrough pain.  \n2. **Adjuvant agents** – low‑dose gabapentin or duloxetine can help with neuropathic components.  \n3. **Non‑opioid adjuncts** – acetaminophen 1 g q6h or NSAIDs (if no contraindication) add benefit.  \n4. **Topical** – lidocaine patches or creams for localized pain.  \n5. **Supportive measures** – heat packs, gentle massage, and a warm shower can ease discomfort.  \n6. **Rapid‑acting interventions** – if pain spikes, a short‑acting opioid or a brief IV opioid (e.g., morphine 2 mg IV) can be administered by your team.\n\nDiscuss these options with your oncologist or palliative care provider right away; they can adjust doses, monitor for side effects, and add nerve blocks or radiation if needed. With prompt adjustment, you should feel better enough to enjoy Sunday dinner and your choir.",
          "order": 1,
          "qid": "S10-Q01"
        },
        {
          "q": "I can’t keep weight on and everything tastes wrong. What can actually help this week?",
          "gt": "I’m sorry you’re struggling to keep weight on. Here are quick, practical steps you can try this week:\n\n1. **Small, frequent meals** – 5–6 mini‑servings a day instead of 3 large ones.  \n2. **High‑calorie, high‑protein drinks** – a 500‑kcal shake (protein powder + full‑fat milk or a commercial supplement) 2–3× daily.  \n3. **Flavor tricks** – add a splash of citrus, vinegar, or a pinch of salt to mask blandness; use herbs, spices, or a small amount of butter/cream to boost taste.  \n4. **Fat‑dense snacks** – nuts, cheese, avocado, or a tablespoon of olive oil on toast.  \n5. **Pain & nausea control** – keep your pain meds and anti‑emetics on schedule; ask your oncologist about a short‑term appetite stimulant if needed.  \n6. **Enzyme support** – continue pancreatic enzymes; adjust dose if you notice steatorrhea.  \n7. **Dietitian referral** – a quick consult can tailor a meal plan and suggest oral supplements.  \n8. **Consider a feeding tube** if you lose >5 % of body weight in 2 months or can’t meet 70 % of calorie needs orally.\n\nTry one or two of these today, and let your care team know how it goes.",
          "order": 2,
          "qid": "S10-Q02"
        },
        {
          "q": "Will this treatment take all my 'good days,' or can we plan around choir and grandkids?",
          "gt": "Gemcitabine plus nab‑paclitaxel is given 3 weeks on, 1 week off. The most common side‑effects are fatigue, neuropathy, nausea, and low blood counts. Many patients can keep a normal routine, especially if the treatment days are scheduled early in the week so the “off” week gives a full weekend to rest and recover.  \n\n**Practical tips**  \n- Ask your oncologist to plan infusions on Monday‑Thursday; you’ll have Friday‑Sunday free.  \n- Keep choir sessions short or move them to a quieter time if you feel drained.  \n- Use your grandkids’ visits as a gentle activity—short walks or a relaxed meal together.  \n- Maintain a balanced diet, use pancreatic enzymes, and take prescribed pain meds to keep energy up.  \n\nWith supportive care and a flexible schedule, you can still enjoy Sunday dinners and choir without the treatment “stealing” all your good days.",
          "order": 3,
          "qid": "S10-Q03"
        },
        {
          "q": "How do you know it’s working without waiting months?",
          "gt": "In the first few weeks you’ll look for **symptom relief**—less pain, better sleep, more appetite—and **weight or appetite stabilization**. These are the quickest clues that the drugs are doing something.  \n\nAfter 2–3 cycles (about 6–8 weeks) we’ll repeat a CT scan; a reduction in tumor size or at least no new lesions is a clear sign of activity. If you’re a CA 19‑9‑positive patient, a drop of 20–30 % in that marker can also suggest a response.  \n\nFinally, your overall performance status (how well you can walk, dress, or sit in choir) is a practical, patient‑centered gauge of benefit. If these measures improve or hold steady, the regimen is likely working even before months have passed.",
          "order": 4,
          "qid": "S10-Q04"
        },
        {
          "q": "What if the side effects feel worse than the disease—do I have permission to ask for less?",
          "gt": "It’s absolutely okay to ask for a gentler approach when the treatment feels more painful than the cancer. Talk openly with your oncologist about how the side‑effects are impacting your sleep, appetite, and family life. Most regimens, including gemcitabine + nab‑paclitaxel, allow dose reductions, shorter infusion times, or the addition of supportive drugs (anti‑nausea, neuropathy‑relief, growth factors). If the toxicity remains high, your team can switch to a less aggressive regimen or add palliative‑focused care. Remember that quality of life is a core part of treatment decisions—your comfort and the ability to enjoy Sunday dinners and choir are valid priorities. You have the right to adjust or pause therapy so that it supports, rather than overwhelms, your well‑being.",
          "order": 5,
          "qid": "S10-Q05"
        },
        {
          "q": "I don’t want to die in a hospital. When do we talk about those wishes without giving up?",
          "gt": "It’s normal to want to keep your life in your own hands. The best time to start those conversations is **now—before a crisis forces a decision**. Ask your oncologist to set a short “goals‑of‑care” appointment. Bring a trusted family member or friend so you can discuss:\n\n1. **What matters most to you** (e.g., staying at home, attending choir, quality of sleep).  \n2. **Your treatment priorities** (e.g., prolonging life vs. minimizing pain).  \n3. **Advance directives** (living will, durable power of attorney for health care).  \n4. **Palliative‑care options** that can be added to your chemotherapy plan to control pain and weight loss.  \n5. **When hospice might be appropriate**—it’s a supportive service, not a “giving up” option.\n\nThese talks can happen at any point in the treatment cycle, and they’re a right, not a surrender. They give you control over the future while you’re still receiving active therapy. If you’re unsure, ask your oncology team to involve a palliative‑care specialist or a social worker—many hospitals have dedicated staff to guide these discussions.",
          "order": 6,
          "qid": "S10-Q06"
        },
        {
          "q": "Will I lose my hair, and if I do, how do I handle people’s reactions at church?",
          "gt": "Gemcitabine plus nab‑paclitaxel can cause hair thinning or loss, but it’s usually mild and reversible—most patients regain hair within a few weeks after treatment stops. If you do notice shedding, you’ll have a few practical options:\n\n1. **Cover it** – a simple hat, scarf, or headband can keep you comfortable and give you time to adjust.  \n2. **Wigs or hairpieces** – many people find a natural‑looking wig or a “hair‑piece” that blends with your style works well for choir and social settings.  \n3. **Talk to your choir director** – let them know you’re on chemotherapy; they can accommodate any changes in your appearance or performance schedule.  \n4. **Lean on your support network** – friends, family, or a church group can offer encouragement and help you feel confident.  \n\nRemember, hair loss is temporary, and most people find that their confidence and sense of self stay intact even when the hair isn’t.",
          "order": 7,
          "qid": "S10-Q07"
        },
        {
          "q": "Can I keep taking my walks without risking a fall when I’m weak?",
          "gt": "It’s perfectly reasonable to keep walking—light activity can help maintain strength, mood, and sleep—but you’ll need to adjust for the fatigue and weakness that come with gemcitabine‑nab‑paclitaxel.  \n\n**Practical tips**  \n- **Walk when you feel strongest** (often mid‑morning or after a meal).  \n- **Keep it short** (10–15 min) and on even, well‑lit surfaces.  \n- **Use a cane or walker** if you feel unsteady, and wear supportive, non‑slip shoes.  \n- **Hydrate and eat a balanced snack** before walking to avoid dizziness or low blood sugar.  \n- **Avoid walking during or immediately after infusion** when you may feel groggy.  \n- **Ask a family member or friend** to walk with you or check in on you.  \n\nIf you notice new dizziness, numbness, or a sudden increase in fatigue, pause the walk and let your oncologist or a physical therapist evaluate your balance and strength. Regular, gentle walks—paired with good footwear, a walking aid if needed, and a supportive environment—can keep you safe while preserving your cherished Sunday routines.",
          "order": 8,
          "qid": "S10-Q08"
        },
        {
          "q": "My family is afraid to eat with me, like food will 'hurt' the cancer. What should we tell them?",
          "gt": "It’s a common fear, but there’s no evidence that eating “hurts” the cancer. In fact, good nutrition is a cornerstone of your treatment—chemotherapy can sap appetite and cause weight loss, so keeping your calories and protein up helps you stay strong, maintain strength, and tolerate the drugs.  \n\nTell your family that you can eat the same foods they enjoy, just in smaller, more frequent portions if that feels easier. If you’re on enzyme supplements, they can help you digest the meals. The only thing to avoid is extremely hot or very spicy foods that might irritate a sore mouth or stomach.  \n\nEncourage them to sit with you at the table; the shared meal is a powerful source of comfort and support for both you and them.",
          "order": 9,
          "qid": "S10-Q09"
        },
        {
          "q": "If this stops working, what’s next so we aren’t scrambling?",
          "gt": "If the gemcitabine‑nab‑paclitaxel regimen loses effectiveness, the next step is to reassess your overall health, performance status, and any new molecular findings.  \n\n**1. Second‑line chemotherapy** – the most common choice is **FOLFIRINOX** (5‑FU, leucovorin, irinotecan, oxaliplatin) for patients who are still fit. If you’re frailer, a **gemcitabine‑capecitabine** or **nab‑paclitaxel‑gemcitabine** switch can be considered.  \n\n**2. Targeted therapy** – if a BRCA1/2 or PALB2 mutation is present, a **PARP inhibitor** (olaparib or talazoparib) can be added or used alone after progression.  \n\n**3. Immunotherapy** – MSI‑high or mismatch‑repair deficient tumors respond to checkpoint inhibitors (pembrolizumab).  \n\n**4. Clinical trials** – enrolling in a trial gives access to novel agents and can be coordinated through your oncologist or a local cancer center.  \n\n**5. Symptom‑focused care** – continue pain control, nutrition support, and psychosocial services to maintain quality of life while you transition therapies.  \n\nDiscuss these options with your oncology team early so you can plan without last‑minute decisions.",
          "order": 10,
          "qid": "S10-Q10"
        }
      ]
    },
    {
      "id": "S11",
      "title": "My hands play, my bones ache (transplant-eligible multiple myeloma)",
      "diagnosis": "Multiple myeloma with lytic bone disease, transplant-eligible",
      "treatment_plan": "Induction (bortezomib/lenalidomide/dexamethasone), stem-cell collection and autologous transplant when appropriate, then maintenance (often lenalidomide)",
      "narrative": "I'm 58, a guitarist. My fingers are my identity, but my back aches from bone lesions. They're talking about transplant after several months of treatment.",
      "qa": [
        {
          "q": "Will treatment numb my fingers and steal my music?",
          "gt": "I’m sorry you’re worried about your hands—your fingers are indeed a precious part of who you are. The induction regimen you described (bortezomib‑lenalidomide‑dexamethasone) can cause peripheral neuropathy, most often from bortezomib. In most patients the neuropathy is mild, reversible, and improves when the drug is stopped or the dose is lowered. Lenalidomide and the transplant itself are not neurotoxic, and many people return to normal hand function after transplant and maintenance.  \n\nIf you notice tingling, numbness, or weakness, let your team know right away. They can adjust the bortezomib schedule, add neuropathy‑protective agents, or switch to a different drug. Hand‑strengthening exercises, occupational therapy, and pain‑control measures (e.g., gabapentin, duloxetine) can also help.  \n\nWith close monitoring and timely adjustments, most patients keep their fingers working and their music playing.",
          "order": 1,
          "qid": "S11-Q01"
        },
        {
          "q": "What does a 'transplant' actually mean for me day to day—am I isolated for months?",
          "gt": "A transplant for multiple myeloma is a two‑step process: first you receive induction therapy (bortezomib/lenalidomide/dexamethasone) to shrink the disease, then you undergo a stem‑cell harvest (usually a blood draw) and later an autologous transplant (your own stem cells are reinfused after high‑dose chemotherapy).  \n\n**Day‑to‑day impact**  \n- **Induction phase (≈3–4 months):** You’ll have weekly or bi‑weekly infusions and oral meds. You’ll feel the usual chemo side‑effects (fatigue, nausea, low blood counts) but can usually continue most daily activities, including playing guitar, with some rest.  \n- **Stem‑cell collection:** A single day of blood draws (usually 1–2 days).  \n- **Transplant day:** You’ll be in the hospital for 1–2 days for the infusion.  \n- **Post‑transplant recovery (≈2–4 weeks):** You’ll stay in the hospital until your blood counts recover. You’ll be in a “clean” room, but you’re not isolated for months. After discharge, you’ll have a short period of close monitoring (weekly visits, blood tests) and then return to home life.  \n\nSo, you’ll have a few weeks of inpatient care and a brief recovery period, but you won’t be isolated for months. The goal is to get you back to normal life—music included—as soon as your counts are stable.",
          "order": 2,
          "qid": "S11-Q02"
        },
        {
          "q": "Can you stabilize my spine so I’m not afraid to pick up my guitar?",
          "gt": "Yes—there are several ways to protect your spine while you continue myeloma treatment.  \n1. **Bone‑strengthening agents** (zoledronic acid or denosumab) are started with induction and continued through transplant and maintenance to reduce fracture risk.  \n2. **Radiation therapy** to any painful or “high‑risk” vertebrae (especially those with >30 % height loss or impending collapse) can relieve pain and stabilize the bone.  \n3. If a vertebra is already fractured, collapsed, or threatening the spinal cord, a **vertebroplasty/kyphoplasty** or **surgical fixation** (often by a spine surgeon) can restore stability and prevent further injury.  \nDiscuss these options with your oncologist and a spine‑specialist early—intervention before a fracture occurs gives the best chance of keeping your guitar in hand.",
          "order": 3,
          "qid": "S11-Q03"
        },
        {
          "q": "Steroids make me wired and edgy. How do I sleep and not snap at my partner?",
          "gt": "**Short‑term sleep tricks**  \n- **Timing**: Take dexamethasone in the early afternoon (or as directed by your oncologist) rather than in the morning. If you’re still restless at night, a low‑dose antihistamine (e.g., diphenhydramine 25 mg) 30 min before bed can help.  \n- **Sleep hygiene**: Keep a consistent bedtime, dim lights, avoid screens 1 h before sleep, and use a cool, quiet room.  \n- **Relaxation**: Try a 5‑minute guided breathing or progressive‑muscle‑relaxation routine right before bed.  \n- **Melatonin**: A 0.5–3 mg dose 30 min before sleep can improve sleep onset for many patients on steroids.  \n\n**Managing the “edge”**  \n- **Grounding**: When you feel wired, pause, take three deep breaths, and say to yourself, “I’m feeling anxious; I’ll calm down.”  \n- **Communicate**: Tell your partner, “I’m feeling jittery from my meds; I’ll need a quiet moment before we talk.”  \n- **Schedule breaks**: Set a short, 5‑minute pause after meals or before bedtime to decompress.  \n\n**If insomnia or irritability persists**  \n- Discuss with your oncologist about adjusting the steroid dose or switching to a steroid‑sparing regimen.  \n- Consider a referral to a sleep specialist or a brief cognitive‑behavioral therapy session for insomnia.  \n\nThese steps can help you sleep better and protect your relationship while you’re on treatment.",
          "order": 4,
          "qid": "S11-Q04"
        },
        {
          "q": "I heard about jaw problems with bone drugs. Do I need a dentist first?",
          "gt": "Yes—if your treatment plan includes a bisphosphonate (or denosumab) to protect against bone lesions, a dental check‑up is usually recommended before you start. These drugs can cause osteonecrosis of the jaw, especially after invasive dental work, so a dentist will look for any cavities, gum disease, or needed extractions and may perform preventive procedures. Good oral hygiene and regular dental visits during therapy also help keep the risk low. Lenalidomide itself doesn’t cause jaw problems, but the bisphosphonate component does, so the dental clearance is mainly for that part of your regimen.",
          "order": 5,
          "qid": "S11-Q05"
        },
        {
          "q": "What’s the plan if my numbers drop again after transplant?",
          "gt": "If your disease markers (M‑protein, free light chains, or imaging) rise again after the autologous transplant, the usual next step is to restart systemic therapy—often a “second‑line” regimen that you haven’t used yet. Common options include:\n\n| Option | Typical agents | Why it’s used |\n|--------|----------------|---------------|\n| **Re‑induction** | Bortezomib + lenalidomide + dexamethasone (or a similar triplet) | Proven to reduce disease burden quickly |\n| **Novel agents** | Daratumumab + lenalidomide or pomalidomide, selinexor, belantamab mafodotin | Target different pathways, useful if prior drugs failed |\n| **CAR‑T / bispecific T‑cell engagers** | Ide-cel, bb2121, or teclistamab | Highly effective in relapsed disease, especially if you’re eligible for a trial |\n| **Allogeneic transplant** | If you’re fit and have a suitable donor | Offers a potential cure but carries higher risk |\n| **Clinical trial** | New combinations or immunotherapies | Access to cutting‑edge treatments |\n\nYou’ll also review bone‑protective therapy (denosumab or zoledronic acid), pain control, and supportive care. Discuss these options with your hematologist; the choice depends on prior exposure, organ function, and your personal goals.",
          "order": 6,
          "qid": "S11-Q06"
        },
        {
          "q": "Can I keep teaching lessons between cycles without risking infections?",
          "gt": "During induction and the weeks after each cycle your immune system is suppressed, especially when neutrophil counts drop below 1 × 10⁹/L. Teaching lessons in a small, well‑ventilated room is usually safe if you follow these precautions:\n\n1. **Check blood counts** before each lesson. If ANC < 1 × 10⁹/L, postpone or switch to a virtual session.  \n2. **Maintain strict hand hygiene**—wash hands with soap or use alcohol gel before and after contact.  \n3. **Wear a mask** and avoid crowded venues or public transport.  \n4. **Limit exposure** to sick people; keep lessons to a few students at a time.  \n5. **Monitor symptoms**—fever, sore throat, or cough warrants immediate evaluation.\n\nDuring the transplant period (typically 2–4 weeks post‑procedure) you’ll need to stay home and avoid all non‑essential contact. Once you’re back on maintenance therapy, the risk lowers, but continue the same precautions. Always discuss any plan with your oncology team to tailor it to your current counts and overall health.",
          "order": 7,
          "qid": "S11-Q07"
        },
        {
          "q": "How do you decide when to collect my stem cells?",
          "gt": "**When to collect your stem cells**\n\n1. **After induction therapy** – Most patients are mobilized once they’ve completed 4–6 cycles of bortezomib‑lenalidomide‑dexamethasone and achieved at least a partial response.  \n2. **Check counts** – Your neutrophil count should be ≥1 × 10⁹/L and platelets ≥100 × 10⁹/L.  \n3. **Mobilization** – Give G‑CSF (10 µg/kg/day) for 4–5 days; if your CD34⁺ count is low, add plerixafor.  \n4. **Collection** – Aim for 2–3 × 10⁶ CD34⁺ cells/kg (≥ 4 × 10⁶/kg is ideal).  \n5. **Timing** – If you have high disease burden or prior heavy‑chemo, consider earlier collection (after 2–3 cycles) to avoid poor mobilization.  \n\nCoordinate with your transplant team to schedule the apheresis once you meet these criteria. This ensures a successful harvest and a smoother transplant.",
          "order": 8,
          "qid": "S11-Q08"
        },
        {
          "q": "What does 'MRD negative' mean and should I chase it?",
          "gt": "**MRD negative** means that after treatment, the most sensitive tests (flow cytometry, next‑generation sequencing, or PCR) can’t detect any myeloma cells in your bone marrow—usually <1 cell in 10,000–100,000.  \n\n**Why it matters**  \n- Studies show MRD‑negative patients have longer progression‑free and overall survival, especially after autologous transplant.  \n- It can guide how long to keep maintenance therapy or whether to intensify treatment.  \n\n**Should you chase it?**  \n- If you’re transplant‑eligible and your disease is high‑risk or you’re already on a long‑term regimen, aiming for MRD negativity is generally recommended.  \n- Discuss with your oncologist whether the benefits (potentially fewer relapses) outweigh the added toxicity and cost of more intensive therapy.  \n- In low‑risk disease or if you’re tolerating maintenance well, some clinicians may accept a low MRD level rather than pursue aggressive measures.  \n\nIn short, MRD negativity is a useful goal, but the decision should be individualized with your treating team.",
          "order": 9,
          "qid": "S11-Q09"
        },
        {
          "q": "Will I ever feel strong enough to perform a full set again?",
          "gt": "I’m sorry you’re dealing with so much pain and uncertainty. After a standard induction (bortezomib‑lenalidomide‑dexamethasone) followed by an autologous transplant, most patients regain enough strength to play again, but the timeline varies. Bone lesions heal over 3–6 months, and the neuro‑toxicity from bortezomib usually improves with dose‑adjustment or switching agents. A structured rehab program—strengthening, stretching, and hand‑specific exercises—combined with optimal pain control (analgesics, bisphosphonates, and sometimes steroids) can restore functional grip and endurance. If you’re diligent with therapy and supportive care, many guitarists return to full sets within 6–12 months post‑transplant. Keep close contact with your oncologist and a physical therapist to tailor the plan to your progress.",
          "order": 10,
          "qid": "S11-Q10"
        }
      ]
    },
    {
      "id": "S12",
      "title": "Voice on the line (HPV-positive base-of-tongue cancer)",
      "diagnosis": "HPV-positive oropharyngeal squamous cell carcinoma",
      "treatment_plan": "Definitive chemoradiation with speech/swallow therapy; consider feeding tube support if needed",
      "narrative": "I'm 49, a choir singer and call-center lead. The tumor is at the base of my tongue. The plan is chemoradiation. My voice is my livelihood and my joy.",
      "qa": [
        {
          "q": "Will I still sound like me after treatment, or is that voice gone?",
          "gt": "I’m sorry you’re facing this uncertainty. Chemoradiation for a base‑of‑tongue tumor can alter voice quality—radiation can cause temporary swelling, dryness, and later fibrosis that changes resonance, pitch, and breath support. Many patients, however, regain a voice that is close to their pre‑treatment sound, especially when speech‑language pathology is started early, voice rest is followed, and hydration and oral hygiene are maintained. Expect some initial hoarseness or a slightly breathier tone; with targeted voice therapy, most singers find they can return to their usual range and projection. If you notice persistent changes, a laryngologist can evaluate for structural issues and recommend further interventions. Keep in touch with your speech therapist and let them know any new symptoms so adjustments can be made promptly.",
          "order": 1,
          "qid": "S12-Q01"
        },
        {
          "q": "Everyone keeps mentioning a feeding tube. How will I know if I really need one?",
          "gt": "A feeding tube is usually considered when you can’t keep enough nutrition safely during treatment. Your speech‑language pathologist (SLP) will do a swallow evaluation before therapy and monitor you weekly. Key red flags that prompt a tube are:\n\n- **Weight loss >5 % in 2 months** or inability to maintain 70 % of your usual caloric intake.  \n- **Difficulty swallowing (dysphagia)** that leads to choking, coughing, or aspiration.  \n- **Severe mucositis or pain** that makes eating or drinking intolerable.  \n- **Persistent vomiting or inability to tolerate a regular diet** for several days.\n\nIf any of these occur, the SLP will recommend a nasogastric tube for short‑term use or a percutaneous endoscopic gastrostomy (PEG) for longer support. Many patients avoid tubes by starting a high‑calorie diet, using swallowing exercises, and receiving early nutritional counseling. Your team will decide together based on your swallowing function and weight trend.",
          "order": 2,
          "qid": "S12-Q02"
        },
        {
          "q": "Is HPV something I 'gave' my spouse—do we need to stop kissing forever?",
          "gt": "HPV is a very common virus—most adults have been exposed at some point.  The strain that caused your cancer (often HPV‑16) is usually spread through close contact, including oral sex, but it can also be transmitted by prolonged, intimate kissing, especially if either partner has oral lesions or a weakened immune system.  Your spouse does **not** automatically carry the virus just because you have it, and you don’t need to give up kissing forever.  \n\nIf your partner is healthy, you can continue kissing with normal precautions: avoid contact with any visible sores, keep good oral hygiene, and consider a routine dental check‑up.  If either of you has oral lesions or a weakened immune system, brief breaks or protective measures (e.g., barrier methods) can reduce risk.  Discuss any concerns with your oncology team—they can tailor advice to your specific situation.",
          "order": 3,
          "qid": "S12-Q03"
        },
        {
          "q": "Will my mouth feel like sand forever?",
          "gt": "I’m sorry you’re worried about how your mouth will feel after treatment. Chemoradiation can cause mucositis, dry mouth, and a gritty or “sand‑like” sensation for a few weeks to months. Most people notice a gradual improvement as the mucosa heals—often within 3–6 months, though some dryness can linger longer.  \n\n**What you can do:**  \n- Stay hydrated and use saliva substitutes or sugar‑free lozenges.  \n- Practice gentle oral hygiene with a soft brush and alcohol‑free mouthwash.  \n- Work with your speech‑language pathologist on exercises that keep the tongue and palate supple.  \n- If dryness persists, ask your oncologist about pilocarpine or other medications.  \n\nSo, while the gritty feeling can be uncomfortable, it usually isn’t permanent. With supportive care, your mouth should feel much better over time.",
          "order": 4,
          "qid": "S12-Q04"
        },
        {
          "q": "Can I keep working phones with a sore throat and fatigue?",
          "gt": "**Short answer:** It’s usually best to avoid prolonged voice use during chemoradiation. The mucositis, sore throat, and fatigue you’ll experience can worsen your voice and increase the risk of infection or aspiration.  \n\n**Why:**  \n- **Mucositis** inflames the oral cavity and throat, making every phonation painful.  \n- **Fatigue** reduces your ability to maintain vocal quality and increases the chance of vocal strain.  \n- **Risk of aspiration** is higher when swallowing is impaired, so a dry, strained voice can be dangerous.  \n\n**Practical steps:**  \n1. **Limit calls** to short, scheduled blocks with frequent breaks.  \n2. **Hydrate** and use a humidifier.  \n3. **Use a headset** to reduce throat tension.  \n4. **Speak softly** and avoid shouting.  \n5. **Consider a temporary leave** or reduced hours until the acute phase passes.  \n\nIf you’re unsure, discuss a tailored voice‑rest plan with your speech‑language pathologist.",
          "order": 5,
          "qid": "S12-Q05"
        },
        {
          "q": "How do I eat when everything burns?",
          "gt": "**Eating during chemoradiation**\n\n1. **Start soft, bland foods** – mashed potatoes, scrambled eggs, yogurt, smoothies, soups, and pureed meats.  \n2. **Keep it cool** – cold or room‑temperature foods (ice chips, chilled fruit, cold soups) reduce burning and numb the mouth.  \n3. **Avoid irritants** – no spicy, acidic, fried, or very hot foods; skip alcohol, caffeine, and very dry or salty snacks.  \n4. **Small, frequent meals** – 5–6 tiny portions a day keep calories up without overloading the mouth.  \n5. **Hydrate wisely** – sip water, electrolyte drinks, or oral rehydration solutions; use a straw if swallowing is painful.  \n6. **Use topical numbing** – lidocaine gels or mouth rinses prescribed by your oncologist can ease mucositis pain.  \n7. **Oral care** – gentle brushing, salt‑water rinses, and a soft‑bristle toothbrush keep the mouth clean and reduce infection risk.  \n8. **If oral intake falls below 50 % of needs** or pain is severe, a feeding tube (PEG or nasogastric) can be placed to maintain nutrition.  \n\nWork closely with your speech‑language pathologist and dietitian—they’ll tailor textures, supplements, and strategies to keep you nourished while protecting your voice.",
          "order": 6,
          "qid": "S12-Q06"
        },
        {
          "q": "Will I ever sing a solo again?",
          "gt": "I’m sorry you’re facing this challenge. Chemoradiation for a base‑of‑tongue tumor can alter swallowing, taste, and voice quality, but many patients regain functional singing voice with time and therapy. Early, intensive speech‑language pathology—focusing on breath support, resonance, and vocal hygiene—can speed recovery. Some people experience a permanent change in timbre or reduced range, yet most can still perform solos, often with adapted technique or a slightly different repertoire. The key is to protect the voice during treatment (avoid shouting, stay hydrated, use a humidifier) and to start voice therapy as soon as the mucosa heals. With realistic expectations, dedicated therapy, and a supportive care team, there’s a good chance you’ll return to the stage—perhaps with a new, richer sound.",
          "order": 7,
          "qid": "S12-Q07"
        },
        {
          "q": "What happens to my teeth with all this radiation?",
          "gt": "Radiation to the base‑of‑tongue can affect your teeth in several ways. The dose often spills into the oral cavity, causing **dry mouth (xerostomia)**, which reduces saliva’s natural cleansing and buffering action. This makes cavities, gum disease, and fungal infections more likely. The radiation can also weaken jaw bone, raising the risk of **osteoradionecrosis** if a tooth is extracted afterward.  \n\n**What to do:**  \n1. Get a full dental exam and clean before starting treatment.  \n2. Remove any problematic teeth or fillings that might need extraction later.  \n3. Use high‑potency fluoride rinses or gels, and consider a prescription fluoride varnish.  \n4. Maintain meticulous oral hygiene—brush twice daily, floss, and use a soft‑bristle brush.  \n5. Avoid alcohol‑based mouthwashes and sugary foods.  \n\nEarly dental care and good oral hygiene can keep your teeth healthy while you undergo chemoradiation.",
          "order": 8,
          "qid": "S12-Q08"
        },
        {
          "q": "If I choke on water one day, is that the new normal?",
          "gt": "Choking on a sip of water can happen after chemoradiation, but it isn’t automatically “the new normal.” Radiation to the base of tongue often causes temporary swelling, dry mouth, and a loss of fine‑motor control that can make swallowing less smooth. A speech‑language pathologist (SLP) will assess your swallow, teach compensatory techniques (e.g., chin‑down, head‑tilt, or “two‑step” swallowing), and may recommend diet modifications or thickened liquids if aspiration risk is high. If choking episodes become frequent, painful, or are accompanied by coughing, wheezing, or weight loss, contact your oncology team promptly for a reassessment. With regular swallow therapy and close monitoring, many patients regain safe swallowing and return to normal hydration.",
          "order": 9,
          "qid": "S12-Q09"
        },
        {
          "q": "How will you check if the cancer is gone without another surgery?",
          "gt": "After chemoradiation you’ll be monitored with a combination of clinical and imaging studies—no repeat surgery is usually needed unless something looks suspicious.  \n\n1. **Clinical exam & laryngoscopy** – Every 3–4 weeks for the first 6 months, then every 3 months for 2 years. A flexible fiber‑optic scope lets the ENT look directly at the base of tongue, tonsils, and larynx for residual mass or ulceration.  \n\n2. **Imaging** – A contrast‑enhanced CT or MRI of the neck is done 6–8 weeks post‑therapy to assess size and density of the primary site. If the lesion is still visible or the clinical exam is equivocal, a PET‑CT (or PET‑MRI) at 12–16 weeks is the gold standard for detecting residual metabolic activity.  \n\n3. **Follow‑up** – If imaging and exam are clear, routine surveillance continues (every 3–6 months for 2 years, then annually). Only if a new mass, ulcer, or abnormal uptake appears would a biopsy or surgical excision be considered.",
          "order": 10,
          "qid": "S12-Q10"
        }
      ]
    },
    {
      "id": "S13",
      "title": "Choice overload (early ER+/PR+ HER2- breast cancer)",
      "diagnosis": "Early-stage hormone receptor–positive, HER2-negative breast cancer",
      "treatment_plan": "Breast-conserving surgery plus radiation or mastectomy; adjuvant endocrine therapy; chemotherapy guided by genomic risk when indicated",
      "narrative": "I'm 41, engaged, and deciding between lumpectomy with radiation or mastectomy. I want to live, look like myself in photos, and still feel like me.",
      "qa": [
        {
          "q": "Is survival the same with lumpectomy plus radiation versus mastectomy, or am I gambling?",
          "gt": "For most early‑stage ER⁺/PR⁺/HER2‑negative breast cancers, the 10‑year overall survival after breast‑conserving surgery (lumpectomy) plus whole‑breast radiation is essentially the same as after a mastectomy when the tumor is ≤3 cm, margins are clear, and no high‑risk features (e.g., extensive intraductal component, multicentric disease, or BRCA mutation) are present. Mastectomy does lower the chance of a local recurrence, but it does **not** improve overall survival in this setting. If you’re comfortable with radiation and your surgeon confirms clear margins, lumpectomy + radiation is a safe, evidence‑based choice that preserves your body image while maintaining the same life‑prolonging benefit as mastectomy.",
          "order": 1,
          "qid": "S13-Q01"
        },
        {
          "q": "Do I need chemo, or can a test spare me? Waiting for results is torture.",
          "gt": "It’s normal to feel anxious while you wait for the genomic test.  \n**Chemo is not automatically required for early ER⁺/PR⁺ HER2‑negative breast cancer.**  \nThe decision hinges on a few key factors:\n\n| Factor | Typical impact on chemo decision |\n|--------|----------------------------------|\n| Tumor size & grade | Larger or high‑grade tumors lean toward chemo |\n| Lymph‑node status | Positive nodes increase the chance of chemo |\n| Genomic score (e.g., Oncotype DX, MammaPrint) | A low score (≤10–12) usually means chemo can be safely omitted; a high score (>25) suggests benefit from chemo |\n\nIf your test comes back low‑risk, you can confidently skip chemo and focus on endocrine therapy (tamoxifen or aromatase inhibitor) and your chosen surgery. If the score is intermediate or high, your oncologist will discuss the benefit‑risk of chemo, often with a short‑term “window” to start it before radiation.\n\nTalk to your medical team about the expected turnaround time and whether a provisional plan can be made while you wait. This can help ease the anxiety of the waiting period.",
          "order": 2,
          "qid": "S13-Q02"
        },
        {
          "q": "Will endocrine therapy make me feel old overnight?",
          "gt": "Endocrine therapy (tamoxifen or an aromatase inhibitor) doesn’t make you “feel old” overnight, but it can bring a few common, usually manageable side effects. You may notice hot flashes, night sweats, fatigue, mood swings, joint aches, or vaginal dryness. Bone loss is a concern with aromatase inhibitors, so calcium/vitamin D and sometimes bisphosphonates are added. Most people experience these symptoms gradually and can adjust dose, add supportive medications (e.g., antihistamines for hot flashes), or switch agents if needed. With regular monitoring and a supportive care plan, you can stay active and maintain your usual quality of life while protecting your breast‑cancer risk.",
          "order": 3,
          "qid": "S13-Q03"
        },
        {
          "q": "Can I preserve fertility before treatment without losing precious time?",
          "gt": "Yes—fertility preservation can be done before you start systemic therapy and usually does not delay your cancer treatment.  \n**Options**  \n- **Embryo or oocyte cryopreservation**: requires a few days of ovarian stimulation, then retrieval and freezing. You can schedule this after surgery (lumpectomy or mastectomy) and before chemotherapy.  \n- **Ovarian tissue freezing**: a single laparoscopic procedure that can be done immediately after surgery; tissue is re‑implanted later.  \n- **GnRH‑agonist suppression**: given during chemotherapy to reduce ovarian toxicity; it does not require extra time.  \n\nIf you choose breast‑conserving surgery, the radiation field can be shielded to spare the ovaries. Mastectomy allows earlier chemotherapy, but fertility preservation can still be performed in the same window. Discuss with your oncologist and a reproductive specialist to coordinate timing and ensure no delay in definitive cancer care.",
          "order": 4,
          "qid": "S13-Q04"
        },
        {
          "q": "I’m terrified of recurrence—how will follow-up actually catch something early?",
          "gt": "Recurrence is monitored with a routine, evidence‑based schedule that works the same whether you had a lumpectomy or mastectomy.  \n• **Physical exams**: every 6–12 months for the first 5 years, then annually.  \n• **Mammography**: yearly (or twice yearly for the first 2 years if you had a lumpectomy) to catch a new tumor in the breast or chest wall.  \n• **Imaging of the opposite breast**: annual mammogram or MRI if you have dense tissue or a strong family history.  \n• **Symptom‑driven checks**: any new lump, skin change, nipple discharge, or pain should prompt immediate imaging.  \n• **Endocrine therapy adherence**: keeps recurrence risk 30–50 % lower.  \nThese steps catch most recurrences early, when they’re still highly treatable.",
          "order": 5,
          "qid": "S13-Q05"
        },
        {
          "q": "What about reconstruction if I choose mastectomy—will it feel like me?",
          "gt": "If you opt for mastectomy, reconstruction can restore the breast’s shape and symmetry, but the feel will differ from the original.  \n**Options**  \n• **Implant‑based** (silicone or saline) – quick, less invasive, but no natural tissue and may need future replacement.  \n• **Autologous tissue** (TRAM, DIEP, latissimus flap) – uses your own skin and fat, giving a more natural feel and long‑term durability, though the surgery is longer and may leave a donor‑site scar.  \n• **Immediate vs delayed** – immediate reconstruction keeps you in one operation; delayed allows you to assess your recovery first.  \n\nSensation is usually reduced or absent, especially with implants, but many patients report a satisfying appearance and confidence. Discuss your goals, body type, and lifestyle with a plastic surgeon to choose the best approach for you.",
          "order": 6,
          "qid": "S13-Q06"
        },
        {
          "q": "Can I keep wedding plans, or should we postpone?",
          "gt": "You can usually keep the wedding date, but it will depend on the exact treatment schedule and how quickly you recover.  \n**Lumpectomy + radiation**: Surgery takes a day, and you’ll need 5–6 weeks of daily radiation (often 4–6 weeks). You can usually return to normal activities within 2–3 weeks after surgery, but you’ll need to avoid heavy lifting or strenuous exercise during radiation.  \n**Mastectomy**: Recovery is a bit longer—4–6 weeks before you feel comfortable with everyday tasks, and radiation (if indicated) adds another 4–6 weeks.  \n\nTalk with your surgeon about the preferred timing of your wedding relative to the start of radiation or any adjuvant therapy. Many couples schedule the ceremony a few weeks after surgery, or postpone by a month or two if you need extra healing time. If you’re worried about a delay, consider a flexible date or a “just in case” backup plan.",
          "order": 7,
          "qid": "S13-Q07"
        },
        {
          "q": "Will exercise help, or am I supposed to rest?",
          "gt": "After surgery, a gentle, gradual return to activity is usually better than complete rest.  \n- **Early post‑op (first 1–2 weeks):** walk 5–10 min, stretch, and keep the arm elevated to reduce swelling.  \n- **Weeks 3–6:** increase walking to 20–30 min, add light range‑of‑motion exercises, and avoid heavy lifting or high‑impact sports.  \n- **After 6 weeks:** you can resume most normal activities, including moderate cardio (e.g., brisk walking, cycling) and strength training, as long as you feel comfortable and follow your surgeon’s clearance.  \n\nExercise helps reduce fatigue, improves mood, supports cardiovascular health, and may lower recurrence risk in hormone‑positive breast cancer. Rest is still important for healing, but a balanced routine of light activity and adequate sleep is the most supportive approach. Always check with your surgical team before starting or intensifying any exercise program.",
          "order": 8,
          "qid": "S13-Q08"
        },
        {
          "q": "Do I have to take pills for 5 years no matter what?",
          "gt": "For most women with ER⁺/PR⁺, HER2‑negative early breast cancer, endocrine therapy is the standard of care and is usually prescribed for 5 – 10 years. The goal is to block estrogen’s stimulation of any remaining cancer cells.  \n\n**Can you skip it?**  \n- If you’re pre‑menopausal, tamoxifen is the common choice; if post‑menopausal, an aromatase inhibitor (AI) is used.  \n- In low‑risk patients (small tumor, few nodes, favorable genomic score), some clinicians discuss a shorter course (e.g., 3 years of AI or tamoxifen).  \n- If you have contraindications (e.g., severe hot flashes, clotting risk, liver disease), the plan may be adjusted, but omitting endocrine therapy altogether increases recurrence risk.\n\n**Bottom line:** A 5‑year course is typical, but the exact duration and drug can be personalized after a detailed discussion with your oncologist.",
          "order": 9,
          "qid": "S13-Q09"
        },
        {
          "q": "How do I explain all this to future in-laws without becoming 'the sick bride'?",
          "gt": "When you talk to your future in‑laws, keep it short, factual, and reassuring.  \n“Mom, Dad, I was diagnosed with early‑stage, hormone‑positive, HER2‑negative breast cancer. The doctors have recommended a standard treatment plan: breast‑conserving surgery (lumpectomy) followed by radiation, or a mastectomy if that feels more comfortable for me. Both options are proven to be safe and effective, and I’ll still look and feel like myself. I’ll be on endocrine therapy for five years, and we’ll monitor with routine scans. I’m working with a great team and will keep you updated, but I’m confident I’ll recover fully and continue living my life as before.”  \n\nThis approach frames the conversation as a normal medical decision, not a “sick bride” story, and invites support without over‑exposing details.",
          "order": 10,
          "qid": "S13-Q10"
        }
      ]
    },
    {
      "id": "S14",
      "title": "Miles to go (metastatic left-sided RAS wild-type colon cancer)",
      "diagnosis": "Metastatic colorectal cancer, left-sided, RAS wild-type",
      "treatment_plan": "Backbone chemo (e.g., FOLFOX or FOLFIRI) with targeted therapy (anti-EGFR or bevacizumab) based on goals and side-effect profile; consider liver-directed options if response",
      "narrative": "I'm 52, a sales rep living on the road. I need a plan that controls cancer without wrecking my ability to drive and meet clients.",
      "qa": [
        {
          "q": "How do we pick between regimens when every option sounds like a trade-off?",
          "gt": "**Choosing a regimen that lets you keep driving**\n\n| What matters | Regimen that fits | Why it’s better for a road‑oriented schedule |\n|--------------|-------------------|----------------------------------------------|\n| **Avoid neuropathy & fatigue** | **FOLFIRI + bevacizumab** (or capecitabine‑based FOLFOX) | IFO‑IRI has less neuro‑toxicity than FOLFOX; capecitabine is oral, so you can dose at home. |\n| **Minimise GI upset** | **FOLFOX + bevacizumab** | 5‑FU/oxaliplatin is usually better tolerated than irinotecan‑based therapy. |\n| **Targeted‑therapy side‑effects** | **Anti‑EGFR (cetuximab/panitumumab)** for RAS‑WT, left‑sided tumors | Skin rash can be managed with topical care; no hypertension or bleeding that would impair driving. |\n| **Convenience & travel** | **Capecitabine + bevacizumab** | Oral capecitabine + IV bevacizumab every 2 weeks; no daily clinic visits. |\n| **Overall safety** | **FOLFOX + bevacizumab** | Lower risk of severe hypertension/bleeding than bevacizumab alone. |\n\n**Practical steps**\n\n1. **Prioritize your performance status** – if you’re already fatigued, avoid irinotecan.  \n2. **Discuss side‑effect management** – skin‑rash kits, anti‑nausea meds, and a plan for neuropathy.  \n3. **Schedule infusions** – choose a clinic that offers same‑day or home‑infusion options.  \n4. **Monitor** – regular labs and imaging every 8–12 weeks; adjust if toxicity rises.  \n\nPick the combo that keeps you symptom‑free, lets you dose at home or on the road, and matches your travel schedule.",
          "order": 1,
          "qid": "S14-Q01"
        },
        {
          "q": "If I get the anti-EGFR drug and my face breaks out, am I stuck hiding at home?",
          "gt": "If an anti‑EGFR agent (e.g., cetuximab or panitumumab) causes a facial rash, you’re not forced to stay home. The rash is a common, manageable side effect. Start with topical steroids (e.g., hydrocortisone 1 % cream) and oral antihistamines to reduce itching. Keep the skin moisturized and avoid harsh soaps. If the rash is severe (grade 3–4), your oncologist may temporarily pause the drug or reduce the dose, but this can often be done while you continue traveling. Regular skin‑care visits and a quick call to your oncology team can keep the rash under control, allowing you to drive and meet clients without hiding.",
          "order": 2,
          "qid": "S14-Q02"
        },
        {
          "q": "Will neuropathy make it unsafe to drive?",
          "gt": "**Short answer:**  \nYes—if your neuropathy is moderate to severe, it can make driving unsafe. Oxaliplatin‑induced neuropathy often causes numbness, tingling, loss of proprioception, and slowed reaction times, all of which impair the fine motor control and rapid reflexes needed for safe driving.\n\n**What to do:**  \n1. **Get an assessment** – an occupational‑therapy or driving‑skills evaluation can quantify how much your neuropathy affects coordination, vision, and reaction time.  \n2. **Monitor symptoms** – if you notice numbness in the hands or feet, loss of balance, or delayed braking, stop driving until symptoms improve.  \n3. **Use supportive measures** – consider adaptive steering wheels or seat adjustments, and take frequent breaks on long trips.  \n4. **Plan alternatives** – rideshare, public transit, or a trusted colleague can cover client visits when neuropathy is at its worst.  \n\nIf your neuropathy is mild and you can still feel and react normally, you may continue driving, but keep the evaluation and monitoring in place.",
          "order": 3,
          "qid": "S14-Q03"
        },
        {
          "q": "Can the liver spots ever be removed, or is that false hope?",
          "gt": "Liver metastases can often be removed, but whether it’s feasible depends on how many lesions you have, their size, location, and how well they respond to systemic therapy.  \n\n**Surgical resection** is the gold‑standard for limited, resectable disease and can be curative in a minority of patients.  \n**Locoregional techniques**—radiofrequency or microwave ablation, stereotactic body radiation, or transarterial chemoembolization—can treat lesions that are too small or too close to vital structures for surgery.  \n\nIf the metastases are numerous or diffuse, removal is usually not possible; instead, systemic chemo‑targeted therapy is used to control growth and prolong survival.  \n\nSo, “removal” is realistic for selected patients, but not a universal option. Discuss your specific disease pattern with your oncologist to see if a liver‑directed approach fits your goals and travel schedule.",
          "order": 4,
          "qid": "S14-Q04"
        },
        {
          "q": "Cold drinks triggering pain—does that mean I’m stuck sipping lukewarm forever?",
          "gt": "Cold‑induced pain is common after chemotherapy, especially with agents that cause mucositis or neuropathy. It doesn’t mean you must stay lukewarm forever. Try these practical steps:\n\n1. **Temperature control** – sip at room temperature or slightly warm; avoid very cold or very hot drinks.  \n2. **Ice chips or cold compresses** – can numb the mouth temporarily if you need a chill.  \n3. **Topical numbing agents** – lidocaine mouthwash or gels (use as directed by your oncologist).  \n4. **Hydration strategy** – drink slowly, use a straw to reduce contact with the painful area.  \n5. **Medication review** – ask your oncologist if a dose adjustment or a different chemo agent could reduce mucositis.  \n\nIf pain persists or worsens, report it promptly; your team can adjust treatment or add supportive care. You can still enjoy drinks—just find the right temperature that keeps you comfortable and on the road.",
          "order": 5,
          "qid": "S14-Q05"
        },
        {
          "q": "How often will I be tethered to an infusion pump?",
          "gt": "For most first‑line regimens you’ll need an infusion pump about once every 2–3 weeks.  \n\n**FOLFOX (oxaliplatin + 5‑FU/LV)** – 2‑hour oxaliplatin infusion followed by a 46‑hour 5‑FU/Leucovorin infusion, usually every 2 weeks.  \n**FOLFIRI (irinotecan + 5‑FU/LV)** – 90‑minute irinotecan infusion plus a 46‑hour 5‑FU/Leucovorin infusion, also every 2 weeks.  \n\n**Targeted agents**  \n- **Bevacizumab** – 5 mg/kg IV every 2 weeks (or 7.5 mg/kg every 3 weeks).  \n- **Anti‑EGFR (cetuximab or panitumumab)** – 400 mg/m² IV every 2 weeks (or 250 mg/m² every 2 weeks after the first dose).  \n\nIf you prefer fewer trips, bevacizumab and panitumumab can be given subcutaneously, eliminating the need for a pump.  \n\nSo, expect about 2–3 infusion visits per month, each lasting 2–3 days (including the 5‑FU infusion). You can schedule these on days that fit your travel, and many centers offer same‑day discharge after the 5‑FU infusion.",
          "order": 6,
          "qid": "S14-Q06"
        },
        {
          "q": "What if my bowels go haywire on a client visit?",
          "gt": "If you’re on a chemo regimen that can trigger diarrhea, have a “client‑visit” kit ready:  \n- **Medications**: Keep loperamide (Imodium) and a short‑course of octreotide or diphenoxylate‑atropine if your oncologist prescribes them.  \n- **Hydration**: Pack a bottle of oral rehydration solution or electrolyte drinks; sip frequently.  \n- **Diet**: Stick to low‑fiber, bland foods (rice, bananas, toast) before and during the trip.  \n- **Supplies**: Carry a discreet stool bag, wipes, and a spare pair of underwear.  \n- **Plan**: Identify the nearest pharmacy or urgent‑care center along your route; let a trusted colleague know your schedule.  \n- **When it happens**: Use your meds immediately, hydrate, and if symptoms persist >24 h or you’re dehydrated, call your oncologist or go to urgent care.  \nIf diarrhea is frequent, discuss switching to a regimen with less GI toxicity (e.g., FOLFOX + bevacizumab) with your oncologist.",
          "order": 7,
          "qid": "S14-Q07"
        },
        {
          "q": "Do second opinions slow me down or strengthen my plan?",
          "gt": "A second opinion can both sharpen and, in rare cases, delay your plan.  \n**Strengths** – A specialist may spot a more effective, less toxic regimen (e.g., a newer anti‑EGFR antibody, a different chemo backbone, or a liver‑directed approach) and can tailor therapy to your travel schedule, minimizing dose‑limiting side effects that would impair driving. They may also identify clinical trials or emerging options that fit your goals.  \n**Potential delay** – Coordinating appointments, transferring records, and waiting for a new plan can add a few weeks, especially if the second center is far from your usual location.  \n**How to mitigate** – Use tele‑oncology, request a rapid review of your pathology and imaging, and ask the second center to provide a concise, actionable plan. This way you gain confidence in your treatment without significant downtime.",
          "order": 8,
          "qid": "S14-Q08"
        },
        {
          "q": "How do you know when to switch before the scan says so?",
          "gt": "**When to switch before the next scan?**  \n1. **Early clinical decline** – new or worsening pain, weight loss, fatigue, or a drop in ECOG performance status (≥ 2) suggests progression.  \n2. **Toxicity that limits activity** – grade ≥ 3 neutropenia, neuropathy, or diarrhea that hampers driving or client meetings warrants dose reduction or a switch.  \n3. **Tumor‑marker trend** – a rise in CEA > 20 % above the nadir or > 50 % above baseline, especially if sustained over two consecutive tests, can precede radiographic change.  \n4. **Imaging schedule** – if scans are every 8–12 weeks, consider a “clinical‑first” switch if any of the above points appear, rather than waiting for the next scan.  \n5. **Patient preference** – if you feel the current regimen is compromising your work or quality of life, discuss an early change with your oncologist.  \n\nThese signals help you act before imaging confirms progression, keeping treatment effective while preserving your ability to drive and meet clients.",
          "order": 9,
          "qid": "S14-Q09"
        },
        {
          "q": "Is it okay to keep small goals, like hitting my sales summit, or is that denial?",
          "gt": "Setting realistic, small goals—like attending a sales summit—can be a healthy way to maintain purpose and normalcy, not denial. It’s important to balance ambition with the physical demands of your treatment. Discuss your travel and activity plans with your oncologist so they can time chemotherapy cycles, dose‑adjust, or add supportive measures (e.g., anti‑nausea, pain control) to keep you functional. Monitor for fatigue, neuropathy, or other side‑effects that could impair driving or client meetings. If symptoms worsen, pause or reschedule. In short, keep your goals, but stay flexible and stay in close touch with your care team so your cancer control and quality of life remain aligned.",
          "order": 10,
          "qid": "S14-Q10"
        }
      ]
    },
    {
      "id": "S15",
      "title": "Sun runner (BRAF V600E metastatic melanoma)",
      "diagnosis": "BRAF V600E positive metastatic melanoma",
      "treatment_plan": "Immunotherapy and/or targeted BRAF/MEK inhibitors depending on goals and disease features",
      "narrative": "I'm 39, a trail runner with metastatic melanoma. I want to keep moving and not lose months to side effects if there’s a path that fits me.",
      "qa": [
        {
          "q": "How do we choose between immunotherapy and targeted pills without gambling my best shot?",
          "gt": "**Choosing the first line for a 39‑year‑old trail runner with BRAF V600E metastatic melanoma**\n\n| Factor | Immunotherapy (nivolumab + ipilimumab or pembrolizumab) | BRAF/MEK (dabrafenib + trametinib) |\n|--------|--------------------------------------------------------|-------------------------------------|\n| **Speed of response** | 4–6 weeks, but many patients need 2–3 months | 2–4 weeks, rapid shrinkage |\n| **Durability** | 5‑year OS ~40 % in trials | 3‑year OS ~30 % (shorter median PFS) |\n| **Tumor burden / symptomatic disease** | Low‑volume, asymptomatic → immunotherapy first | High‑volume, pain, organ compromise → targeted first |\n| **Brain metastases** | Limited CNS penetration | Better CNS activity |\n| **LDH / performance status** | Normal LDH, ECOG 0–1 → immunotherapy | Elevated LDH, poor PS → targeted |\n| **Side‑effect tolerance** | Immune‑related AEs (colitis, dermatitis) | On‑target AEs (rash, fever, fatigue) |\n| **Prior therapy** | If previously on BRAF/MEK → switch to immunotherapy | If previously on immunotherapy → switch to BRAF/MEK |\n| **Patient preference** | Prefers fewer pills, willing to accept infusion risk | Prefers oral pills, wants quick relief |\n\n**Practical algorithm**\n\n1. **Assess tumor burden, LDH, and symptoms.**  \n   *High burden or symptomatic → start BRAF/MEK.*  \n   *Low burden → start immunotherapy.*\n\n2. **Check for brain mets.**  \n   *If present → consider BRAF/MEK first.*\n\n3. **Consider prior treatments and comorbidities.**  \n   *If you’ve had immunotherapy → switch to BRAF/MEK, and vice‑versa.*\n\n4. **Discuss side‑effect profiles and lifestyle impact.**  \n   *Oral pills + manageable rash → BRAF/MEK; infusions + potential colitis → immunotherapy.*\n\n5. **Re‑evaluate after 8–12 weeks.**  \n   *If progression → switch to the other modality.*\n\n**Bottom line:** For a fit, low‑volume patient who wants to keep running, start with **nivolumab + ipilimumab** (or pembrolizumab alone). If you have high tumor burden, symptomatic disease, or brain mets, begin **dabrafenib + trametinib** for rapid shrinkage, then consider immunotherapy for long‑term control. Always coordinate with your oncology team to tailor the plan to your specific disease features and lifestyle goals.",
          "order": 1,
          "qid": "S15-Q01"
        },
        {
          "q": "What side effects stop runs versus ones I can work around?",
          "gt": "**Side effects that usually make running impossible (or unsafe)**  \n- **Severe fatigue or malaise** (often from ipilimumab or high‑dose steroids).  \n- **Cardiotoxicity** (e.g., reduced ejection fraction, arrhythmias) from some BRAF/MEK combos.  \n- **Severe neuropathy** (hand‑foot syndrome or peripheral neuropathy) that limits weight‑bearing.  \n- **Severe GI toxicity** (diarrhea, colitis) that can cause dehydration and electrolyte loss.  \n- **Severe skin reactions** (ulcerative rash, blistering) that impair mobility.  \n\n**Side effects you can usually work around with adjustments**  \n- **Mild to moderate fatigue** – schedule runs during peak energy times, shorten distance, or add rest days.  \n- **Hand‑foot syndrome** – use protective footwear, apply barrier creams, and reduce intensity.  \n- **Mild neuropathy** – incorporate low‑impact cross‑training (swimming, cycling) and use supportive orthotics.  \n- **Mild GI upset** – stay hydrated, eat small frequent meals, and avoid high‑fiber foods before runs.  \n- **Skin irritation** – keep skin clean, use sunscreen, and apply topical steroids as prescribed.  \n\nAlways monitor symptoms, keep your oncology team informed, and adjust training intensity or pause activity if any side effect worsens.",
          "order": 2,
          "qid": "S15-Q02"
        },
        {
          "q": "If I spike fevers on pills, am I done running for good?",
          "gt": "A fever (≥38 °C) that appears after starting a BRAF/MEK inhibitor or immunotherapy is a common side effect. Running can raise core temperature and may worsen the fever or fatigue, but it does **not** automatically mean you must quit running forever.  \n\n**Practical steps:**  \n1. **Monitor** your temperature and symptoms before, during, and after runs.  \n2. **Hydrate** well, run in cooler conditions, and keep the intensity moderate.  \n3. If the fever persists or you feel dizzy, stop the run, rest, and contact your oncology team.  \n4. Discuss dose adjustments or supportive medications (e.g., antipyretics) with your oncologist.  \n\nIn short, you can keep moving—just stay vigilant, adjust intensity, and seek medical advice if the fever or other side effects worsen.",
          "order": 3,
          "qid": "S15-Q03"
        },
        {
          "q": "Will immunotherapy make my body attack my thyroid or gut forever?",
          "gt": "Immunotherapy (e.g., anti‑PD‑1/PD‑L1) can trigger immune‑related adverse events (irAEs) such as thyroiditis or colitis, but most are **reversible** with prompt treatment.  \n- **Thyroid**: About 10–20 % develop transient or permanent dysfunction. Most recover after steroids or thyroid hormone replacement; only a minority remain permanently hypothyroid or hyperthyroid.  \n- **Gut**: Colitis occurs in ~5–10 %. Steroids, infliximab, or vedolizumab usually resolve symptoms; chronic disease is uncommon.  \n\nIf an irAE appears, it is usually managed early and the drug can be paused or stopped. Long‑term “forever” damage is rare. Regular labs (TSH, free T4, stool calprotectin) and symptom checks help catch issues before they become severe. Discuss your activity goals with your oncologist; they can tailor the schedule to keep you running while monitoring for side effects.",
          "order": 4,
          "qid": "S15-Q04"
        },
        {
          "q": "Can I still race this season if scans look better?",
          "gt": "If your scans show a response but you still have metastatic disease, most oncologists allow continued training—exercise is linked to better outcomes and fewer side‑effects. However, keep a few practical rules in mind:\n\n1. **Check with your oncology team first.** They’ll confirm that your current regimen (immunotherapy or BRAF/MEK inhibitors) is stable and that you’re not at risk for rapid flare‑ups or new lesions that could compromise safety.\n\n2. **Monitor for treatment‑related fatigue, neuropathy, or skin changes.** If you feel unusually tired, develop a rash, or notice new pain, cut back or pause until you’re cleared.\n\n3. **Avoid high‑impact or extreme heat if you have bone metastases or are on BRAF/MEK therapy (cardiotoxicity risk).** Stick to moderate‑intensity runs, stay hydrated, and use sunscreen.\n\n4. **Keep routine scans and check‑ins.** Adjust your training plan if the disease pattern changes.\n\nIn short, you can race this season, but stay in close touch with your oncologist, listen to your body, and be ready to modify intensity or take a break if symptoms arise.",
          "order": 5,
          "qid": "S15-Q05"
        },
        {
          "q": "Do I need to hide from the sun now?",
          "gt": "After a melanoma diagnosis, you should treat the sun as a potential risk factor rather than “hide” entirely. Sun exposure can promote new lesions and may worsen photosensitivity from therapy (especially BRAF/MEK inhibitors). You can keep running, but use a comprehensive sun‑protection plan:\n\n1. **Sunscreen**: Broad‑spectrum SPF ≥ 30, reapply every 2 h and after sweating or rinsing.  \n2. **Protective clothing**: Long‑sleeve, UPF‑rated shirts, wide‑brim hat, UV‑blocking sunglasses.  \n3. **Timing**: Run early‑morning or late‑afternoon when UV index is lower; avoid peak 10 am‑4 pm.  \n4. **Shade breaks**: Take short rests under trees or portable shade.  \n5. **Monitor skin**: Check for new or changing spots weekly; report any changes to your oncology team.  \n\nWith these measures, you can continue trail running while minimizing additional melanoma risk and photosensitivity.",
          "order": 6,
          "qid": "S15-Q06"
        },
        {
          "q": "If brain spots show up later, does that end everything?",
          "gt": "Brain metastases don’t automatically mean “end of the road.”  In melanoma, especially BRAF‑positive disease, many patients survive years after a brain lesion is detected.  Treatment options include stereotactic radiosurgery (SRS), whole‑brain radiation, surgical resection for a single large lesion, and systemic therapy (BRAF/MEK inhibitors or immunotherapy) that can cross the blood‑brain barrier.  Prognosis depends on how many lesions you have, their size, how well your systemic disease is controlled, and your performance status.  With aggressive local therapy plus continued systemic treatment, many patients maintain a good quality of life and remain active.  Discuss your specific situation with your oncology team to tailor a plan that keeps you moving.",
          "order": 7,
          "qid": "S15-Q07"
        },
        {
          "q": "Can I keep my job while doing this, or should I plan leave?",
          "gt": "Many patients with metastatic melanoma can maintain employment while receiving treatment, but it depends on how the drugs affect you.  \n**Immunotherapy (nivolumab/ipilimumab)** often causes fatigue, rash, colitis, and occasional high‑grade immune‑related events that may require dose delays or hospitalization.  \n**Targeted BRAF/MEK therapy** can produce fatigue, rash, diarrhea, arthralgia, and, rarely, cardiotoxicity or liver injury.  \n\nIf you feel you can tolerate the side‑effect profile, a flexible schedule, remote work, or short breaks during flare‑ups can keep you on the job. Discuss your treatment plan with your oncologist and occupational health team; they can help you anticipate periods of higher toxicity and plan for temporary leave or reduced hours if needed. In short, many people stay employed, but plan for possible short‑term absences and keep open communication with your employer.",
          "order": 8,
          "qid": "S15-Q08"
        },
        {
          "q": "What signals tell me to call you the same day?",
          "gt": "**Call me the same day if you experience any of the following:**\n\n| Treatment | Red‑flag symptoms |\n|-----------|-------------------|\n| **Immunotherapy (PD‑1/CTLA‑4)** | • Fever ≥ 38 °C or chills<br>• Severe rash, itching, or blistering<br>• Diarrhea ≥ 3 loose stools/day, or bloody stools<br>• Shortness of breath, cough, or chest pain (pneumonitis)<br>• Jaundice, dark urine, or abdominal pain (hepatitis)<br>• New or worsening fatigue, headache, vision changes, or confusion (endocrine or CNS toxicity) |\n| **BRAF/MEK inhibitors** | • Fever ≥ 38 °C or chills<br>• Severe rash, photosensitivity, or blistering<br>• Persistent nausea/vomiting, severe abdominal pain, or bloody stools (GI toxicity)<br>• New or worsening shortness of breath, chest pain, palpitations (cardiotoxicity)<br>• Vision changes, eye pain, or sudden visual loss (ocular toxicity)<br>• Severe fatigue, muscle pain, or unexplained weakness (myopathy) |\n| **General** | • Any sudden severe pain, bleeding, or swelling<br>• New neurological deficits (weakness, numbness, vision loss)<br>• Signs of infection (fever, chills, purulent drainage)<br>• Unexplained weight loss, dizziness, or fainting |\n\nIf you notice any of these signs, call immediately (or go to the nearest emergency department). Prompt action can prevent complications and keep you on track with your training goals.",
          "order": 9,
          "qid": "S15-Q09"
        },
        {
          "q": "If I choose wrong first, did I ruin my chance at the other option?",
          "gt": "Choosing the first line of therapy doesn’t permanently lock you out of the other option. In metastatic BRAF‑V600E melanoma, most patients start with either immunotherapy (e.g., anti‑PD‑1/PD‑L1) or a BRAF/MEK inhibitor (dabrafenib + trametinib). If you begin with immunotherapy and it’s ineffective or you develop unacceptable toxicity, you can switch to targeted therapy, and vice‑versa. The key is to monitor response and side‑effects closely and to discuss with your oncologist the best sequencing for your goals (e.g., rapid disease control vs. long‑term durability). Early switching is common and usually safe, so you’re not “ruining” your options—just tailoring the approach to how you respond.",
          "order": 10,
          "qid": "S15-Q10"
        }
      ]
    },
    {
      "id": "S16",
      "title": "Hospital or home (newly diagnosed AML at 67)",
      "diagnosis": "Acute myeloid leukemia in a 67-year-old",
      "treatment_plan": "Either intensive inpatient induction or lower-intensity therapy (hypomethylating agent + venetoclax) with transfusion support; infection prophylaxis; consider trial",
      "narrative": "I'm 67 and blindsided by leukemia. They’re talking about weeks in the hospital or a gentler plan mostly at home. I want time, but I also want myself.",
      "qa": [
        {
          "q": "If I choose the hospital route, how long am I really there and what does a day look like?",
          "gt": "**Typical inpatient induction for AML (age 67)**  \n\n- **Length of stay:** 7–10 days of continuous chemotherapy (e.g., cytarabine + anthracycline). After that, you’re usually discharged for 2–4 weeks of close outpatient monitoring (labs, imaging, transfusion support).  \n- **Daily routine while in the hospital:**  \n  1. **Morning** – blood counts, electrolytes, and a quick physical exam.  \n  2. **Chemotherapy** – usually a 24‑hour infusion of cytarabine (or a 3‑day “7‑day” course) with an anthracycline on day 1.  \n  3. **Supportive care** – IV fluids, antibiotics (often prophylactic), antifungals, and growth factors as needed.  \n  4. **Transfusions** – packed red cells or platelets if counts fall below thresholds.  \n  5. **Monitoring** – continuous vitals, frequent labs (CBC, CMP) every 6–12 hours, and assessment for infection or bleeding.  \n  6. **Evening** – review of labs, medication adjustments, and planning for the next day.  \n\nAfter the induction phase, you’ll transition to outpatient care for the next 2–4 weeks while your marrow recovers and you receive transfusion support and infection prophylaxis.",
          "order": 1,
          "qid": "S16-Q01"
        },
        {
          "q": "If I choose the at-home regimen, am I less likely to be alive for my granddaughter’s birthday?",
          "gt": "I’m sorry you’re facing this difficult choice. In older adults (≥65 y) with AML, the two common approaches have similar overall survival—roughly 12–18 months median—when matched for fitness and cytogenetics. Intensive induction (cytarabine + anthracycline) can produce deeper remissions but carries higher early‑death risk (≈10–15 % in the first 30 days). The hypomethylating agent + venetoclax regimen is less toxic, often given at home, and has a lower early‑death rate, but relapse can occur sooner. Which plan will keep you alive for your granddaughter’s birthday can’t be predicted; it depends on many factors (comorbidities, response, infections). Discuss with your hematologist the expected response, side‑effect profile, and your personal priorities—quality of life versus aggressive cure—to make the best decision for you.",
          "order": 2,
          "qid": "S16-Q02"
        },
        {
          "q": "Will I be transfusion-dependent for months?",
          "gt": "**Short answer:**  \nIt depends on how your blood counts recover and which treatment you choose.  \n\nDuring **intensive induction** (e.g., cytarabine + anthracycline), most patients need packed‑red‑cell and platelet transfusions for several weeks while the marrow is wiped out. After remission, many become transfusion‑independent, but some may still need occasional transfusions for a few months.  \n\nWith **lower‑intensity therapy** (hypomethylating agent + venetoclax), the marrow is less suppressed, so transfusion needs are usually lower and often limited to the first 1–3 months. Some patients never become transfusion‑dependent, while others may need periodic support until counts recover.  \n\nYour hematologist can estimate the likely duration based on your baseline counts, comorbidities, and early response. Discuss transfusion thresholds, iron‑chelation plans, and monitoring to stay ahead of any need.",
          "order": 3,
          "qid": "S16-Q03"
        },
        {
          "q": "How do we prevent infections when my immune system vanishes?",
          "gt": "**Infection prevention while your immune system is low**\n\n| What to do | Why it matters |\n|------------|----------------|\n| **Prophylactic antibiotics** (e.g., levofloxacin or ciprofloxacin) | Reduces bacterial sepsis during neutropenia. |\n| **Antifungal prophylaxis** (posaconazole, voriconazole, or fluconazole) | Prevents invasive molds and yeasts that thrive when neutrophils are absent. |\n| **Antiviral prophylaxis** (acyclovir or valacyclovir) | Stops HSV/CMV reactivation, common in AML patients. |\n| **Granulocyte‑colony stimulating factor (G‑CSF)** | Shortens the duration of neutropenia, lowering infection risk. |\n| **Transfusion support** (red cells, platelets, cryoprecipitate) | Maintains oxygen delivery and clotting, reducing complications. |\n| **Strict infection control** | Hand‑washing, mask use, avoid crowds, keep pets and raw foods away, and use clean water. |\n| **Vaccinations** (influenza, pneumococcal, COVID‑19) | Updated before therapy starts; boosters as needed. |\n| **Regular monitoring** | CBCs, cultures, and prompt treatment of fevers or symptoms. |\n\nFollow your oncology team’s specific protocol, and keep a list of all medications and doses so you can review them with your nurse or doctor whenever you’re uncertain.",
          "order": 4,
          "qid": "S16-Q04"
        },
        {
          "q": "What if the plan isn’t working—do we know early enough to pivot?",
          "gt": "In both approaches you’re monitored closely for early response.  \n\n**Intensive induction** – a bone‑marrow aspirate is usually done at day 14 (or day 21 if you’re still febrile). If blasts remain >5 % or you’re not improving clinically, the plan is changed (second‑line chemo, allogeneic transplant, or supportive‑only care).  \n\n**Hypomethylating agent + venetoclax** – after 4–6 cycles you repeat a marrow. If blasts stay >10 % or you’re not tolerating the regimen, you can switch to a different hypomethylating agent, add a different targeted drug, or move to a clinical trial.  \n\n**Early warning signs** in either setting are persistent fevers, worsening cytopenias, or new organ dysfunction. Your team will discuss a “pivot point” before the next cycle so you’re not stuck on a failing plan. Regular blood counts, infection markers, and, when available, minimal residual disease testing help catch failure early and keep you in control.",
          "order": 5,
          "qid": "S16-Q05"
        },
        {
          "q": "Can I appoint my daughter to make decisions if I’m too sick?",
          "gt": "Yes. In most states you can appoint a **health‑care proxy** (also called a durable power of attorney for health care) who will make medical decisions if you become unable to do so. The proxy must be someone you trust—often a spouse, adult child, or close friend—and the appointment is valid as soon as the document is signed and witnessed (or notarized, depending on your state).  \n\nAsk your oncologist to review the form and discuss your wishes (e.g., preferred treatments, comfort‑care goals, DNR/DNI orders).  You can also create a **living will** to outline specific treatment limits.  If you’re unsure, a brief consultation with a lawyer or your hospital’s patient‑advocate office can help you complete the paperwork correctly.",
          "order": 6,
          "qid": "S16-Q06"
        },
        {
          "q": "Will chemo steal my mind or only my hair?",
          "gt": "Intensive induction chemotherapy for AML can cause a “chemo‑cognitive” syndrome—short‑term fog, fatigue, and difficulty concentrating that usually improves a few weeks after treatment. It does not permanently steal your mind. Hair loss is common with many induction regimens, but it’s temporary; most patients regrow hair within 3–6 months. Lower‑intensity therapy (hypomethylating agent + venetoclax) is less myelosuppressive, has fewer neuro‑cognitive side effects, and can be managed largely at home with transfusion and infection‑prophylaxis support. If you’re concerned about cognitive impact, discuss pre‑ and post‑treatment cognitive screening with your oncologist and consider supportive measures (adequate sleep, hydration, gentle exercise). Ultimately, the choice balances disease control with quality‑of‑life goals.",
          "order": 7,
          "qid": "S16-Q07"
        },
        {
          "q": "Do I have to stop my daily walk?",
          "gt": "You don’t have to quit walking entirely, but the type and intensity of your walks should be adjusted to how you feel and where you are in treatment.\n\n**During induction (intensive inpatient therapy)**  \n- You’ll likely be in the hospital for 4–6 weeks.  \n- Short, gentle walks around the ward or in the hospital courtyard are fine if you’re feeling up to it.  \n- Avoid strenuous activity, heavy lifting, or anything that could cause bruising or falls, especially when your platelet count is low or you’re neutropenic.\n\n**During lower‑intensity therapy at home**  \n- Continue your daily walk if you feel energetic and have no bleeding or infection symptoms.  \n- Keep it moderate (e.g., 10–20 min at a comfortable pace).  \n- Monitor for fatigue, dizziness, or new bruises; stop and rest if any of these occur.\n\nIn short, keep walking as long as it feels safe and you’re not experiencing severe fatigue, bleeding, or infection. If in doubt, check with your oncology team before changing your routine.",
          "order": 8,
          "qid": "S16-Q08"
        },
        {
          "q": "How do costs and caregiver time differ between options?",
          "gt": "**Intensive inpatient induction (4–6 weeks)**  \n- **Cost:** Hospital stay, ICU, transfusions, antibiotics, and the 3‑day “7‑plus‑3” chemotherapy course can run **$200 k–$300 k** (depending on complications).  \n- **Caregiver time:** Minimal day‑to‑day care is needed because nursing staff handle most tasks; you might spend 1–2 hours a day on visits, paperwork, and emotional support.\n\n**Lower‑intensity outpatient/home therapy (venetoclax + hypomethylating agent, 6–12 months)**  \n- **Cost:** Drug acquisition (~$30 k–$40 k per year) plus outpatient transfusions, monitoring labs, and infection prophylaxis usually totals **$150 k–$200 k** over the course.  \n- **Caregiver time:** You’ll need to manage medication schedules, arrange weekly transfusions, monitor for fever or bleeding, and coordinate appointments—often **4–6 hours per week** of hands‑on care.\n\nIn short, the inpatient route is a short, expensive burst with less caregiver burden, while the home‑based plan spreads costs over a longer period and requires more ongoing caregiver involvement.",
          "order": 9,
          "qid": "S16-Q09"
        },
        {
          "q": "If I want to switch paths later, can I?",
          "gt": "If you start with low‑intensity therapy (e.g., hypomethylating agent + venetoclax) and later feel you need more aggressive treatment, you can usually switch to intensive induction—provided you’re still fit enough for it. Your treating oncologist will reassess organ function, performance status, and infection risk before making that jump. Conversely, if you begin intensive induction but the disease is refractory or you’re too frail, you can transition to a lower‑intensity regimen or a clinical trial. Timing matters: a short break (a few weeks) is often enough for the body to recover, but prolonged gaps may reduce the chance of successful conversion. Keep close contact with your team, and discuss any change in goals or side‑effect burden as early as possible.",
          "order": 10,
          "qid": "S16-Q10"
        }
      ]
    },
    {
      "id": "S17",
      "title": "Waiting feels like doing nothing (CLL watch-and-wait)",
      "diagnosis": "Chronic lymphocytic leukemia, asymptomatic",
      "treatment_plan": "Active surveillance with regular labs and exams; start treatment when specific triggers are met",
      "narrative": "I'm 63 and told we aren't treating yet. It feels like ignoring a ticking clock.",
      "qa": [
        {
          "q": "How is 'watch and wait' not just 'wait and worry'?",
          "gt": "**Watch‑and‑wait is a structured, evidence‑based plan, not passive neglect.**  \n- **Scheduled monitoring**: labs, imaging, and physical exams at defined intervals (e.g., every 3–6 months).  \n- **Clear triggers**: treatment starts only when specific, measurable changes occur (e.g., rising lymphocyte count, new symptoms, organ involvement).  \n- **Early intervention**: you’re not “waiting” until the disease is advanced; you intervene promptly when the plan signals it.  \n- **Reduced toxicity**: avoiding unnecessary chemo or radiation spares you side‑effects and preserves quality of life.  \n- **Psychological support**: regular visits give you a chance to discuss concerns, ask questions, and adjust coping strategies.  \n\nSo, watch‑and‑wait is a proactive, monitored approach that balances vigilance with the goal of minimizing harm.",
          "order": 1,
          "qid": "S17-Q01"
        },
        {
          "q": "What exact signs mean it’s time to act so I’m not guessing?",
          "gt": "**When to start therapy in “watch‑and‑wait” CLL**\n\n| Trigger | Typical threshold |\n|---------|-------------------|\n| **Progressive lymphocytosis** | Absolute lymphocyte count (ALC) > 30 000/µL or > 5 % of peripheral smear |\n| **Bone‑marrow involvement** | > 5 % lymphocytes in marrow aspirate |\n| **Cytopenias** | Hemoglobin < 11 g/dL, platelets < 100 000/µL, or neutrophils < 1 000/µL |\n| **Organomegaly or lymphadenopathy** | New or enlarging nodes > 3 cm, splenomegaly, or liver involvement |\n| **Constitutional symptoms** | Unexplained fever, night sweats, > 10 lb weight loss in 6 mo |\n| **New infections** | Recurrent or severe infections despite antibiotics |\n| **Other organ dysfunction** | Evidence of marrow failure, renal impairment, or neurologic signs |\n\n**Practical tip:** Labs every 3–6 months; if any threshold is crossed or symptoms appear, discuss starting therapy (e.g., ibrutinib, venetoclax). This keeps you from “guessing” and ensures timely treatment.",
          "order": 2,
          "qid": "S17-Q02"
        },
        {
          "q": "Can I still travel without labs every month?",
          "gt": "Yes—you can still travel, but you’ll need to keep your labs on schedule. Most watch‑and‑wait protocols call for CBCs and basic chemistry every 1–3 months. If you’re away from your usual lab, arrange a local facility or a home‑phlebotomy service to draw blood before you leave or upon return. If you’re traveling to a remote area, consider getting a quick CBC at a nearby hospital and sending the results to your oncologist. Skipping labs entirely risks missing early progression, so keep your doctor informed and plan for at least one lab draw during any extended trip.",
          "order": 3,
          "qid": "S17-Q03"
        },
        {
          "q": "Will my immunity be weak even without treatment?",
          "gt": "I’m sorry you’re feeling uneasy about the “watch‑and‑wait” plan. In untreated chronic lymphocytic leukemia (CLL), the disease itself can gradually impair immune function—especially the ability to fight bacterial and viral infections—because malignant B cells crowd out normal immune cells. However, many people with early, asymptomatic CLL have normal or only mildly reduced immunity for years. The risk of serious infections rises mainly when the absolute lymphocyte count is very high, when you develop cytopenias, or when you start immunosuppressive therapy. Regular monitoring (CBC, immunoglobulin levels, and infection history) helps catch any decline early. If you notice new fevers, infections, or fatigue, let your hematologist know promptly. In short, untreated CLL can weaken immunity over time, but it often remains functional for a while, and close surveillance keeps you protected.",
          "order": 4,
          "qid": "S17-Q04"
        },
        {
          "q": "Should I change my diet or supplements to slow this down?",
          "gt": "For most people with watch‑and‑wait CLL, there’s no proven diet or supplement that reliably slows disease progression. The best evidence‑based approach is a balanced, nutrient‑dense diet that supports overall health and immune function:\n\n- **Mediterranean‑style eating** (fruits, vegetables, whole grains, legumes, nuts, olive oil, moderate fish) is linked to lower inflammation and better outcomes in many cancers.\n- **Maintain a healthy weight**; excess body fat can increase inflammation and may worsen prognosis.\n- **Limit added sugars, refined carbs, and processed meats**—they can promote systemic inflammation.\n- **Adequate protein** (lean meats, dairy, plant sources) helps preserve muscle mass, especially as you age.\n- **Omega‑3 fatty acids** (from fatty fish or a high‑quality fish‑oil supplement) may modestly reduce inflammation, but high doses can interfere with blood clotting—talk with your doctor first.\n- **Vitamin D** is often low in older adults; a supplement to keep levels in the 30–50 ng/mL range is reasonable, but again discuss with your hematologist.\n\n**Avoid “miracle” supplements** (e.g., high‑dose antioxidants, herbal extracts) that have no evidence for CLL and may interact with future therapies.  \n\n**Key take‑away:** Focus on a wholesome diet, regular physical activity, and routine monitoring. Discuss any supplements with your oncologist or a registered dietitian to ensure they’re safe and appropriate for your specific situation.",
          "order": 5,
          "qid": "S17-Q05"
        },
        {
          "q": "Will insurance balk when I’m not 'actively' treated?",
          "gt": "In most U.S. plans, a “watch‑and‑wait” strategy for asymptomatic CLL is covered as long as the physician documents that the patient meets the standard criteria for surveillance (e.g., no cytopenias, no organ involvement, normal LDH, no B‑symptoms). Insurers typically require a clear clinical indication that treatment is not yet warranted—often a letter from the oncologist stating the patient’s Rai/Binet stage, lab values, and the plan to re‑evaluate at set intervals. If you start therapy later, the insurer will usually cover it. Problems arise only if the plan’s policy excludes “watchful waiting” or if the documentation is vague. Keep a copy of the physician’s note and the scheduled follow‑up dates; this protects you and the insurer from disputes.",
          "order": 6,
          "qid": "S17-Q06"
        },
        {
          "q": "Is there a benefit to clinical trials now?",
          "gt": "I understand how unsettling it can feel to “wait” when your body is ticking. Clinical trials can offer early access to new drugs, but they’re not always a fit for someone who is asymptomatic and under watch‑and‑wait.\n\n**When a trial might help now:**\n- **Early‑intervention studies** that enroll patients with minimal disease but high risk of progression (e.g., high‑risk cytogenetics, high β‑2‑microglobulin).  \n- **Targeted‑agent trials** that have shown benefit in early CLL and have a favorable side‑effect profile.  \n\n**When it may not be useful:**\n- Trials that require measurable disease or a certain level of symptoms.  \n- Studies with high toxicity that could outweigh the benefit of delaying treatment.\n\nDiscuss your specific risk factors and preferences with your hematologist; they can screen you for eligible trials and help you weigh the potential benefits against the risks.",
          "order": 7,
          "qid": "S17-Q07"
        },
        {
          "q": "How do I tell family I’m okay when the word leukemia scares them?",
          "gt": "When you talk to family, keep it simple and factual.  \n1. **Explain the plan** – “I’m in a watch‑and‑wait phase. My doctor monitors blood counts and scans every few months. If any of the specific triggers (e.g., rising lymphocytes, anemia, symptoms) appear, treatment starts right away.”  \n2. **Reassure them** – “This is a standard approach for early CLL. Most people live many years without needing therapy, and the risk of sudden complications is low.”  \n3. **Use analogies** – “Think of it like a health check‑up for a chronic condition; we’re just keeping an eye on it.”  \n4. **Invite questions** – “I’m happy to share the latest guidelines or talk with the oncologist if you’d like.”  \n5. **Offer resources** – give a reputable website or pamphlet that explains watch‑and‑wait in plain language.  \nBy framing it as routine monitoring rather than a looming crisis, you help your loved ones feel informed and calm.",
          "order": 8,
          "qid": "S17-Q08"
        },
        {
          "q": "Can stress make this speed up?",
          "gt": "In the current evidence, psychological stress does **not** accelerate the natural course of chronic lymphocytic leukemia (CLL). Large cohort studies and clinical trials have found no link between anxiety, depression, or chronic stress and faster disease progression or earlier need for treatment. Stress can, however, affect immune function and overall well‑being, which may influence how you feel and how you manage appointments and labs.  \n\nPractical steps:  \n- Practice relaxation techniques (deep breathing, meditation, gentle exercise).  \n- Stay connected with supportive friends, family, or a counselor.  \n- Keep a symptom diary to discuss any changes with your hematologist.  \n\nThese measures help you feel more in control and may improve quality of life while you remain under watch‑and‑wait.",
          "order": 9,
          "qid": "S17-Q09"
        },
        {
          "q": "How often do people never need treatment?",
          "gt": "In the watch‑and‑wait approach, most people never receive therapy during the first several years.  \n- About **70–80 %** of newly diagnosed CLL patients are asymptomatic and are observed for at least 5 years.  \n- Roughly **30–40 %** of patients with low‑risk disease (e.g., normal karyotype, no del (17p) or TP53 mutation, low‑grade Rai/Binet stage) **never start treatment** in their lifetime, or only after many years.  \n- The remaining 60–70 % eventually need therapy, usually within 5–10 years, when blood counts drop or symptoms appear.  \n\nSo, while a significant minority never need treatment, most patients will eventually require therapy, and regular monitoring is essential to catch that transition early.",
          "order": 10,
          "qid": "S17-Q10"
        }
      ]
    },
    {
      "id": "S18",
      "title": "Finding my voice again (papillary thyroid cancer)",
      "diagnosis": "Papillary thyroid carcinoma after thyroidectomy",
      "treatment_plan": "Surgery followed by thyroid hormone replacement; consider radioactive iodine based on risk; lifelong surveillance",
      "narrative": "I'm 35, a teacher. Surgery took my thyroid. My voice is hoarse and the scar is new territory. I’m trying to feel normal again.",
      "qa": [
        {
          "q": "Will my voice return to my old classroom strength?",
          "gt": "After a thyroidectomy the recurrent laryngeal nerves that control the vocal cords can be stretched or bruised. Most patients notice hoarseness for a few weeks to a few months, and many regain near‑normal voice strength with time, especially if the nerves were only irritated. Persistent changes are less common but can occur if the nerves were partially damaged.  \n\n**What you can do:**  \n- **Voice rest** (avoid shouting or whispering).  \n- **Speech‑language therapy**: a trained therapist can teach gentle vocal exercises and breathing techniques that strengthen the cords.  \n- **Follow‑up laryngoscopy**: your surgeon can check nerve function and guide further treatment if needed.  \n\nWith patience and targeted therapy, many teachers return to their pre‑surgery vocal power. If you notice no improvement after 3–4 months, discuss a second opinion or additional interventions with your ENT.",
          "order": 1,
          "qid": "S18-Q01"
        },
        {
          "q": "Do I need radioactive iodine, or can we skip it safely?",
          "gt": "**Short answer:**  \nWhether you need radioactive iodine (RAI) depends on your individual risk profile. For many low‑risk papillary cancers—tumor ≤2 cm, no extrathyroidal extension, no lymph‑node metastasis—RAI can be safely omitted. If your tumor is larger, has spread to lymph nodes, shows aggressive features, or you’re in a higher‑risk category, RAI is usually recommended to reduce recurrence risk.  \n\n**What to do next:**  \n1. Ask your surgeon or endocrinologist for a risk‑stratification summary (tumor size, pathology, nodal status).  \n2. If low‑risk, you can discuss skipping RAI and rely on lifelong surveillance with thyroglobulin monitoring and periodic ultrasounds.  \n3. If higher‑risk, RAI is the standard of care; it also helps with thyroglobulin suppression and makes surveillance easier.  \n\nYour voice recovery and scar healing are separate issues; RAI decisions are based on cancer biology, not voice status. Discuss the plan with your team to make the safest choice for you.",
          "order": 2,
          "qid": "S18-Q02"
        },
        {
          "q": "How do we set my hormone dose so I’m not anxious and sleepless?",
          "gt": "After thyroidectomy you’ll need levothyroxine to keep your TSH in the target range (usually 0.5‑2.5 mIU/L for a cancer patient).  \n1. **Baseline labs** – get TSH, free T4, and a repeat TSH 6–8 weeks after starting the first dose.  \n2. **Titration** – increase the dose by 12.5–25 µg every 4–6 weeks until TSH is within range.  \n3. **Re‑check** – repeat TSH 4–6 weeks after any change; avoid over‑replacement (TSH < 0.5) which can cause anxiety, palpitations, and insomnia.  \n4. **Lifestyle** – take levothyroxine on an empty stomach, avoid caffeine and large meals within 2 h, and keep a consistent sleep schedule.  \n5. **Follow‑up** – if symptoms persist, discuss a possible dose adjustment or sleep‑supportive measures with your endocrinologist.",
          "order": 3,
          "qid": "S18-Q03"
        },
        {
          "q": "Will this scar always shout 'cancer' at people?",
          "gt": "A thyroid‑ectomy scar is a normal part of healing, not a sign of cancer. Over the next months to years it will fade, flatten, and blend with your skin tone. With proper scar care—keeping it moisturized, protecting it from sun, and using silicone sheets or gels—you can reduce redness and thickness. If the scar remains bothersome, a dermatologist or plastic surgeon can offer revision or laser therapy to make it less noticeable. Importantly, the scar does **not** indicate recurrence; routine imaging and thyroglobulin checks are what monitor cancer status. So, while the scar may be visible for a while, it won’t “shout” cancer to others—just a reminder of your recovery.",
          "order": 4,
          "qid": "S18-Q04"
        },
        {
          "q": "Can I get pregnant safely on these medicines?",
          "gt": "Yes—pregnancy is safe while on thyroid‑hormone replacement after thyroidectomy. Levothyroxine is not teratogenic; in fact, adequate thyroid hormone is essential for fetal brain development.  \n\n**Key points for a healthy pregnancy**\n\n| Step | What to do | Why |\n|------|------------|-----|\n| **Pre‑conception** | Aim for a TSH < 2.5 mIU/L (or < 2.0 mIU/L if you have a history of high‑risk disease). | Keeps maternal and fetal thyroid function optimal. |\n| **If you had radioactive iodine** | Wait at least 6–12 months after RAI before conceiving. | Allows iodine‑based therapy to clear and reduces any theoretical risk. |\n| **During pregnancy** | Increase levothyroxine dose by ~30 % (or as directed by your endocrinologist). | Pregnancy raises thyroid‑binding globulin and metabolic demand. |\n| **Monitoring** | Check TSH every 4 weeks in the first trimester, then every 6–8 weeks. | Adjust dose promptly to avoid hypothyroidism or hyperthyroidism. |\n| **Voice changes** | Hoarseness from nerve injury is unrelated to pregnancy; voice therapy or ENT follow‑up can help. | Pregnancy hormones do not worsen nerve injury. |\n\nDiscuss your plan with your endocrinologist and obstetrician; they’ll tailor the dose and monitoring schedule for you. With proper management, you can have a healthy pregnancy and maintain your thyroid health.",
          "order": 5,
          "qid": "S18-Q05"
        },
        {
          "q": "What follow-up keeps me safe without over-testing?",
          "gt": "**Follow‑up that protects you without excess tests**\n\n1. **TSH & thyroglobulin (Tg)** – Check TSH every 6 months (or sooner if symptoms) and Tg (with anti‑Tg antibodies) every 6–12 months. Rising Tg or a high TSH is the first sign of recurrence.  \n2. **Neck ultrasound** – Do a baseline scan 6–12 weeks after surgery, then annually for 5 years. After that, only if Tg rises or symptoms appear.  \n3. **Voice & scar care** – If hoarseness persists, see a speech‑language pathologist; scar monitoring is routine—no imaging needed unless it’s painful or changing.  \n4. **Annual check‑in** – A brief visit with your endocrinologist to review labs, adjust hormone dose, and address any new symptoms.  \n\nThis schedule balances safety with avoiding unnecessary imaging or blood draws.",
          "order": 6,
          "qid": "S18-Q06"
        },
        {
          "q": "Is my calcium low forever after surgery?",
          "gt": "After a total thyroidectomy the most common issue is **transient** low calcium caused by temporary injury or devascularization of the parathyroid glands. In most people calcium levels return to normal within a few weeks to months. Permanent hypocalcemia is relatively uncommon (≈5 % of cases) and usually occurs only if a parathyroid gland was removed or its blood supply was permanently damaged.\n\n**What to do next**\n\n1. **Check labs** – Your surgeon will order a serum calcium and intact PTH level a few days after surgery and again at follow‑up.  \n2. **Supplement if needed** – If calcium is low, oral calcium (1 g day⁻¹) and vitamin D (800–1 000 IU day⁻¹) are started.  \n3. **Monitor** – Repeat calcium/PTH every 4–6 weeks until stable.  \n4. **Symptoms** – Tingling, muscle cramps, or seizures warrant immediate evaluation.\n\nIf calcium normalizes, you’ll no longer need supplements. If it remains low, lifelong supplementation may be required, but this is rare. Discuss your specific results with your surgeon or endocrinologist for personalized guidance.",
          "order": 7,
          "qid": "S18-Q07"
        },
        {
          "q": "Can I sing in choir again?",
          "gt": "After a thyroidectomy the recurrent laryngeal nerves can be stretched or injured, which often causes hoarseness or a weak voice. Most people recover enough to sing, but the timing and intensity matter.\n\n**What to do next**\n\n1. **Voice assessment** – Have an ENT or laryngologist do a laryngoscopy to check vocal‑cord mobility.  \n2. **Voice therapy** – A speech‑language pathologist can teach gentle, efficient singing technique and safe vocal warm‑ups.  \n3. **Gradual return** – Start with short, low‑volume practice, then slowly increase duration and volume as your voice tolerates it.  \n4. **Protective measures** – Stay hydrated, avoid yelling or whispering, and rest your voice if it feels strained.\n\nIf your cords are mobile and you’re following a structured voice‑therapy plan, you can usually rejoin choir safely. If paralysis or significant weakness is present, a specialist will advise a more cautious approach or alternative vocal activities.",
          "order": 8,
          "qid": "S18-Q08"
        },
        {
          "q": "Do I need to avoid certain foods because of iodine?",
          "gt": "After a thyroidectomy you no longer need to limit iodine unless you’re scheduled for radioactive‑iodine (RAI) therapy.  \n• **If RAI is planned**: stop iodine‑rich foods (seaweed, iodized salt, dairy, eggs, certain fish) 4–6 weeks before the scan and keep iodine‑free salt for the same period.  \n• **If you’re not receiving RAI**: there’s no medical reason to avoid iodine. Your body can use whatever iodine you consume for other functions, and most people keep a normal diet.  \n\nSo, unless your oncologist orders RAI, you can eat regular foods—including iodized salt, dairy, and seafood—without worry. If you’re ever unsure, a quick check with your endocrinologist or dietitian can confirm the best plan for you.",
          "order": 9,
          "qid": "S18-Q09"
        },
        {
          "q": "How do I keep from defining myself by this scar?",
          "gt": "Your scar is a reminder of a life‑saving journey, not a label.  \n1. **Reframe the narrative** – view the scar as a badge of resilience, not a flaw.  \n2. **Focus on strengths** – celebrate the teacher you are, the lessons you share, the people you inspire.  \n3. **Professional support** – a therapist or counselor can help you process body‑image changes and build self‑esteem.  \n4. **Voice care** – if hoarseness persists, a speech‑language pathologist can offer exercises and strategies to regain confidence.  \n5. **Scar management** – gentle massage, silicone sheets, or laser therapy (if recommended by your surgeon) can improve texture and appearance, easing self‑consciousness.  \n6. **Community** – join a thyroid‑cancer support group; hearing others’ stories normalizes the experience.  \nRemember, identity is built from actions, relationships, and values—your scar is just one small part of that whole picture.",
          "order": 10,
          "qid": "S18-Q10"
        }
      ]
    },
    {
      "id": "S19",
      "title": "Runner with a new scar (high-grade thigh sarcoma)",
      "diagnosis": "High-grade soft tissue sarcoma of the thigh",
      "treatment_plan": "Limb-sparing surgery with radiation (pre- or post-operative) and rehabilitation",
      "narrative": "I'm 46, a half-marathoner. A deep thigh mass turned out to be sarcoma. I want to keep my leg strong and my life moving.",
      "qa": [
        {
          "q": "Will surgery steal my stride, or can I run again?",
          "gt": "It’s common to worry that a thigh sarcoma resection will ruin your running. In most limb‑sparing cases the muscle and nerve bundles are preserved or reconstructed, and with a structured rehab program you can regain most of your stride.  \n\n**Key points**\n\n| Factor | Impact on running | Typical outcome |\n|--------|------------------|-----------------|\n| **Tumor size/grade** | Larger, high‑grade tumors may need wider margins, sometimes sacrificing part of the quadriceps or hamstrings. | Strength can be rebuilt; you may need a slightly slower pace initially. |\n| **Nerve involvement** | If the femoral or sciatic nerve is cut, you’ll feel weakness or numbness. | Nerve repair or grafting can restore function; full return is possible but may take 6–12 months. |\n| **Radiation** | Post‑op radiation can cause fibrosis and stiffness. | Physical therapy focuses on flexibility; most patients run again within 9–12 months. |\n| **Rehabilitation** | Early, progressive physiotherapy (strength, balance, gait) is essential. | With adherence, many return to half‑marathons or longer within 12–18 months. |\n\n**Practical advice**\n\n1. **Start early** – begin gentle range‑of‑motion and isometric exercises within days of surgery.  \n2. **Progress gradually** – add weight‑bearing, then plyometrics, then distance running once pain and swelling are controlled.  \n3. **Monitor** – keep an eye on any new pain, swelling, or numbness; report promptly.  \n4. **Set realistic goals** – aim for a “modified” stride first (shorter strides, less impact), then rebuild to your pre‑tumor pace.\n\nIn short, surgery doesn’t have to steal your stride. With careful surgical planning, radiation timing, and a disciplined rehab program, many patients return to running—often at or near their former level—within a year.",
          "order": 1,
          "qid": "S19-Q01"
        },
        {
          "q": "Pre-op or post-op radiation—what protects my leg best?",
          "gt": "**Pre‑operative vs. post‑operative radiation**\n\n- **Pre‑op radiation** (usually 50 Gy in 25 fractions) is given before surgery.  \n  - **Pros:** Smaller total dose → less late fibrosis and better preservation of muscle, tendons, and nerves.  \n  - **Cons:** Slightly higher risk of wound complications; may make the surgical field more fibrotic, but this is usually manageable with careful technique.  \n\n- **Post‑op radiation** (typically 60–66 Gy in 30–33 fractions) is delivered after resection.  \n  - **Pros:** Allows precise dose to the surgical bed and any residual tumor cells; better local control if margins are close or positive.  \n  - **Cons:** Higher dose → greater risk of late fibrosis, joint stiffness, and impaired muscle function.\n\n**What protects the leg best?**  \nFor most limb‑sparing cases, **pre‑operative radiation** tends to preserve leg strength and function because it uses a lower dose and spares surrounding tissues. However, if the surgical margins are uncertain or the tumor is large, a post‑op boost may be required for optimal control. Discuss with your radiation oncologist and surgeon to tailor the plan to your specific tumor size, location, and functional goals.",
          "order": 2,
          "qid": "S19-Q02"
        },
        {
          "q": "How do I avoid lymphedema or swelling that ends training?",
          "gt": "After limb‑sparing surgery and radiation, the key to preventing lymphedema is early, consistent mobilization and compression.  \n1. **Start gentle range‑of‑motion and strengthening** as soon as your surgeon allows—this keeps lymph fluid moving.  \n2. **Wear a compression garment or stockings** (usually 20–30 mm Hg) during the first 6–12 weeks; keep them snug but not tight.  \n3. **Elevate the leg** for 15–20 min after activity and avoid prolonged standing or sitting.  \n4. **Hydrate and maintain a healthy weight**—both help reduce fluid retention.  \n5. **Use manual lymphatic drainage or gentle massage** (under a trained therapist) to encourage flow.  \n6. **Monitor for early signs**—swelling, heaviness, or tightness—and report them promptly.  \nWith these steps, you can keep your leg strong and stay on track with training.",
          "order": 3,
          "qid": "S19-Q03"
        },
        {
          "q": "If margins are close, does that mean I’ll lose the leg?",
          "gt": "Close surgical margins mean the tumor was near the edge of the tissue removed, but it does **not automatically mean you’ll lose the leg**. In most limb‑sparing cases, a close margin triggers additional treatment:  \n\n1. **Re‑excision** – a second, targeted surgery to remove any remaining tumor cells.  \n2. **Radiation** – pre‑ or post‑operative radiation can sterilize microscopic disease.  \n3. **Chemotherapy** – sometimes added for high‑grade sarcomas.  \n\nIf these measures fail to achieve clear margins and the tumor recurs or is too extensive, amputation may become necessary, but that is a last resort. Your multidisciplinary team will tailor the plan to preserve as much function as possible while ensuring oncologic safety. Keep the conversation open with your surgeon and radiation oncologist; they’ll guide you through each step.",
          "order": 4,
          "qid": "S19-Q04"
        },
        {
          "q": "Can I work remotely during recovery?",
          "gt": "Absolutely—remote work is a realistic option during your recovery. After limb‑sparing surgery and radiation, you’ll likely experience fatigue, pain, and limited mobility, but you can stay productive from home with a few adjustments:\n\n1. **Ergonomic setup** – use a supportive chair, a standing desk if you can tolerate it, and keep your screen at eye level to reduce strain.  \n2. **Schedule breaks** – short, frequent breaks help manage fatigue and prevent stiffness.  \n3. **Communicate with your employer** – let them know your expected limitations (e.g., need to avoid heavy lifting or prolonged standing) and request reasonable accommodations.  \n4. **Follow medical advice** – your oncologist and occupational therapist can recommend specific restrictions and exercises to protect the surgical site and radiation‑treated area.  \n\nWith these measures, you can keep your leg strong and your training goals on track while working remotely.",
          "order": 5,
          "qid": "S19-Q05"
        },
        {
          "q": "What about nerve damage—will my foot drop?",
          "gt": "It’s understandable to worry about foot drop after a thigh sarcoma resection. Foot drop occurs when the peroneal (fibular) nerve, which supplies ankle dorsiflexion, is injured. In limb‑sparing surgery the surgeon will map and protect this nerve; most high‑grade thigh sarcomas are located away from the nerve, so the risk is low. If the nerve is stretched or partially cut, it can recover over weeks to months, especially with early physiotherapy and ankle‑foot orthoses. In rare cases where the nerve is sacrificed, a permanent foot‑drop may result, but this is uncommon. Your surgeon will discuss the exact anatomy and any intra‑operative nerve monitoring. Post‑op, a structured rehab program and regular neurologic checks will help you regain strength and prevent or manage foot drop.",
          "order": 6,
          "qid": "S19-Q06"
        },
        {
          "q": "Are scans forever, and how often?",
          "gt": "After limb‑sparing surgery and radiation, most high‑grade soft‑tissue sarcomas are monitored with routine imaging to catch local or distant recurrence early. The schedule is usually:\n\n| Time after treatment | Typical imaging |\n|----------------------|-----------------|\n| 0–2 years | MRI of the thigh (or CT if MRI contraindicated) **every 3–4 months**; chest CT **every 3–4 months** |\n| 3–5 years | MRI **every 6 months**; chest CT **every 6 months** |\n| >5 years | MRI **annually**; chest CT **annually** (or as clinically indicated) |\n\nMost centers stop routine scans after about 10 years, because the risk of recurrence drops sharply. However, if you develop new symptoms or your doctor sees a suspicious finding, additional imaging may be ordered sooner. Discuss your exact surveillance plan with your oncologist, as individual risk factors can modify the schedule.",
          "order": 7,
          "qid": "S19-Q07"
        },
        {
          "q": "Is chemo part of this?",
          "gt": "For most high‑grade soft‑tissue sarcomas of the thigh, the standard approach is limb‑sparing surgery plus radiation (pre‑ or post‑operative) and a structured rehab program. Systemic chemotherapy is **not routinely required** for localized disease. It is usually reserved for:\n\n- **Very high‑risk features** (e.g., >5 cm, grade 3, deep location, close/positive margins) where the chance of micrometastasis is higher.\n- **Specific histologic subtypes** (e.g., synovial sarcoma, alveolar rhabdomyosarcoma) that respond better to chemo.\n- **Metastatic or unresectable disease**.\n\nIf your oncologist recommends adjuvant chemotherapy, it will likely be a short course of agents such as doxorubicin ± ifosfamide. Discuss the potential benefits versus side‑effects with your multidisciplinary team. In many cases, surgery + radiation alone will provide excellent local control while preserving your leg strength and running goals.",
          "order": 8,
          "qid": "S19-Q08"
        },
        {
          "q": "How do I fuel healing without gaining weight when I can’t run?",
          "gt": "**Quick plan for healing without weight gain**\n\n1. **Calorie‑controlled meals** – Aim for a 200–300 kcal deficit from your maintenance level. Use a food‑tracking app or a registered dietitian to set a realistic target.  \n2. **Protein first** – 1.2–1.5 g/kg body weight daily (e.g., 90–110 g) to support tissue repair and preserve lean mass. Good sources: chicken, fish, Greek yogurt, legumes, and protein shakes if needed.  \n3. **Smart carbs** – Prioritize complex carbs (whole grains, sweet potatoes, oats) around your rehab sessions; keep simple sugars to a minimum.  \n4. **Healthy fats** – Include 20–30 % of calories from nuts, seeds, avocado, and olive oil; they’re anti‑inflammatory and satiating.  \n5. **Low‑impact activity** – Replace running with cycling, swimming, or elliptical work 3–4 × 20–30 min to burn calories and keep circulation.  \n6. **Strength training** – 2–3 × week of resistance work (body‑weight, bands, light weights) to maintain muscle mass and boost metabolism.  \n7. **Hydration & sleep** – 2–3 L water/day and 7–9 h sleep; both aid recovery and appetite control.  \n8. **Monitor & adjust** – Weigh weekly, tweak calories by 100 kcal if you’re gaining >0.5 kg/week.  \n\nStay in touch with your oncology team and a sports‑nutritionist to personalize this plan as your treatment progresses.",
          "order": 9,
          "qid": "S19-Q09"
        },
        {
          "q": "What if I trip on fear every time I lace up?",
          "gt": "It’s normal to feel anxious after a cancer diagnosis, especially when you love running. Fear can feel like a “trip” that stops you from lacing up, but it’s a manageable emotion, not a permanent barrier.  \n\n1. **Acknowledge the fear** – write it down or talk to a therapist. Cognitive‑behavioral therapy (CBT) is proven to reduce anxiety in cancer survivors.  \n2. **Set realistic, graded goals** – start with short, supervised walks, then progress to easy jogs, always listening to your body and the rehab team.  \n3. **Use a “fear‑buffer” routine** – before each run, do a 5‑minute breathing or mindfulness exercise; this primes the nervous system and reduces panic.  \n4. **Re‑frame the narrative** – view each lace‑up as a step toward reclaiming strength, not a test of survival.  \n5. **Build a support network** – connect with fellow runners, a support group, or a sports psychologist.  \n\nIf anxiety feels overwhelming, medication (e.g., SSRIs) can be added under a psychiatrist’s guidance. Remember, the body’s healing and the mind’s resilience are both trainable. Keep the goal in sight, and let each step be a small victory.",
          "order": 10,
          "qid": "S19-Q10"
        }
      ]
    },
    {
      "id": "S20",
      "title": "Left the field mid-game (stage II testicular cancer)",
      "diagnosis": "Stage II testicular cancer (seminoma or nonseminoma)",
      "treatment_plan": "Orchiectomy followed by surveillance, chemotherapy, or radiation depending on type and spread; fertility preservation recommended",
      "narrative": "I'm 28, play in a weekend soccer league, and just lost a testicle to cancer. I’m scared about fertility, masculinity, and telling my team.",
      "qa": [
        {
          "q": "Is banking sperm urgent, or can I wait until after the next scan?",
          "gt": "You should bank sperm as soon as possible—ideally before any chemotherapy begins. The orchiectomy has already removed one testicle, but if you need cisplatin‑based chemotherapy, the remaining testis can still be damaged. Sperm banking can be done at any time, but waiting until after a scan could delay treatment and reduce fertility chances. Discuss the plan with your oncologist; they can arrange a sperm bank appointment quickly.  \n\nRegarding your team, you can share what you’re comfortable with—many players appreciate honesty and support. Focus on recovery first; the rest will follow.",
          "order": 1,
          "qid": "S20-Q01"
        },
        {
          "q": "Will chemo wreck my lungs or stamina permanently?",
          "gt": "Chemotherapy for stage II testicular cancer (usually BEP: bleomycin, etoposide, cisplatin) can cause short‑term lung irritation and fatigue, but permanent lung damage is uncommon—especially if you’re a healthy 28‑year‑old with no pre‑existing lung disease. Bleomycin’s pulmonary toxicity is dose‑dependent; most patients recover fully and can resume normal activity, including soccer, after treatment. You’ll be monitored with chest X‑ray/CT and pulmonary function tests during and after therapy. Fatigue may linger for weeks, but most men return to their usual stamina within a few months. Discuss any breathing issues with your oncologist; they can adjust the regimen or add supportive care to protect lung function.",
          "order": 2,
          "qid": "S20-Q02"
        },
        {
          "q": "Do I need a prosthesis to feel 'normal'?",
          "gt": "A testicular prosthesis is **optional**, not a medical necessity. It can help with the cosmetic appearance and may ease body‑image concerns, but it does not affect fertility, hormone production, or sexual function. Many men choose not to get one and feel perfectly normal without it. If you’re worried about how you look or feel, a prosthesis can be considered after you’ve recovered and discussed it with a urologist or plastic surgeon. In the meantime, focus on your recovery, sperm banking (if you haven’t already), and any counseling you need. Whether you decide to get a prosthesis or not, you’ll still be a capable, confident player on the field.",
          "order": 3,
          "qid": "S20-Q03"
        },
        {
          "q": "Is radiation still used, and will it affect fertility?",
          "gt": "**Radiation use**  \nFor stage II seminoma, radiation to the retro‑peritoneal lymph nodes is still a standard option (often 20–30 Gy). For non‑seminoma, radiation is rarely used; most patients receive cisplatin‑based chemotherapy instead.\n\n**Impact on fertility**  \n- **Radiation**: The testes are highly radiosensitive. Even a single testis left in the body can be damaged by pelvic or retro‑peritoneal fields, leading to reduced sperm count or azoospermia.  \n- **Chemotherapy**: Cisplatin regimens also impair spermatogenesis, but the effect is usually reversible after 6–12 months if sperm banking was done beforehand.\n\n**What to do**  \n1. **Sperm banking** before surgery and before any adjuvant therapy.  \n2. Discuss with your oncologist whether radiation or chemotherapy is preferred; many non‑seminoma patients will get chemo.  \n3. If you choose radiation, the remaining testis may still be affected; consider a second sperm bank if you’re concerned about long‑term fertility.\n\nIn short, radiation is still used for seminoma and can harm fertility, so sperm banking is essential.",
          "order": 4,
          "qid": "S20-Q04"
        },
        {
          "q": "What if tumor markers bounce—am I relapsing?",
          "gt": "A “bounce” in tumor markers (AFP, β‑hCG, LDH) can happen for a few reasons: lab variation, a transient inflammatory response, or a true recurrence. In surveillance protocols, a single isolated rise is usually repeated in 1–2 weeks. If the level stays above the upper limit of normal or rises again, that is the hallmark of relapse and warrants a full work‑up (CT chest/abdomen/pelvis, PET if needed) and discussion of treatment (chemo, radiation, or surgery).  \n\nIf the marker falls back to normal on repeat testing, it is usually considered a benign fluctuation and you can continue routine surveillance. Always keep your oncologist informed and follow the scheduled imaging and marker schedule. A single spike alone does not automatically mean cancer has returned.",
          "order": 5,
          "qid": "S20-Q05"
        },
        {
          "q": "Can I be intimate during treatment?",
          "gt": "**Short answer:** Yes—sexual activity is usually safe during treatment, but it may need to be adjusted for side‑effects, medications, and timing of fertility preservation.\n\n**Details**\n\n- **Orchiectomy**: You’ll have one healthy testis left. If you bank sperm before starting chemo/radiation, you’ll have options later.  \n- **Chemotherapy**: Avoid intercourse during periods of low white‑cell counts (neutropenia) to reduce infection risk. Fatigue, nausea, or medication side‑effects may make sex uncomfortable; use a lubricant or take breaks.  \n- **Radiation**: If the pelvis is treated, sperm quality can be affected. Discuss timing with your oncologist; barrier methods (condoms) protect both partners.  \n- **Fertility & Masculinity**: One testis can produce enough testosterone for normal sexual function. Discuss any concerns with your team or a counselor if you feel uneasy.  \n\nAlways check with your oncology team before changing sexual activity, and consider sperm banking if you plan to have children.",
          "order": 6,
          "qid": "S20-Q06"
        },
        {
          "q": "How do I tell my teammates without jokes swallowing the room?",
          "gt": "**Short, honest, and supportive**  \n1. **Pick a calm moment** – after a warm‑up or during a break, not in the middle of a game.  \n2. **Keep it brief** – “I had a testicle removed for cancer. I’m doing well and on track with treatment. I just wanted to let you know.”  \n3. **Invite questions** – “If you’re curious about anything, feel free to ask.”  \n4. **Set boundaries** – “I’d appreciate it if we keep the conversation respectful; jokes about it aren’t helpful.”  \n5. **Offer reassurance** – “I’m still the same teammate, and I’m looking forward to playing with you all.”  \n\nIf a teammate jokes, calmly say, “I’m not comfortable with that. Let’s keep it supportive.” This keeps the conversation respectful, lets you share what matters, and protects your dignity and team spirit.",
          "order": 7,
          "qid": "S20-Q07"
        },
        {
          "q": "Will insurance question a prosthesis?",
          "gt": "Most insurers treat a testicular prosthesis as a medically‑necessary device rather than an elective cosmetic item, so coverage is common. However, policies vary: some plans require a pre‑authorization or a documented “medical necessity” note from your surgeon.  \n\n**What to do:**  \n1. **Check your policy** – look for “prosthetic devices” or “cosmetic surgery” sections.  \n2. **Ask your surgeon** – they can provide a letter explaining the prosthesis is needed for physical and psychological well‑being.  \n3. **Submit a pre‑authorization** – include the surgeon’s note, imaging, and any relevant guidelines (e.g., NCCN).  \n4. **Follow up** – if the insurer denies, appeal with the supporting documentation.  \n\nIn most cases, once the paperwork is in place, the prosthesis is covered without extra cost.",
          "order": 8,
          "qid": "S20-Q08"
        },
        {
          "q": "Does losing a testicle change my hormones forever?",
          "gt": "A single healthy testicle usually produces enough testosterone to keep your hormone levels in the normal range. Most men who have one testicle after an orchiectomy have normal libido, erectile function, and secondary sexual characteristics. However, a small drop in testosterone can occur, especially if the remaining testicle is smaller or has impaired function. Your doctor will check your testosterone levels and, if needed, prescribe a low‑dose replacement.  \n\nFertility is more affected: sperm production comes from the removed testicle, so sperm count may drop. If you wish to have children, sperm banking before surgery is recommended. In short, losing one testicle rarely causes permanent hormonal problems, but regular monitoring and, if necessary, hormone therapy can keep everything balanced.",
          "order": 9,
          "qid": "S20-Q09"
        },
        {
          "q": "If I relapse, is cure still on the table?",
          "gt": "Yes—relapse after stage II testicular cancer still offers a very good chance of cure, especially for seminoma and for non‑seminoma that responds to platinum‑based chemotherapy.  In most centers, 5‑year survival after relapse is 70–90 % when appropriate salvage therapy (e.g., BEP, VIP, or second‑line regimens) is given promptly.  The key is early detection: routine tumor‑marker checks and imaging every 3–6 months in the first 2 years, then annually.  If relapse is localized, surgery or radiation may be curative; if it’s metastatic, high‑dose chemotherapy with stem‑cell rescue can still achieve long‑term remission.  Discussing your specific pathology, prior treatment, and overall health with a medical‑onco‑fertility team will help tailor the best salvage plan.",
          "order": 10,
          "qid": "S20-Q10"
        }
      ]
    },
    {
      "id": "S21",
      "title": "Keys and the road (brain metastases, stereotactic radiosurgery)",
      "diagnosis": "Limited brain metastases from solid tumor",
      "treatment_plan": "Stereotactic radiosurgery (SRS) to brain lesions; systemic therapy continues or adjusts; seizure precautions and neuro follow-up",
      "narrative": "I'm 56, I drive for work and play piano at church. Small brain spots showed up on my scan. They recommend focused radiation.",
      "qa": [
        {
          "q": "Can I still legally drive after SRS?",
          "gt": "After stereotactic radiosurgery (SRS) most patients can resume driving within 24–48 hours **if** they have no seizures, no new neurological deficits, and are not on medications that impair alertness (e.g., high‑dose steroids, certain anti‑epileptics). However, driving laws vary by state/country. Many jurisdictions require a medical clearance or a “fit‑to‑drive” certificate from your oncologist or neurologist.  \n\n**Practical steps:**\n\n1. **Check local regulations** – some places mandate a 7‑day waiting period or a formal clearance.  \n2. **Discuss with your treating physician** – they can assess your neurological status and any medication side‑effects.  \n3. **Monitor for seizures or visual changes** – if you experience any, delay driving until fully evaluated.  \n\nOnce you receive a medical clearance and feel symptom‑free, you can legally drive again.",
          "order": 1,
          "qid": "S21-Q01"
        },
        {
          "q": "Will radiation change how I think or play music?",
          "gt": "Stereotactic radiosurgery (SRS) delivers a very high dose of radiation to a tiny target while sparing the surrounding brain. Because the beam is so precise, most people experience little or no change in thinking, memory, or fine‑motor skills such as playing piano. The most common side effects are mild fatigue, headaches, or a brief “brain fog” that usually resolves within a few weeks. Rarely, patients may have subtle memory or concentration changes, especially if the lesion is near language or memory areas, but these are usually mild and reversible.  \n\n**What to do:**  \n- Keep a regular piano practice schedule; if you notice any new difficulty, let your oncologist know.  \n- Attend scheduled neuro‑cognitive follow‑ups and imaging.  \n- Report new headaches, seizures, or cognitive changes promptly.  \n\nWith close monitoring, SRS is unlikely to impair your musical abilities.",
          "order": 2,
          "qid": "S21-Q02"
        },
        {
          "q": "Do I lose my hair in patches?",
          "gt": "Stereotactic radiosurgery (SRS) delivers a high‑dose beam to a very small target, usually within a few millimeters of the tumor. Because the beam is tightly collimated, the surrounding scalp receives only a fraction of the dose that would be given in conventional whole‑brain radiation. In most patients, SRS does **not** cause noticeable hair loss or patchy alopecia. You might experience mild scalp redness or a temporary “sunburn” sensation, but the hair typically remains intact. If you have concerns about scalp toxicity, your radiation oncologist can tailor the plan to keep the dose to the skin as low as reasonably achievable. So, you can expect to keep your hair in place while receiving SRS for your brain lesions.",
          "order": 3,
          "qid": "S21-Q03"
        },
        {
          "q": "How do you decide which lesions to treat now versus watch?",
          "gt": "Deciding which brain metastases to treat with SRS now versus watchful waiting is a balance of lesion characteristics, patient factors, and systemic disease status.  \n**Immediate SRS** is usually chosen for:  \n- symptomatic lesions or those causing mass effect  \n- size > 3 mm (or > 2 cm if causing edema)  \n- rapid growth on serial imaging  \n- lesions in eloquent or deep brain regions when systemic disease is controlled and you want to preserve neuro‑cognition  \n\n**Observation** may be reasonable for:  \n- asymptomatic, < 3 mm, stable lesions  \n- deep but non‑eloquent sites  \n- patients with uncontrolled systemic disease or poor performance status  \n\nA multidisciplinary tumor‑board review, NCCN guidelines, and your goals (e.g., driving, piano) guide the final plan. Seizure prophylaxis and neuro‑cognitive monitoring are added for all patients.",
          "order": 4,
          "qid": "S21-Q04"
        },
        {
          "q": "Does this mean my systemic treatment failed?",
          "gt": "It’s understandable to worry, but a new brain lesion doesn’t automatically mean your systemic therapy has failed. Brain metastases can arise even when the primary cancer is controlled elsewhere, because the blood‑brain barrier limits drug penetration. Stereotactic radiosurgery (SRS) is a targeted way to treat those lesions while you continue systemic therapy that may still be effective for the rest of your disease. Your oncologist will review the overall pattern of spread and may adjust systemic treatment if needed, but the appearance of a brain metastasis alone isn’t a definitive sign of systemic failure. Discuss the findings with your team; they’ll tailor a plan that balances local control with systemic disease management.",
          "order": 5,
          "qid": "S21-Q05"
        },
        {
          "q": "If a new spot appears later, do we do SRS again?",
          "gt": "If a new metastasis appears, repeat SRS is usually considered—provided the lesion is small (≤3–4 cm), the patient has a limited number of lesions overall, and the cumulative dose to surrounding brain tissue remains within safe limits. The decision is made by a multidisciplinary team (radiation oncologist, medical oncologist, neurosurgeon) after a repeat MRI and a review of prior SRS doses.  \n\nIf the new lesion is large, the patient already has many treated sites, or the cumulative dose would exceed tolerance, alternative strategies are discussed: a second course of SRS may still be possible, but whole‑brain radiotherapy (WBRT) or systemic therapy (e.g., targeted agents, immunotherapy) may be preferred.  \n\nIn short, repeat SRS is often feasible for a single new spot, but the overall treatment plan is individualized based on lesion size, number, prior dose, and systemic disease status.",
          "order": 6,
          "qid": "S21-Q06"
        },
        {
          "q": "What symptoms should make me call immediately?",
          "gt": "If you develop any of the following, call your oncologist or go to the nearest emergency department right away:\n\n- **Severe or worsening headache** that is new, persistent, or not relieved by usual pain medication.  \n- **New or worsening neurological deficits** – weakness, numbness, difficulty speaking, vision changes, or coordination problems.  \n- **Seizures** (even a single episode).  \n- **Sudden confusion, disorientation, or altered mental status** (e.g., trouble recognizing people, memory loss, or changes in personality).  \n- **Vomiting** that is persistent or accompanied by headache.  \n- **Signs of increased intracranial pressure** – persistent nausea, vomiting, blurred vision, or double vision.  \n\nThese symptoms may indicate increased pressure, tumor progression, or radiation‑related changes that need prompt evaluation.",
          "order": 7,
          "qid": "S21-Q07"
        },
        {
          "q": "Can I fly for work next week?",
          "gt": "After stereotactic radiosurgery (SRS) the brain can develop a small amount of swelling (edema) that may be worsened by the lower cabin pressure of an airplane. Most radiation‑oncology guidelines recommend waiting **at least 24–48 hours** after the SRS session before flying. If you had the treatment last week, you’re likely past that window, but you should still confirm with your radiation oncologist or the treating physician—especially if you’re on steroids, have had a recent seizure, or have other risk factors. If the doctor clears you, ensure you have your anti‑seizure medication, a clear flight plan, and a plan for any sudden neurological changes. If in doubt, postpone the flight until you’re fully cleared.",
          "order": 8,
          "qid": "S21-Q08"
        },
        {
          "q": "Will steroids make me jittery or hungry?",
          "gt": "**Short answer:**  \nYes—steroids can make you feel jittery, hungry, or both. They raise blood sugar, increase appetite, and can cause mood swings, insomnia, or a “high” feeling, especially when taken in the morning or at higher doses.\n\n**What to watch for**\n\n| Symptom | Why it happens | Practical tip |\n|---------|----------------|---------------|\n| **Jitteriness / anxiety** | Cortisol‑like effect on the nervous system | Take the dose in the evening or with food; avoid caffeine; talk to your doctor if it’s severe. |\n| **Increased hunger / weight gain** | Stimulates appetite and fluid retention | Eat balanced meals, monitor blood glucose if diabetic, and keep a food diary. |\n| **Insomnia / mood changes** | Hormonal shift can disturb sleep and mood | Stick to a regular sleep schedule; use relaxation techniques; report persistent changes. |\n\n**When to call your doctor**\n\n- If you feel unusually nervous, restless, or have a rapid heartbeat.  \n- If you notice a sudden spike in blood sugar or significant weight gain.  \n- If mood swings or insomnia interfere with daily life.\n\nYour oncologist can adjust the dose or timing, or add medications to help manage these side effects. Keep a log of how you feel and bring it to your next visit.",
          "order": 9,
          "qid": "S21-Q09"
        },
        {
          "q": "How often are MRIs after this?",
          "gt": "After stereotactic radiosurgery (SRS) for limited brain metastases, most oncologists follow a routine imaging schedule to monitor for recurrence or new lesions:\n\n1. **Baseline** – MRI before SRS (already done).  \n2. **First follow‑up** – 3 months post‑SRS to assess the treated sites.  \n3. **Subsequent scans** – Every 6 months for the first 2 years, then annually if stable.  \n4. **Symptom‑driven** – Any new neurological symptoms (headache, seizures, focal deficits) warrant an immediate MRI regardless of the routine schedule.\n\nThese intervals are based on NCCN guidelines and most institutional protocols. Adjustments may be made if you have a high‑risk primary tumor or if new lesions appear early. Keep your follow‑up appointments and report any new symptoms promptly.",
          "order": 10,
          "qid": "S21-Q10"
        }
      ]
    },
    {
      "id": "S22",
      "title": "Second chances (liver cancer with cirrhosis)",
      "diagnosis": "Hepatocellular carcinoma in the setting of cirrhosis",
      "treatment_plan": "Locoregional therapy (e.g., ablation or embolization) or systemic therapy; transplant evaluation when appropriate; manage liver function",
      "narrative": "I'm 64 with cirrhosis and now a liver tumor. I quit drinking last year. I want to live long enough to walk my daughter down the aisle.",
      "qa": [
        {
          "q": "Am I a transplant candidate, or did I miss that window?",
          "gt": "A liver transplant is still an option if your tumor meets the **Milan criteria** (single lesion ≤5 cm or up to 3 lesions each ≤3 cm) and your liver function is acceptable (MELD < 15–20, no refractory ascites or variceal bleeding). Even if the tumor is slightly larger, some centers use the **UNOS/ELITA expanded criteria** or consider **down‑staging** with ablation/embolization first.  \n\n**What to do next:**  \n1. Get a high‑resolution MRI/CT and AFP level.  \n2. Have a transplant hepatology consult to review MELD, portal hypertension, and comorbidities.  \n3. If you qualify, you’ll be listed immediately; if not, bridging therapy (ablation, TACE) can keep the tumor within transplant limits while you wait.  \n\nSo you haven’t missed the window—evaluation is the first step.",
          "order": 1,
          "qid": "S22-Q01"
        },
        {
          "q": "Does treatment hurt my liver more than the cancer does?",
          "gt": "**Short answer:** In most cases, the goal of treatment is to control the cancer while preserving as much liver function as possible. The impact on the liver depends on the type of therapy and your baseline liver health.\n\n**Ablation (radiofrequency or microwave)**  \n- Localized heat destroys the tumor and a small rim of normal tissue.  \n- In a cirrhotic liver, the injury is usually limited to a few centimeters; liver function often stays stable, especially if the tumor is small (<3 cm) and you have a good Child‑Pugh score.\n\n**Transarterial chemo‑embolization (TACE)**  \n- Blocks the tumor’s blood supply and delivers chemotherapy.  \n- It can cause transient liver enzyme spikes and, in some patients, a drop in synthetic function.  \n- In well‑compensated cirrhosis (Child‑A), most patients tolerate TACE without long‑term decline, but repeated sessions increase risk.\n\n**Systemic therapy (e.g., atezolizumab‑bevacizumab, sorafenib, lenvatinib)**  \n- These drugs can cause fatigue, hypertension, and mild liver enzyme elevations.  \n- Serious hepatotoxicity is uncommon in patients with preserved liver function, but close monitoring is essential.\n\n**Transplant**  \n- If you qualify, transplant removes the diseased liver entirely, eliminating the cancer and cirrhosis.  \n- The surgery itself carries risks, but post‑transplant liver function is normal.\n\n**Bottom line:**  \n- For a single small tumor, ablation usually causes less liver injury than the cancer would if it grew unchecked.  \n- TACE and systemic drugs are designed to be tolerable in cirrhosis, but they can worsen liver function if repeated or if you already have advanced disease.  \n- Your transplant team will weigh the benefits of each option against the potential liver damage.  \n\nDiscuss your specific liver function tests, tumor size, and overall health with your hepatologist and oncologist to choose the safest, effective plan.",
          "order": 2,
          "qid": "S22-Q02"
        },
        {
          "q": "What if my legs swell and I can’t fit shoes—does that mean it’s all downhill?",
          "gt": "Leg swelling (edema) is common in cirrhosis and can signal worsening portal hypertension, but it isn’t a death sentence. It usually responds to a few simple measures:  \n- **Sodium restriction** (≤ 2 g/day) and **diuretics** (spironolactone ± furosemide) under your hepatologist’s guidance.  \n- **Compression stockings** and keeping your legs elevated when possible.  \n- **Regular weight checks** (daily or weekly) to catch rapid fluid gain early.  \n- **Avoid alcohol** (you’ve already stopped) and keep your liver‑supporting medications up to date.  \n\nIf edema worsens or you develop pain, shortness of breath, or sudden weight gain, contact your care team promptly. With proper management, many patients keep their legs comfortable and continue to enjoy life—so don’t let swelling make you think it’s all downhill.",
          "order": 3,
          "qid": "S22-Q03"
        },
        {
          "q": "Do I have to swear off every celebration forever?",
          "gt": "You don’t have to give up every celebration, but you do need to keep your liver safe.  \n- **Alcohol:** Avoid it entirely. Even a single drink can worsen cirrhosis and interfere with cancer treatment.  \n- **Food & drinks:** Stick to low‑fat, low‑salt meals and plenty of water. Skip heavy, greasy dishes that can strain the liver.  \n- **Medication & supplements:** Check with your oncologist before taking any over‑the‑counter or herbal products.  \n- **Stress & sleep:** Try to keep a regular routine and get enough rest; stress can affect liver function.  \n\nSo you can still celebrate—just choose alcohol‑free drinks, healthy snacks, and keep your doctor in the loop. This approach lets you enjoy the moment while protecting your liver and cancer treatment.",
          "order": 4,
          "qid": "S22-Q04"
        },
        {
          "q": "How risky is bleeding during procedures with my platelets low?",
          "gt": "In cirrhosis, low platelets (thrombocytopenia) and impaired clotting make any invasive procedure higher‑risk for bleeding.  Generally, a platelet count <50 × 10⁹/L (≈ 50 000/µL) is considered a threshold where the risk of significant bleeding rises sharply, especially for percutaneous ablation or embolization.  If your count is 30–50 × 10⁹/L, we usually give a platelet transfusion (1–2 units) or a single dose of thrombopoietin‑receptor agonist (e.g., avatrombopag) 5–7 days before the procedure to raise platelets above 50 × 10⁹/L.  For counts <30 × 10⁹/L, we often postpone the procedure or use a minimally invasive technique, and we correct any coagulopathy with vitamin K, plasma, or antifibrinolytics.  Discuss your exact platelet number and any prior bleeding events with your interventional radiologist to tailor the plan.",
          "order": 5,
          "qid": "S22-Q05"
        },
        {
          "q": "If the tumor shrinks, can I get on a transplant list?",
          "gt": "If your tumor responds to locoregional or systemic therapy, it can improve your transplant candidacy—but it doesn’t automatically put you on the list.  Transplant centers use strict criteria (e.g., Milan or UCSF limits: ≤3 cm single tumor or ≤3 tumors ≤3 cm, no macro‑vascular invasion, AFP <400 ng/mL, and adequate liver function).  A reduction in size or number can move you into that window, but you still need a comprehensive evaluation: imaging, liver function tests, MELD score, and assessment of portal‑vein patency.  If you meet the criteria, the transplant team will place you on the waiting list and may use bridging therapy (ablation, TACE, or systemic drugs) to keep the tumor controlled while you wait.  Discuss your response with your oncologist and transplant coordinator to determine the next steps.",
          "order": 6,
          "qid": "S22-Q06"
        },
        {
          "q": "What does a bad day look like so my family knows when to act?",
          "gt": "A “bad day” is when new or worsening signs of liver decompensation appear. Watch for:\n\n- **Sudden abdominal pain or distension** (possible bleeding or tumor rupture).  \n- **Nausea/vomiting** that is persistent or leads to dehydration.  \n- **Confusion, drowsiness, or a change in mental status** (hepatic encephalopathy).  \n- **Jaundice** (yellowing of skin or eyes) or dark urine.  \n- **Easy bruising or bleeding** (nosebleeds, gum bleeding, blood in stool).  \n- **Rapid weight gain** from fluid retention or new swelling in legs/abdomen.  \n- **Sudden drop in blood pressure or heart rate** (sign of shock).  \n\nIf any of these occur, call your oncologist or go to the nearest emergency department immediately. Early intervention can prevent irreversible complications.",
          "order": 7,
          "qid": "S22-Q07"
        },
        {
          "q": "Can I still walk the neighborhood safely?",
          "gt": "It’s generally safe to walk, and regular, moderate‑intensity walking can actually help maintain muscle mass and improve portal circulation. However, your safety depends on how well your liver is functioning and whether you have complications of cirrhosis.  \n\n**Ask your hepatologist for a quick “walk‑check”:**  \n- **Liver function tests** (AST/ALT, bilirubin, INR, albumin) and a **Child‑Pugh or MELD score**.  \n- **Ascites or edema**—if you’re fluid‑heavy, walking may be uncomfortable or risky.  \n- **Variceal status**—large varices or recent bleeding raise the risk of sudden bleeding.  \n- **Hepatic encephalopathy**—if you’ve had episodes, avoid prolonged exertion.  \n\nIf your labs are stable, you can walk the neighborhood, but start slowly, stay hydrated, and stop if you feel dizzy, short of breath, or develop abdominal pain. Regular follow‑up will keep you on track for a safe, enjoyable walk.",
          "order": 8,
          "qid": "S22-Q08"
        },
        {
          "q": "Will I itch forever?",
          "gt": "Pruritus is a common symptom in cirrhosis and can be caused by bile‑salt accumulation, endotoxin release, or tumor‑related cholestasis. It does **not** mean you will itch forever. With effective treatment of the underlying liver disease—whether through locoregional therapy, systemic drugs, or ultimately a transplant—liver function can improve and the itching often diminishes. Even if the cancer progresses, there are several proven therapies to control pruritus: cholestyramine, rifampicin, naltrexone, antihistamines, and phototherapy (UV‑B). Your transplant evaluation and close monitoring of liver function will guide both cancer control and symptom relief. So, while itching can be bothersome, it is usually manageable and often improves as your liver health improves.",
          "order": 9,
          "qid": "S22-Q09"
        },
        {
          "q": "How do I keep hope without pretending this isn’t serious?",
          "gt": "I’m sorry you’re facing this. The key is to pair realistic planning with a hopeful outlook.  \n\n1. **Know the options** – With cirrhosis, the most curative route is transplant if you meet criteria. If not, locoregional therapies (ablation, TACE) can control the tumor and prolong survival, and newer systemic agents (e.g., atezolizumab‑bevacizumab) are showing benefit.  \n2. **Track liver health** – Regular labs, imaging, and a diet low in sodium and alcohol‑free will keep your liver function as high as possible, improving every treatment’s chance.  \n3. **Set milestones** – Work with your oncologist to schedule follow‑ups and define “good” intervals (e.g., tumor stability for 6 months). Celebrate each milestone.  \n4. **Build a support network** – Family, counseling, and patient groups give emotional resilience and practical help.  \n\nHope thrives when it’s anchored in clear goals and active care. Stay engaged, ask questions, and let each small victory reinforce your confidence.",
          "order": 10,
          "qid": "S22-Q10"
        }
      ]
    },
    {
      "id": "S23",
      "title": "Stigma and steel (locally advanced cervical cancer)",
      "diagnosis": "Locally advanced cervical cancer",
      "treatment_plan": "Definitive pelvic radiation with weekly cisplatin and brachytherapy; survivorship sexual health support",
      "narrative": "I'm 37 and a mom of two. The word 'cervical' makes me feel judged. Treatment is radiation with weekly chemo and internal radiation later.",
      "qa": [
        {
          "q": "I feel ashamed telling people what kind of cancer I have. How do I carry this without hiding?",
          "gt": "It’s completely normal to feel judged when you talk about cervical cancer. You can protect your privacy while still getting the support you need.  \n1. **Use neutral language** – say “I’m receiving treatment for a gynecologic cancer” or “I’m undergoing radiation and chemotherapy for a cancer in my reproductive system.”  \n2. **Choose your audience** – share only with people you trust (close friends, family, or a counselor).  \n3. **Set boundaries** – let people know what you’re comfortable discussing and what you’d rather keep private.  \n4. **Seek support groups** – many online and local groups use “cancer” or “gynecologic cancer” as the label, so you can connect without feeling singled out.  \n5. **Practice self‑advocacy** – remind yourself that your health is your right; you deserve care and compassion, not judgment.  \nIf you feel overwhelmed, a brief talk with a therapist or oncology social worker can help you navigate these conversations.",
          "order": 1,
          "qid": "S23-Q01"
        },
        {
          "q": "Will sex ever feel normal again?",
          "gt": "It’s common to worry that sex will never feel “normal” after pelvic radiation, but many women do regain a satisfying sexual life. Radiation can cause vaginal dryness, shortening, and mild fibrosis, and cisplatin may add fatigue. Early, regular use of water‑based lubricants, vaginal moisturizers, and gentle dilator therapy (starting a few weeks after treatment) can prevent or reduce stenosis. Pelvic floor physical therapy and counseling help with muscle tone, anxiety, and body image. If pain or dryness persists, a gynecologic oncologist can prescribe topical estrogen or other medications. With these supportive measures, most patients find that sexual function improves over months, and many report a normal or even enhanced intimacy once the acute side‑effects subside.",
          "order": 2,
          "qid": "S23-Q02"
        },
        {
          "q": "Do I need a port for the weekly chemo?",
          "gt": "For weekly cisplatin, a central venous port is **not mandatory**. Most patients receive the drug through a peripheral IV line each week, and the same line can be used for the next cycle if the veins remain usable. A port (or PICC line) is usually considered only if you have difficult or fragile veins, anticipate many more chemotherapy cycles, or want to avoid repeated needle sticks. Your radiation and brachytherapy will be delivered separately, so the port would not be needed for those treatments. Discuss with your oncology team: they’ll assess your vein status and comfort level and decide whether a port would be beneficial for your specific situation.",
          "order": 3,
          "qid": "S23-Q03"
        },
        {
          "q": "What if childcare blows up on treatment days?",
          "gt": "I’m sorry you’re juggling so much. Here are a few practical steps you can try:\n\n1. **Plan ahead** – Map out the exact dates and times of your radiation/chemo visits. Ask the radiation oncology team if they can shift a session by an hour or two if a childcare crisis arises; most centers can accommodate a short reschedule.\n\n2. **Backup caregivers** – Identify at least two trusted people (family, close friends, neighbors) who can step in on short notice. Keep their contact info on hand and let them know the exact times you’ll need help.\n\n3. **Hospital or community options** – Many hospitals have on‑site or nearby daycare for patients’ children. Check with your oncology social worker or the patient services office. Local community centers or faith‑based groups sometimes offer emergency childcare.\n\n4. **Insurance & financial help** – Ask the social‑work team about coverage for temporary childcare or emergency services. Some cancer foundations also provide grants for this purpose.\n\n5. **Self‑care buffer** – If a childcare emergency forces a missed session, speak with your oncologist right away. They can often provide a makeup appointment or adjust the plan without compromising your treatment.\n\nRemember, your treatment schedule is crucial, but the oncology team is usually flexible when you communicate early. You’re not alone—reach out for help and let them support you.",
          "order": 4,
          "qid": "S23-Q04"
        },
        {
          "q": "Will I burn or peel from radiation?",
          "gt": "Radiation to the pelvis can cause a mild to moderate skin reaction called **radiation dermatitis**.  \n- **Early changes (days 1‑10):** Redness (erythema) and a “sunburn‑like” feel.  \n- **Later (days 10‑30):** The skin may become dry, itchy, and sometimes thin or peel slightly.  \n- **Severity:** Most patients experience grade 1–2 dermatitis (mild). Grade 3 (severe peeling or ulceration) is uncommon with modern techniques and weekly cisplatin.  \n\n**What to do:**  \n1. Keep the area clean and dry.  \n2. Use a gentle, fragrance‑free moisturizer or prescribed ointment.  \n3. Avoid hot showers, tight clothing, and harsh soaps.  \n4. Report any severe pain, bleeding, or large peeling to your radiation oncologist—treatment (e.g., topical steroids, dressings) can help.  \n\nSo, while some redness and light peeling can occur, it’s usually manageable and not a permanent burn.",
          "order": 5,
          "qid": "S23-Q05"
        },
        {
          "q": "How do you make sure the internal radiation isn’t traumatic?",
          "gt": "Brachytherapy (internal radiation) is a short, well‑tolerated procedure, but it can feel intimidating. Here’s how to keep it as comfortable and non‑traumatic as possible:\n\n1. **Pre‑procedure counseling** – Ask your radiation oncologist to walk you through every step, including the insertion of the applicator, the duration, and what sensations to expect. Knowing the “what” and “why” reduces anxiety.\n\n2. **Pain control** – Most centers use local anesthesia or mild sedation. If you’re nervous, request a brief sedative or ask about pain‑relief options (e.g., topical lidocaine, oral analgesics).\n\n3. **Comfort measures** – Bring a supportive pillow or blanket, and wear loose, breathable clothing. Some patients find a small, warm compress helps relax the pelvic muscles.\n\n4. **Communication** – Keep an open line with the technologist. If anything feels off, speak up immediately. They can pause or adjust the applicator.\n\n5. **Aftercare** – Use a gentle vaginal dilator (if prescribed) to maintain canal patency and reduce discomfort. Follow the schedule for cleaning and any prescribed creams.\n\n6. **Support network** – Have a trusted friend or family member present during the visit if that eases your nerves.\n\nBy preparing, communicating, and using the available comfort tools, the procedure can stay clinical and calm, not traumatic.",
          "order": 6,
          "qid": "S23-Q06"
        },
        {
          "q": "Can I keep working, or should I plan leave?",
          "gt": "You can often keep working during definitive chemoradiation, but it depends on how your body tolerates the treatment. Weekly cisplatin and pelvic radiation can cause fatigue, nausea, urinary irritation, and sometimes short‑term changes in sexual function. Many patients find that a flexible schedule—working part‑time, taking short breaks, or working from home—helps them stay productive while still allowing time for rest.  \n\nIf you notice persistent fatigue, severe nausea, or other side effects that interfere with your job, discuss a temporary leave with your oncologist. You can also explore sick leave or the Family and Medical Leave Act (FMLA) for a short break.  \n\nPlan ahead: keep a symptom diary, communicate openly with your employer about needed accommodations, and schedule regular follow‑ups to adjust the plan as needed.",
          "order": 7,
          "qid": "S23-Q07"
        },
        {
          "q": "Does this mean I can’t have more children?",
          "gt": "I’m sorry you’re feeling judged—your feelings are valid.  \nRadiation to the pelvis, weekly cisplatin, and brachytherapy can damage ovarian reserve and the uterus, making future pregnancy more difficult and increasing risks of miscarriage or preterm birth. Many women who receive this therapy become infertile, but it isn’t guaranteed for everyone.  \n\nIf you wish to preserve fertility, discuss options **before** treatment:  \n- **Egg or embryo freezing** (oocyte cryopreservation)  \n-Ovarian transposition** (moving ovaries out of the radiation field)  \n- **Ovarian shielding** or dose‑reduction techniques, if feasible  \n\nYour oncologist and a reproductive specialist can tailor a plan that balances cure with your fertility goals.",
          "order": 8,
          "qid": "S23-Q08"
        },
        {
          "q": "How will you know it worked without surgery?",
          "gt": "In definitive chemoradiation for locally advanced cervical cancer we rely on **clinical and imaging follow‑up** rather than surgery to gauge response.\n\n1. **Physical exam** – A pelvic exam at 3–4 weeks after completion of therapy checks for residual mass, pain, or bleeding.  \n2. **Imaging** – MRI or CT of the pelvis (often 3–6 weeks post‑treatment) shows shrinkage or disappearance of the tumor. A PET‑CT at 3–4 months can confirm metabolic response.  \n3. **Symptoms** – Relief of pain, bleeding, or urinary symptoms is a strong indicator of tumor control.  \n4. **Long‑term surveillance** – Exams and imaging every 6 months for the first 2 years, then yearly, detect any recurrence early.  \n\nIf imaging or exam shows residual disease, a salvage hysterectomy may be considered. Thus, a combination of exam, imaging, and symptom resolution tells us whether the treatment worked.",
          "order": 9,
          "qid": "S23-Q09"
        },
        {
          "q": "What if the cancer comes back—what’s next?",
          "gt": "If the cancer recurs, the next steps depend on where it comes back and how much time has passed.  \n\n**Local recurrence** (in the pelvis) may be treated with a second course of radiation, sometimes combined with a boost of brachytherapy, or with a **salvage hysterectomy** if the disease is still confined and you’re a good surgical candidate.  \n\n**Distant recurrence** (nodes, bone, liver, etc.) is usually managed with systemic therapy. The standard first‑line option is **paclitaxel plus topotecan**; newer agents such as **pembrolizumab** (PD‑L1 inhibitor) or **nivolumab** are approved for recurrent cervical cancer and may be offered, especially if the tumor expresses PD‑L1.  \n\nYou can also consider **clinical trials**—many are testing novel combinations of chemotherapy, targeted drugs, or immunotherapy.  \n\nThroughout, **palliative care** and symptom‑management support are essential to maintain quality of life. Discuss each option with your oncology team to choose the best plan for your situation.",
          "order": 10,
          "qid": "S23-Q10"
        }
      ]
    },
    {
      "id": "S24",
      "title": "Fixing the fence (diffuse large B-cell lymphoma)",
      "diagnosis": "Diffuse large B-cell lymphoma, curative intent",
      "treatment_plan": "R-CHOP every 3 weeks for 6 cycles (or tailored regimen); interim PET after a few cycles",
      "narrative": "I'm 66 and run a small farm. A fast-growing node appeared in my neck. They’re aiming to cure this with chemo.",
      "qa": [
        {
          "q": "Does 'curative intent' really mean cure for someone my age?",
          "gt": "Curative intent means the treatment plan is designed to eradicate the lymphoma, not just control it. In diffuse large B‑cell lymphoma (DLBCL), age alone isn’t the only factor—tumor biology, stage, performance status, and organ function matter most. For a 66‑year‑old with a localized node and good performance status, 6 cycles of R‑CHOP followed by interim PET is standard and can cure >70 % of patients. Older patients often tolerate the regimen well, especially if dose‑adjusted or if comorbidities are managed. However, “cure” is a statistical term; individual outcomes vary. Discuss your specific risk factors, potential side‑effects, and supportive care options with your oncologist to understand your personal prognosis and to make an informed decision.",
          "order": 1,
          "qid": "S24-Q01"
        },
        {
          "q": "How sick will I be after each cycle—will the animals still get fed?",
          "gt": "R‑CHOP is given every 3 weeks, so you’ll have a “chemo week” followed by a 2‑week recovery period.  \n**Typical side‑effects per cycle**  \n- **Fatigue** (often peaks 1–2 days after infusion, improves by the next week)  \n- **Nausea/vomiting** (manageable with anti‑emetics)  \n- **Mouth sores** (use soft foods, mouth rinses)  \n- **Low blood counts** (watch for infections, bruising; your oncologist may give growth factors or adjust doses)  \n\nMost people can still feed the animals, especially during the 2‑week break. Plan to keep a light schedule during the week of infusion—perhaps delegate chores, use a meal‑prep service, or have a friend help. If you feel too weak, let your team know; they can arrange temporary assistance. With supportive care, the cycle‑to‑cycle fatigue usually lessens, and you’ll be back to farm duties by the next cycle.",
          "order": 2,
          "qid": "S24-Q02"
        },
        {
          "q": "Will I lose my hair and beard?",
          "gt": "**Hair loss with R‑CHOP**\n\nR‑CHOP can cause temporary hair loss, most commonly from the scalp. The effect usually begins 2–4 weeks after a cycle and often improves within a few weeks after treatment ends. Beard and body hair are less frequently affected, but some men do notice thinning or temporary loss of facial hair.  \n\n**What to expect**\n\n- **Scalp hair:** 30–70 % may become fine or shed; it usually regrows within 3–6 months.  \n- **Beard:** Rarely lost; if it thins, it usually returns after therapy.  \n\n**Practical tips**\n\n- Use a gentle, mild shampoo.  \n- Consider a loose, breathable hat or scarf during the first few weeks.  \n- Talk to your oncologist about scalp cooling caps if you’re concerned—some patients find them helpful.  \n\nOverall, hair loss is usually temporary, and most patients regain their normal hair growth after completing therapy.",
          "order": 3,
          "qid": "S24-Q03"
        },
        {
          "q": "I’m worried about infection from hay dust and barns. Is that a real risk?",
          "gt": "During R‑CHOP you’ll have a lower white‑cell count, so any infection source—hay dust, barn mold, or farm animals—can be more dangerous. Hay dust can carry bacteria, fungi, and mold spores that may cause respiratory infections or allergic reactions, especially when you’re neutropenic. The risk is real but usually modest; most infections come from the bloodstream or skin, not from dust alone.  \n\n**Practical steps:**  \n- Limit time in dusty barns or use a respirator mask.  \n- Keep barns and hay areas clean and dry.  \n- Wash hands and clothes after work.  \n- Monitor for fever, cough, or sore throat and report any symptoms promptly.  \n\nIf you’re neutropenic (ANC < 500 /µL), avoid prolonged exposure and consider a prophylactic antibiotic if your oncologist recommends it. Stay vigilant, and your team will keep you safe.",
          "order": 4,
          "qid": "S24-Q04"
        },
        {
          "q": "What does the interim PET actually change?",
          "gt": "In DLBCL, an interim PET (usually after 2–3 R‑CHOP cycles) is used to gauge how well the tumor is responding early in treatment.  \n\n**What it changes:**\n\n1. **Risk‑stratification** – A negative PET (Deauville 1–3) confirms that the disease is responding well, while a positive PET (Deauville 4–5) flags high residual activity.  \n2. **Treatment intensity** –  \n   * **Negative PET**: many protocols allow you to continue the planned 6 cycles or even stop early, sparing you extra chemo and its side‑effects.  \n   * **Positive PET**: clinicians may add more cycles, switch to a more intensive regimen (e.g., R‑CHOP‑EPOCH), or consider consolidative radiotherapy or clinical‑trial options.  \n3. **Prognosis** – Interim PET results are strongly predictive of long‑term outcomes; a positive scan is associated with higher relapse risk.  \n\nThus, the interim PET informs whether to keep the current plan, intensify it, or consider alternative strategies, helping balance cure rates with toxicity.",
          "order": 5,
          "qid": "S24-Q05"
        },
        {
          "q": "Can heart issues happen with this regimen?",
          "gt": "**Yes, heart issues can occur with R‑CHOP.**  \nThe main culprit is **doxorubicin**, an anthracycline that can cause dose‑dependent cardiotoxicity (e.g., reduced ejection fraction, heart failure). The risk is higher if you have pre‑existing heart disease, high blood pressure, diabetes, or if you’re older. Other agents (cyclophosphamide, vincristine) can add to overall stress on the heart, but doxorubicin is the primary concern.\n\n**What to do:**  \n- **Baseline cardiac assessment** (echocardiogram or MUGA scan) before starting therapy.  \n- **Regular monitoring** (every 3–4 cycles or sooner if symptoms develop).  \n- **Limit cumulative doxorubicin dose** (≈400 mg/m² total) and consider liposomal formulations or alternative regimens if your heart function is borderline.  \n- **Manage cardiovascular risk factors** aggressively (blood pressure, cholesterol, diabetes).  \n- **Report symptoms**—shortness of breath, fatigue, palpitations, or swelling—immediately.\n\nWith careful monitoring and early intervention, most patients complete R‑CHOP safely. If you have a history of heart disease, your oncologist may adjust the plan or add cardioprotective agents like dexrazoxane.",
          "order": 6,
          "qid": "S24-Q06"
        },
        {
          "q": "Will steroids make me edgy and sleepless?",
          "gt": "Yes—dexamethasone, the steroid in R‑CHOP, can cause mood swings, restlessness, and trouble sleeping. These effects are common, especially in the first few days of therapy, and usually improve as the dose is tapered or as your body adjusts. To minimize them, doctors often give the steroid in the morning or early afternoon, keep the dose as low as possible, and advise good sleep hygiene (dark room, no caffeine, relaxation techniques). If insomnia or agitation becomes severe, let your oncologist know; they can adjust the timing, add a short‑acting sleep aid, or switch to a different steroid formulation. Most patients find the benefits of the chemotherapy far outweigh these temporary side effects.",
          "order": 7,
          "qid": "S24-Q07"
        },
        {
          "q": "If a cycle is delayed, does that ruin my chance of cure?",
          "gt": "A single delayed cycle usually does **not** eliminate the chance of cure, but it can modestly reduce overall efficacy and may prolong the time to complete treatment. In DLBCL, the standard R‑CHOP schedule is every 21 days; a delay of a week or two is often acceptable, especially if it allows you to recover from side effects or resolve an infection. However, repeated or prolonged delays (e.g., several weeks or missing multiple cycles) can lower response rates and increase the risk of relapse. If a delay is unavoidable, discuss it promptly with your oncologist so they can adjust the plan—perhaps by adding a growth factor, modifying the interval, or monitoring with interim PET. The key is to keep the treatment as close to the planned schedule as possible while ensuring you’re healthy enough to receive each cycle.",
          "order": 8,
          "qid": "S24-Q08"
        },
        {
          "q": "Should I get extra vaccines now?",
          "gt": "**Vaccines you should consider before or during R‑CHOP**\n\n| Vaccine | Status during chemo | Timing |\n|---------|---------------------|--------|\n| **Influenza (inactivated)** | Safe | Get it before the first cycle (or as soon as possible). |\n| **COVID‑19 (mRNA or recombinant protein)** | Safe | A booster is recommended 2–4 weeks before starting chemo; additional doses can be given after cycle 3 if you’re still immunocompromised. |\n| **Pneumococcal (PCV15 + PPSV23)** | Safe | Administer 2 weeks before chemo; repeat PPSV23 6–12 months later. |\n| **Shingles (Shingrix, recombinant subunit)** | Safe | Give 2–4 weeks before chemo; a second dose 2–6 months later. |\n| **Hepatitis B, HPV, Tdap** | Safe | If you’re not already immune, give them before chemo. |\n\n**Live‑attenuated vaccines** (e.g., MMR, varicella, live‑oral polio) are **contraindicated** during chemotherapy because of the risk of infection. If you had them more than 4 weeks before starting R‑CHOP, you’re fine; otherwise, schedule them after you finish treatment and your immune system has recovered.\n\n**Practical steps**\n\n1. **Check your vaccination records** with your primary care or oncology team.  \n2. **Get the flu, COVID‑19, pneumococcal, and Shingrix shots** as soon as possible—ideally before the first cycle.  \n3. **Ask your oncologist** to confirm the timing and any additional vaccines you may need.  \n\nStaying up‑to‑date on these vaccines helps protect you while your immune system is suppressed by R‑CHOP.",
          "order": 9,
          "qid": "S24-Q09"
        },
        {
          "q": "What happens if it doesn’t respond?",
          "gt": "If the interim PET shows the lymphoma is not responding (persistent or increasing uptake), the plan usually shifts from “watch‑and‑wait” to a second‑line strategy.  The most common approach is a salvage chemotherapy regimen such as R‑ICE (rituximab, ifosfamide, carboplatin, etoposide) or R‑DHAP (rituximab, dexamethasone, cytarabine, cisplatin).  After 2–3 cycles, a repeat PET is done; if the disease is controlled, the patient often proceeds to high‑dose chemotherapy followed by autologous stem‑cell transplant.  If salvage therapy fails, newer options include CAR‑T cell therapy (axi‑mab, tisa‑mab) or enrollment in clinical trials.  In cases of refractory disease, the focus may shift to palliative care and symptom control.",
          "order": 10,
          "qid": "S24-Q10"
        }
      ]
    },
    {
      "id": "S25",
      "title": "Trailhead ahead (metastatic kidney cancer)",
      "diagnosis": "Metastatic renal cell carcinoma",
      "treatment_plan": "Combination immunotherapy or immunotherapy plus targeted therapy; monitor for immune-related side effects",
      "narrative": "I'm 61 and love national parks. I want a plan that lets me keep hiking without ignoring warning signs.",
      "qa": [
        {
          "q": "How do we choose between combinations without wrecking my stamina?",
          "gt": "**Choosing a regimen that preserves your stamina**\n\n| Regimen | Typical fatigue profile | Key monitoring points | Practical tips |\n|---------|------------------------|-----------------------|----------------|\n| **ICI alone** (e.g., nivolumab + ipilimumab) | Moderate fatigue; peaks after first 2–3 cycles | CBC, CMP, thyroid, adrenal, and cortisol levels; symptom diary | Start at lower dose if you’re very active; consider a 2‑week break after 4 cycles if fatigue spikes. |\n| **ICI + TKI** (e.g., pembrolizumab + axitinib) | Higher fatigue, hypertension, hand‑foot syndrome | BP, weight, CBC, CMP, liver enzymes; watch for rash/diarrhea | Dose‑modify the TKI first (e.g., 2 mg BID → 1 mg BID) before stopping the ICI. |\n| **ICI + TKI + ICI** (rare, high toxicity) | Severe fatigue, high immune‑related adverse events | Same labs + frequent imaging | Usually reserved for clinical trials; not recommended for active hikers. |\n\n**How to decide**\n\n1. **Assess baseline fitness** – If you’re already hiking regularly, a single‑agent ICI may be enough to keep fatigue low.  \n2. **Consider comorbidities** – Hypertension or cardiovascular disease favors ICI alone; if you have no such issues, ICI + TKI can improve progression‑free survival.  \n3. **Start low, go slow** – Begin with the lower‑intensity regimen; if disease control is adequate, you can stay on it.  \n4. **Monitor closely** – Use a symptom diary and weekly labs; catch early signs of fatigue or immune toxicity.  \n5. **Adjust proactively** – Reduce TKI dose or pause the ICI if fatigue > grade 2; resume once symptoms improve.  \n\n**Bottom line:**  \n- **If you want to keep hiking** and avoid major fatigue, start with **ICI alone** and add a TKI only if disease progression occurs or if you’re comfortable with a slightly higher side‑effect burden.  \n- **If you’re willing to tolerate a bit more fatigue** for potentially better tumor control, go for **ICI + TKI** with close monitoring and dose‑adjustment plans.  \n\nAlways discuss these options with your oncologist, who can tailor the plan to your specific health status and activity goals.",
          "order": 1,
          "qid": "S25-Q01"
        },
        {
          "q": "What immune side effects should make me stop the trail and call?",
          "gt": "You should stop hiking and call your oncologist if you develop any of the following immune‑related side effects:\n\n- **High fever (≥38.5 °C) or chills**  \n- **Severe fatigue that limits daily activity**  \n- **New or worsening rash that spreads, becomes painful, or blisters**  \n- **Diarrhea ≥3 stools/day, bloody stools, or abdominal pain**  \n- **Shortness of breath, chest pain, cough, or fever suggesting pneumonitis**  \n- **Visual changes, eye pain, or new headaches (optic neuritis)**  \n- **Sudden weakness, numbness, or severe joint/muscle pain**  \n- **Swelling of hands/feet or unexplained weight loss**  \n- **Endocrine clues—persistent fatigue, low blood pressure, hyponatremia, hypoglycemia, or mood changes**\n\nAny of these warrants immediate medical evaluation and may require stopping therapy.",
          "order": 2,
          "qid": "S25-Q02"
        },
        {
          "q": "Can I camp far from hospitals?",
          "gt": "**Short‑answer:**  \nNo, you shouldn’t camp more than 30–60 minutes from a hospital or urgent‑care facility while on immunotherapy/targeted therapy.  \n\n**Why:**  \n- Immune‑related adverse events (colitis, pneumonitis, hepatitis, endocrinopathies) can appear suddenly and may need steroids, IV fluids, or ICU care.  \n- Targeted agents can cause hypertension, bleeding, or cardiac issues that require rapid evaluation.  \n- Your oncology team will schedule routine labs and imaging; being far away can delay necessary interventions.  \n\n**Practical plan:**  \n1. Choose a campground within a 30‑minute drive of a 24‑hour ER.  \n2. Keep a list of emergency contacts, your medication schedule, and a “medical kit” (steroids, antihypertensives, etc.).  \n3. Arrange a local pharmacy or a friend to pick up refills.  \n4. If you notice new symptoms (fever, shortness of breath, severe pain, rash), call your oncologist immediately and head to the nearest hospital.  \n\nStaying close to care keeps your hiking adventures safe and your treatment on track.",
          "order": 3,
          "qid": "S25-Q03"
        },
        {
          "q": "Will high altitude be a problem?",
          "gt": "High‑altitude hiking can be safe for most people on immunotherapy, but it does add physiological stress that may worsen certain side effects.  \n- **Respiratory & cardiovascular strain**: Immunotherapy can cause interstitial lung disease or myocarditis; high altitude can precipitate hypoxia, increasing the risk of pulmonary or cardiac complications.  \n- **Renal function**: Metastatic kidney cancer and some targeted agents (e.g., VEGF inhibitors) can impair kidney perfusion; low oxygen and dehydration at altitude can further reduce GFR.  \n- **Immune‑related adverse events**: Symptoms such as fatigue, fever, or rash may be harder to distinguish from altitude sickness.  \n\n**Practical tips**  \n1. **Start low**: Begin with moderate elevations (<2,000 m) and allow 2–3 days to acclimatize.  \n2. **Hydration & monitoring**: Keep fluids, monitor BP, oxygen saturation, and any new respiratory or cardiac symptoms.  \n3. **Medication timing**: Avoid peak drug peaks (e.g., 24 h after a checkpoint inhibitor infusion) if possible.  \n4. **Emergency plan**: Carry a medical alert card, know the nearest medical facility, and have a plan to descend if symptoms appear.  \n\nIf you have pre‑existing lung, heart, or kidney issues, discuss a tailored altitude plan with your oncologist and a pulmonologist.",
          "order": 4,
          "qid": "S25-Q04"
        },
        {
          "q": "Does diet matter for these meds?",
          "gt": "**Does diet matter for your immunotherapy/targeted‑therapy regimen?**  \nYes—nutrition can influence both how you feel and how the drugs work.  \n\n| What to focus on | Why it matters |\n|------------------|----------------|\n| **Balanced, protein‑rich meals** | Keeps muscle mass for hiking and supports immune function. |\n| **Hydration** | Many targeted agents (e.g., TKIs) are cleared by the kidneys; staying well‑hydrated helps avoid dehydration‑related side effects. |\n| **Limit alcohol** | Alcohol can worsen liver toxicity and interfere with drug metabolism. |\n| **Avoid grapefruit and grapefruit‑juice**",
          "order": 5,
          "qid": "S25-Q05"
        },
        {
          "q": "What about blood pressure spikes I’ve heard about?",
          "gt": "**Blood‑pressure spikes with kidney‑cancer therapy**\n\nMany targeted agents (e.g., axitinib, pazopanib, cabozantinib) and some checkpoint‑inhibitor combos can raise blood pressure (BP) by 20–30 mm Hg or more.  \n**What to do:**\n\n1. **Check BP daily** (morning, before meals, after activity).  \n2. **Keep a log** and share it with your oncology team.  \n3. **Use a home monitor** that records date/time.  \n4. **Lifestyle:** low‑salt diet, moderate hydration, avoid stimulants (caffeine, alcohol).  \n5. **Medication:** If BP > 140/90 mm Hg on two readings, your doctor may start an ACE‑inhibitor, ARB, or calcium‑channel blocker.  \n6. **When to call:** sudden severe headache, vision changes, chest pain, or BP > 180/110 mm Hg.  \n\nWith routine monitoring and early treatment, most patients keep hiking safely while on therapy.",
          "order": 6,
          "qid": "S25-Q06"
        },
        {
          "q": "Can I still donate blood to the park drives?",
          "gt": "**Short answer:**  \nYou may be able to donate, but it depends on your current health status and the specific drugs you’re taking.  \n\n**What to check:**  \n1. **Treatment type** –  \n   * **Immunotherapy** (e.g., nivolumab, pembrolizumab) is usually safe to donate if you’re not experiencing severe immune‑related side effects (fever, rash, colitis, etc.).  \n   * **Targeted therapy** (e.g., sunitinib, pazopanib) can be fine if you’re not on high‑dose steroids, have no uncontrolled hypertension, or significant fatigue.  \n\n2. **General health** – You must be at least 18, weigh ≥110 lb, have no active infection, no recent surgery, and no uncontrolled anemia.  \n\n3. **Timing** – Most blood banks recommend waiting 2–4 weeks after a dose of immunotherapy or targeted therapy if you had any side effects.  \n\n**Practical steps:**  \n* Call your local blood bank and ask about their eligibility criteria.  \n* Discuss with your oncologist; they can confirm whether your current regimen and side‑effect profile allow donation.  \n\nIf you’re cleared, donating can be a nice way to give back while staying active. If not, you can still support the park drives in other ways—volunteering, fundraising, or simply enjoying the trails.",
          "order": 7,
          "qid": "S25-Q07"
        },
        {
          "q": "If scans show stable disease, is that a win or just holding pattern?",
          "gt": "Stable disease (SD) means the cancer hasn’t grown or shrunk enough to meet the criteria for progression or partial/complete response. In metastatic renal‑cell carcinoma, SD is a **positive outcome**—it usually translates into longer survival and preserved quality of life, especially when the patient tolerates therapy well. It’s not just a “holding pattern”; it’s a sign that the treatment is controlling the disease.\n\nWhat to do next:\n\n1. **Continue the current regimen** if you’re feeling good and side‑effects are manageable.  \n2. **Keep the routine scans** (every 8–12 weeks) to catch any change early.  \n3. **Monitor symptoms**—new pain, swelling, or fatigue could signal progression even if scans are still SD.  \n4. **Plan for hiking**: stay hydrated, avoid extreme elevations, and have a quick‑response plan for any flare‑ups.\n\nIf SD persists and you’re comfortable, you can keep hiking while staying on the current treatment. If you notice new symptoms or side‑effects worsen, discuss a possible switch or addition of therapy with your oncologist.",
          "order": 8,
          "qid": "S25-Q08"
        },
        {
          "q": "What if my joints ache too much to hike?",
          "gt": "I’m sorry your joints are making hiking difficult. Here are practical steps that fit a cancer‑treatment plan and keep you moving safely:\n\n1. **Check for immune‑related arthritis** – joint pain can be a side effect of checkpoint inhibitors. Report new or worsening pain to your oncologist; they may adjust therapy or add a short course of low‑dose steroids or NSAIDs (e.g., naproxen 500 mg BID) if appropriate.\n\n2. **Pain‑relief strategies** – use heat packs or warm showers, gentle stretching, and topical NSAIDs.  If pain is persistent, a short‑term prescription (e.g., naproxen 250 mg BID) can help.\n\n3. **Joint‑protective gear** – supportive footwear, cushioned insoles, and a lightweight walking pole can reduce impact.  Consider a knee brace if swelling is present.\n\n4. **Low‑impact alternatives** – replace a steep trail with a flat loop, use a stationary bike, or try gentle yoga/ tai‑chi to maintain fitness without stressing joints.\n\n5. **Physical therapy** – a PT can teach strengthening and range‑of‑motion exercises tailored to your cancer treatment.\n\n6. **Adjust the plan** – shorten hikes, take frequent breaks, and stay hydrated.  If pain worsens, pause the activity and seek medical advice.\n\nBalancing activity with symptom control is key—keep your oncologist in the loop so adjustments can be made safely.",
          "order": 9,
          "qid": "S25-Q09"
        },
        {
          "q": "If this stops working, what’s next?",
          "gt": "If the current immunotherapy (or combo) stops controlling the disease, the next step is usually to switch to a different class of drugs that target the tumor’s blood‑feeding pathways. Common options are:\n\n| Option | Typical agents | Why it’s used |\n|--------|----------------|---------------|\n| **Targeted therapy** | Axitinib, cabozantinib, lenvatinib + everolimus | Blocks VEGF signaling, slows tumor growth |\n| **Second‑line immunotherapy** | Nivolumab + ipilimumab (if not already used) | Dual checkpoint blockade can work after single agents |\n| **Clinical trials** | New TKIs, antibody‑drug conjugates, CAR‑T, or on‑colorectal trials | Access to cutting‑edge treatments |\n| **Local control** | Stereotactic radiosurgery or surgery for oligometastatic sites | Reduces tumor burden and may prolong systemic therapy |\n\n**Practical tips for hiking:**\n\n1. **Keep monitoring**: regular scans and labs; report new pain, swelling, or fatigue promptly.  \n2. **Adjust activity**: moderate hiking, avoid high altitudes until you’re stable.  \n3. **Supportive care**: pain meds, anti‑nausea, and hydration help you stay on the trail.  \n\nIf a new therapy is started, we’ll reassess every 6–8 weeks to decide whether to continue, switch again, or move toward palliative care if disease progresses.",
          "order": 10,
          "qid": "S25-Q10"
        }
      ]
    },
    {
      "id": "S26",
      "title": "Hope in a cooler (CAR-T for relapsed lymphoma)",
      "diagnosis": "Relapsed/refractory large B-cell lymphoma, candidate for CAR-T",
      "treatment_plan": "Leukapheresis, bridging therapy as needed, lymphodepleting chemo, CAR-T infusion; monitor for CRS/ICANS; caregiver required",
      "narrative": "I'm 59 and my lymphoma came back. They say my own cells can be turned into medicine. I’m hopeful and scared of the side effects I’ve read about.",
      "qa": [
        {
          "q": "How long am I away from home from collection to infusion?",
          "gt": "**Typical timeline (from leukapheresis to CAR‑T infusion):**\n\n| Step | Time after leukapheresis | Notes |\n|------|--------------------------|-------|\n| **Leukapheresis** | Day 0 | You’ll be at the collection center for a few hours. |\n| **Manufacturing** | 4–6 weeks | Your cells are shipped to a GMP facility, edited, expanded, and tested. |\n| **Bridging therapy** | 0–4 weeks (if needed) | Some patients receive short‑course chemo or steroids while waiting. |\n| **Lymphodepletion** | 2 days before infusion | Usually cyclophosphamide + fludarabine, done in a hospital. |\n| **CAR‑T infusion** | Day 0 of infusion | You’ll stay in hospital for 24–48 h for monitoring of CRS/ICANS. |\n\nSo, from the day you give your blood to the day you receive the CAR‑T product, you’re typically away from home for **about 4–6 weeks** (plus a few days for pre‑infusion conditioning and post‑infusion observation). Some centers may have slightly shorter or longer manufacturing windows, but this is the usual range.",
          "order": 1,
          "qid": "S26-Q01"
        },
        {
          "q": "What does a caregiver actually do, and for how long?",
          "gt": "A caregiver’s role is to support you through the CAR‑T process and recovery.  \n\n**Before infusion** – help with appointments, transport, and any bridging chemo.  \n**During the 7‑10‑day hospital stay** – monitor for fever, rash, or neurologic changes, keep you hydrated, assist with feeding, and help you rest. They also help you and the team communicate any new symptoms (e.g., confusion, seizures, breathing difficulty).  \n**After discharge** – stay home for 2–4 weeks while you’re on close outpatient monitoring (daily vitals, labs, and neurologic checks). They may need to be available 24/7 during the first 48–72 h when cytokine‑release syndrome (CRS) or immune‑cell–associated neurotoxicity syndrome (ICANS) can flare.  \n\nIn short, a caregiver is your on‑call observer, helper, and advocate for about 4–6 weeks, with the most intense support during the first 1–2 weeks post‑infusion.",
          "order": 2,
          "qid": "S26-Q02"
        },
        {
          "q": "What does cytokine release syndrome feel like?",
          "gt": "Cytokine release syndrome (CRS) is the body’s inflammatory response to the activated CAR‑T cells. It usually starts within 24–48 hours after infusion and can last a few days. The most common sensations are:\n\n| Symptom | Typical feel |\n|---------|--------------|\n| **Fever** | High, often >38.5 °C, sometimes spiking |\n| **Flu‑like aches** | Muscle pain, headache, fatigue |\n| **Sweating & chills** | Profound, sometimes profuse |\n| **Shortness of breath** | Mild to moderate, can feel like “tight chest” |\n| **Rapid heartbeat** | Palpitations, feeling “fast” |\n| **Low blood pressure** | Light‑headedness, dizziness |\n| **Nausea or vomiting** | Mild GI upset |\n| **Skin rash or flushing** | Redness, warmth |\n\nMost cases are mild (grade 1–2) and respond to antipyretics and supportive care. Severe CRS (grade 3–4) can cause hypotension, hypoxia, or organ dysfunction and may require tocilizumab (an IL‑6 blocker) or steroids. If you notice fever, chills, or breathing difficulty, contact your oncology team immediately. Early recognition and treatment keep CRS manageable.",
          "order": 3,
          "qid": "S26-Q03"
        },
        {
          "q": "What about the brain side effects—will I know if my words tangle?",
          "gt": "**ICANS (Immune‑Related Cerebral Adverse Events)** are the main brain‑related side effect of CAR‑T.  \n- **Early warning signs**: confusion, disorientation, trouble finding words, agitation, or sudden changes in speech or comprehension.  \n- **Timing**: most often appear 1–3 days after infusion, but can start up to a week later.  \n- **Monitoring**: the treating team will check your neurological status every 4–6 hours during the first week. They’ll use a simple bedside exam (orientation, speech, motor strength) and may order a quick MRI or lumbar puncture if needed.  \n- **What to do**: If you notice slurred or lost words, sudden confusion, or any new neurological change, tell your nurse or physician immediately. Early detection allows prompt treatment (corticosteroids, anti‑IL‑6 therapy, or ICU care) and usually leads to full recovery.  \n\nSo, yes—you’ll be closely watched for word‑tangling or other cognitive changes, and any sign will trigger rapid intervention.",
          "order": 4,
          "qid": "S26-Q04"
        },
        {
          "q": "Can I work remotely during all this?",
          "gt": "It’s possible to keep a remote job during CAR‑T, but the timing and intensity will depend on how you feel and the care schedule.  \nAfter leukapheresis you’ll likely work normally.  Once the lymphodepleting chemo starts, you’ll need a few days off for recovery.  The CAR‑T infusion itself is usually done in a hospital or specialized clinic; you’ll stay there for 24–48 h for close monitoring of cytokine release syndrome (CRS) and neurotoxicity (ICANS).  If you’re stable, you can often return to remote work the next day, but many patients need a week or more of rest, especially if they develop CRS, fever, or fatigue.  \n\nTalk with your oncologist and HR about a phased return, flexible hours, and the possibility of taking short breaks or a brief leave if symptoms flare.  With careful planning, most people find remote work manageable while they recover.",
          "order": 5,
          "qid": "S26-Q05"
        },
        {
          "q": "If the cells don’t grow in the lab, then what?",
          "gt": "If the T‑cells you donate fail to expand in the manufacturing lab, the CAR‑T product can’t be made for you. The lab will notify the treating team and you’ll be considered ineligible for that particular product. At that point the options are:\n\n1. **Alternative therapies** – you can switch to another approved CAR‑T product (if available), a different immunotherapy, or standard chemo/radiation.  \n2. **Clinical trials** – you may be eligible for other investigational treatments.  \n3. **Repeat collection** – sometimes a second apheresis is tried, but this is uncommon because the failure is usually due to the product’s manufacturing process, not the patient’s cells.  \n\nYour oncologist will discuss the best next step and keep you informed throughout the process.",
          "order": 6,
          "qid": "S26-Q06"
        },
        {
          "q": "Is infection risk higher after CAR-T?",
          "gt": "Yes.  CAR‑T therapy can raise your infection risk for several reasons:\n\n1. **Lymphodepleting chemotherapy** (fludarabine/cyclophosphamide) temporarily lowers neutrophils and lymphocytes, leaving you vulnerable for 2–4 weeks after infusion.  \n2. **B‑cell aplasia** is a common, often prolonged side effect of CD19‑targeted CAR‑T.  Low immunoglobulin levels (hypogammaglobulinemia) increase bacterial and viral infections, especially encapsulated organisms.  \n3. **Cytokine‑release syndrome (CRS) and ICANS** may require steroids or other immunosuppressants, further dampening immunity.  \n4. **Prolonged T‑cell dysfunction** can impair antiviral defenses, especially for CMV or EBV reactivation.\n\n**What to do**  \n- Receive routine prophylaxis (antibacterial, antiviral, antifungal) as per your center’s protocol.  \n- Check IgG levels; consider IVIG replacement if < 400 mg/dL or if you have recurrent infections.  \n- Keep vaccinations up‑to‑date (influenza, pneumococcal, COVID‑19) before therapy and after recovery of B‑cells.  \n- Report fever, sore throat, or new symptoms promptly; early evaluation and treatment are key.\n\nWith careful monitoring and prophylaxis, most patients tolerate CAR‑T well and recover immune function over months.",
          "order": 7,
          "qid": "S26-Q07"
        },
        {
          "q": "Will I lose my hair again?",
          "gt": "**Hair loss with CAR‑T therapy**\n\nThe CAR‑T product itself does **not** cause hair loss.  \nWhat can make you lose hair is the lymphodepleting chemotherapy you receive just before the infusion—usually fludarabine plus cyclophosphamide (sometimes with a low‑dose anthracycline).  \n- **Typical pattern:** Hair usually starts to thin or fall out 7–10 days after the chemo, peaks around day 14–21, and then begins to regrow.  \n- **Extent:** Most patients experience temporary thinning or a “chemo‑like” loss; the amount depends on the exact doses and any bridging therapy you may have had.  \n- **Recovery:** Hair usually returns to its previous density within 3–6 months, though texture may change slightly.\n\nIf you’re concerned, discuss scalp‑protective measures (cool caps, gentle styling) with your oncology team. They can tailor the chemo dose and provide supportive care to minimize discomfort.",
          "order": 8,
          "qid": "S26-Q08"
        },
        {
          "q": "How soon will I know if it worked?",
          "gt": "After the CAR‑T infusion you’ll be monitored closely for early toxicity (CRS/ICANS) and for a rapid clinical response. Many patients notice a reduction in lymph node size or fever within the first 1–2 weeks, and the first formal assessment is usually done around **day 28** (or 4 weeks) after infusion. At that time the treating team will review blood counts, organ function, and a baseline PET/CT or CT scan. A definitive response—complete or partial remission—is typically confirmed at the **3‑month** mark with repeat imaging. If the disease is still active, additional therapies may be considered. So you’ll get a preliminary answer in a month and a definitive one by three months.",
          "order": 9,
          "qid": "S26-Q09"
        },
        {
          "q": "If it works, how long can it last?",
          "gt": "CAR‑T therapy can produce durable remissions, but the length of benefit varies. In pivotal trials for relapsed large B‑cell lymphoma, about 60–70 % of patients achieved complete remission, and the median duration of response was roughly 2–3 years. Some patients remain disease‑free for 5 years or longer, especially if they achieve a deep, early response and have no high‑risk features (e.g., bulky disease, high LDH). However, relapse can occur anytime, and long‑term data are still evolving. Regular follow‑up imaging and clinical exams are essential to detect recurrence early. Discuss with your oncologist the specific durability data for the CAR‑T product you’ll receive and any planned maintenance strategies.",
          "order": 10,
          "qid": "S26-Q10"
        }
      ]
    },
    {
      "id": "S27",
      "title": "Semester on hold (acute lymphoblastic leukemia, young adult)",
      "diagnosis": "Ph-negative acute lymphoblastic leukemia in a 24-year-old",
      "treatment_plan": "Multi-phase chemotherapy (induction, consolidation, maintenance); CNS prophylaxis; central line; fertility counseling",
      "narrative": "I'm 24 and in grad school. The schedule looks like a second full-time job. I want to live—and still graduate.",
      "qa": [
        {
          "q": "How much of my semester is realistically salvageable?",
          "gt": "You’ll likely be in the induction phase for 4–6 weeks, followed by 4–6 weeks of consolidation, then maintenance that continues for 2–3 years. During the first 8–12 weeks you’ll have frequent chemo‑infusions, hospital visits, and side‑effects that make attending classes in person hard.  \n\n**Realistic salvage:**  \n- **Remote learning**: Most professors will allow you to take a few online or recorded lectures.  \n- **Reduced course load**: Aim for 1–2 courses (≈6–8 credits) per semester; you can add a third if you feel up to it.  \n- **Academic leave**: If you can’t keep up, a one‑semester leave of absence is often available and can be taken without penalty.  \n\nCoordinate early with your registrar and a faculty advisor; most schools have a “medical leave” policy that lets you pause or reduce your schedule while you focus on treatment and still graduate on time.",
          "order": 1,
          "qid": "S27-Q01"
        },
        {
          "q": "Will a central line change how I sleep or shower?",
          "gt": "A central line (usually a PICC or tunneled catheter) can affect your daily routine, but many people adapt quickly.\n\n**Sleeping** – You can sleep in most positions, but avoid sleeping on the side with the line if it’s a PICC, as the catheter can kink. Some patients prefer a pillow to keep the arm slightly elevated. If you’re on a tunneled line, you can sleep on either side; just keep the dressing clean and dry.\n\n**Showering** – You can shower, but keep the line out of direct water spray. Use a shower cap or a plastic bag to cover the exit site, and avoid soaking the dressing. If you’re using a PICC, a short shower (5–10 min) is usually fine; longer baths or swimming should be avoided until the line is removed.\n\nWith proper care, most people resume normal sleeping and showering habits within a few days. If you notice redness, swelling, or pain, contact your oncology team right away.",
          "order": 2,
          "qid": "S27-Q02"
        },
        {
          "q": "How do I handle friends who say 'you don’t look sick' when I’m exhausted?",
          "gt": "It’s normal to feel frustrated when people say “you don’t look sick.”  \n1. **Set a gentle boundary** – a quick, “I’m exhausted, but I’m okay. I appreciate your concern.”  \n2. **Educate, not lecture** – share that fatigue, brain fog, and emotional exhaustion are real, often invisible side‑effects of chemo.  \n3. **Use “I” statements** – “I feel drained and need rest, even if I look fine.”  \n4. **Ask for specific help** – “Could you help me with X or just check in tomorrow?”  \n5. **Model self‑care** – when you’re rested, you’ll feel less defensive.  \n6. **Lean on supportive friends** – those who listen without judgment will be your strongest allies.  \n\nRemember, you’re allowed to set limits; your health comes first.",
          "order": 3,
          "qid": "S27-Q03"
        },
        {
          "q": "What does 'maintenance' actually feel like?",
          "gt": "**Maintenance** is the longest phase—often 18–24 months of low‑dose chemotherapy (e.g., 6‑mercaptopurine, methotrexate, vincristine) given weekly or bi‑weekly. It’s usually less intense than induction, but you’ll still feel the “chemo‑fatigue,” mild nausea, and a higher risk of infections. You’ll have routine clinic visits (every 2–4 weeks) for blood counts and medication refills, and you’ll need to keep a strict medication schedule at home. Most people can return to school, but you may miss a few days for appointments or when your immune system is low. The key is to plan your coursework around clinic days, stay hydrated, and report fevers or bruising right away. With good support, many graduate on time.",
          "order": 4,
          "qid": "S27-Q04"
        },
        {
          "q": "Can we preserve fertility without delaying induction?",
          "gt": "**Short answer:** Yes—fertility preservation can be done right before induction without delaying the start of chemotherapy.\n\n**What you can do:**\n\n| Patient | Quick option | Time needed | Notes |\n|---------|--------------|-------------|-------|\n| **Male** | Sperm banking (or cryopreservation of testicular tissue if you’re azoospermic) | < 24 h | Done at a fertility clinic or hospital lab; no impact on induction. |\n| **Female** | Ovarian tissue cryopreservation (or oocyte freezing with minimal stimulation) | 1–2 weeks | Ovarian tissue can be removed during a laparoscopic procedure; oocyte freezing requires 2–3 weeks of stimulation but can be started immediately. |\n| **Both** | GnRH‑agonist (leuprolide) during induction | 1–2 weeks | Helps protect ovarian reserve; not a substitute for tissue or sperm banking but can reduce ovarian damage. |\n\n**Practical steps**\n\n1. **Speak with your oncologist and a reproductive specialist ASAP.** They’ll coordinate the timing so you’re ready for induction the next day or two.\n2. **Schedule the fertility procedure the day before induction** (or the morning of induction if the clinic allows). Most sperm banks accept samples on the same day; ovarian tissue can be harvested during a brief laparoscopic procedure.\n3. **If you’re a woman and need ovarian stimulation,** the cycle can start immediately; the first dose of chemo can begin once the eggs are retrieved (usually 2–3 weeks later). If that delay is unacceptable, discuss GnRH‑agonist protection instead.\n\n**Bottom line:** Fertility preservation is feasible without postponing induction. Early, coordinated planning with your oncology and fertility teams will keep both your treatment and your future family goals on track.",
          "order": 5,
          "qid": "S27-Q05"
        },
        {
          "q": "Do I have to give up my apartment with roommates?",
          "gt": "You don’t have to abandon your apartment, but you’ll need to manage infection risk carefully.  \n- **Central line care**: You can keep it at home if you’re trained, but you’ll need a clean, dry environment and a dedicated area for line care.  \n- **Roommates**: They should be healthy, not immunocompromised, and avoid close contact during periods of neutropenia (usually the first 7–10 days after each chemo cycle).  \n- **Hygiene**: Keep the apartment spotless, use disinfectants, and avoid pets or raw food.  \n- **Isolation**: If you’re severely neutropenic, your oncologist may recommend a temporary stay elsewhere or a “clean” room.  \n- **Communication**: Discuss your schedule with your roommates and the oncology team; they can help you plan visits and cleaning.  \n\nIn short, staying is possible with precautions, but always follow your team’s infection‑control guidance.",
          "order": 6,
          "qid": "S27-Q06"
        },
        {
          "q": "What if chemo brain wrecks my studying?",
          "gt": "Chemo‑brain—short‑term memory lapses, slowed processing, and difficulty concentrating—affects up to 70 % of ALL patients. It usually peaks during induction and eases over months, but it can still interfere with coursework.  \n\n**Practical steps:**  \n1. **Talk to your school** early. Most universities grant extensions, reduced‑workload semesters, or online options for patients on active treatment.  \n2. **Schedule study sessions** during your “brain‑best” times (often mid‑morning or early afternoon). Use short, frequent blocks (25‑30 min) with 5‑min breaks.  \n3. **Leverage tools**—voice‑to‑text, note‑taking apps, and color‑coding—to reduce cognitive load.  \n4. **Prioritize sleep, hydration, and light exercise**; these improve cognition and mood.  \n5. **Consider cognitive rehabilitation** or a neuropsychologist if symptoms persist.  \n\nWith these supports, many patients finish their degrees while undergoing therapy. Stay in touch with your oncology team and academic advisors—they’re there to help you succeed.",
          "order": 7,
          "qid": "S27-Q07"
        },
        {
          "q": "How strict is infection prevention during exams on campus?",
          "gt": "During periods of neutropenia (ANC < 500 cells/µL) your risk of serious infection is high, so campus infection‑control rules are usually very strict for you. Most universities require:\n\n1. **Mask‑wearing** in all indoor spaces, especially lecture halls and exam rooms.  \n2. **Hand‑washing or sanitizer** before and after exams.  \n3. **Avoiding large crowds**—you may be asked to sit at the back or in a separate area.  \n4. **Vaccinations** (influenza, COVID‑19, pneumococcal) should be up‑to‑date; discuss with your oncologist.  \n5. **Remote or proctored online exams** are often offered for immunocompromised students; request this in advance.  \n\nIf you’re in a very low ANC phase, the school may allow you to sit outside the exam hall or take the test at a different time. Coordinate with the disability services office and your oncology team to get a written accommodation that protects you while keeping you on track to graduate.",
          "order": 8,
          "qid": "S27-Q08"
        },
        {
          "q": "If a phase is delayed, does it ruin the whole plan?",
          "gt": "Delaying a phase can compromise the overall cure rate, but it doesn’t automatically “ruin” the plan. In most ALL protocols, a single short delay (e.g., a week or two) is tolerated if the next cycle is started on time and the total duration of therapy is kept within the recommended window. However, cumulative delays—especially beyond the first few weeks of induction or during consolidation—can reduce the intensity of the regimen and increase relapse risk.  \n\n**What to do:**  \n1. Notify your team immediately if a dose or day is missed.  \n2. Ask whether a dose‑adjusted or “catch‑up” schedule is possible.  \n3. Prioritize supportive care (growth factors, infection prophylaxis) to keep you on schedule.  \n4. Keep your fertility and academic plans in the conversation—your oncologist can coordinate with a fertility specialist and academic advisors.  \n\nIn short, a brief hiccup is manageable, but repeated or prolonged delays should be avoided and addressed promptly.",
          "order": 9,
          "qid": "S27-Q09"
        },
        {
          "q": "What’s plan B if remission isn’t complete?",
          "gt": "If induction fails to achieve a complete remission, the next step is “salvage” therapy—usually a different multi‑agent regimen (e.g., hyper‑CVAD, L-asparaginase‑based combos, or a high‑dose methotrexate‑based protocol). The goal is to reduce disease enough to qualify for an allogeneic stem‑cell transplant (SCT), which offers the best chance for cure in adults with relapsed ALL. If transplant isn’t feasible (due to age, comorbidities, or donor availability), enrollment in a clinical trial or a compassionate‑use protocol is the next option. Throughout, maintain close monitoring of organ function, infection risk, and fertility status, and keep open communication with your oncology team and support network.",
          "order": 10,
          "qid": "S27-Q10"
        }
      ]
    },
    {
      "id": "S28",
      "title": "Which way do I pee (muscle-invasive bladder cancer)",
      "diagnosis": "Muscle-invasive urothelial carcinoma",
      "treatment_plan": "Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with urinary diversion (ileal conduit or neobladder)",
      "narrative": "I'm 65. They’re removing my bladder after chemo, and I have to choose how I’ll pee for the rest of my life. I want dignity and practicality.",
      "qa": [
        {
          "q": "Is there a way to avoid removing the bladder if chemo works well?",
          "gt": "For muscle‑invasive bladder cancer the standard of care is radical cystectomy after neoadjuvant cisplatin‑based chemotherapy.  In a small subset of patients whose disease responds completely to chemo, a “bladder‑sparing” strategy can be considered.  This usually involves a transurethral resection of the tumor (TURBT) followed by definitive radiation therapy with concurrent chemotherapy (trimodality therapy).  To qualify, the tumor must be localized, the patient must tolerate radiation, and the response must be confirmed by cystoscopy, imaging, and sometimes repeat biopsies.  Because the risk of recurrence is high, close surveillance is mandatory.  Discuss with your oncologist and radiation specialist to see if you meet the strict criteria for a bladder‑sparing protocol.",
          "order": 1,
          "qid": "S28-Q01"
        },
        {
          "q": "Which diversion lets me travel without constant bathroom scouting?",
          "gt": "**Travel‑friendly choice:** **Ileal conduit (external pouch)**\n\n- **Why it’s easier on the road:**  \n  • You never have to hunt for a toilet to “go.” The conduit drains into a small, discreet pouch that you can empty at any restroom (or even at home).  \n  • No need to plan voiding times or worry about finding a private space to sit and empty a neobladder.  \n  • The pouch can be carried in a bag or a small pouch case, and it’s easy to replace or empty on the go.\n\n- **Neobladder note:**  \n  • Gives a more “natural” feel and no external bag, but you must locate a toilet to void, which can be inconvenient on long trips or in places with limited restroom access.  \n  • Requires a schedule (usually 4–6 times a day) and can be uncomfortable if you’re in a hurry.\n\n**Bottom line:** If you want the least hassle while traveling, an ileal conduit is the practical, dignified option. It lets you move freely without constant bathroom scouting.",
          "order": 2,
          "qid": "S28-Q02"
        },
        {
          "q": "Will intimacy be possible after surgery?",
          "gt": "After a radical cystectomy, sexual activity is usually still possible, but it often requires some adjustments.  \n\n**Men** – If the surgery is nerve‑sparing, erections can be preserved, but many men experience erectile dysfunction.  Oral phosphodiesterase‑5 inhibitors, vacuum devices, or penile implants can restore function.  The urinary diversion (ileal conduit or neobladder) does not directly affect sexual organs, but the change in body image and the need for catheter care (in a conduit) can influence intimacy.  \n\n**Women** – The bladder removal does not remove the vagina, so intercourse is usually possible.  Pelvic floor therapy, lubricants, and sometimes vaginal dilators help maintain comfort.  \n\nIn both cases, counseling, pelvic‑floor exercises, and open communication with your partner help maintain a satisfying intimate life.",
          "order": 3,
          "qid": "S28-Q03"
        },
        {
          "q": "How visible is an external bag under clothes?",
          "gt": "An ileal‑conduit bag is a small, flat pouch that sits on the lower abdomen and is connected to a stoma.  It’s usually 3–4 inches wide and 2–3 inches tall, so it can be hidden under most everyday clothing.  With a snug, low‑cut top or a loose shirt, the bag is often invisible to others—though a light‑colored or patterned shirt can help disguise it.  Some people choose a discreet “conduit cover” or a small pocket in a waistband to keep the bag out of sight.  If you’re opting for a neobladder, no external bag is needed, so there’s no visibility concern.  Ultimately, most patients find the conduit is well concealed in normal attire, and you can adjust clothing and accessories to feel comfortable and dignified.",
          "order": 4,
          "qid": "S28-Q04"
        },
        {
          "q": "Will chemo damage my hearing or nerves permanently?",
          "gt": "Cisplatin can cause both hearing loss (ototoxicity) and peripheral neuropathy, but the risk varies. About 10‑30 % of patients develop some hearing loss, usually in the high‑frequency range, and it can be permanent if the drug accumulates. Neuropathy is less common (≈5‑10 %) and often reversible, but severe cases can persist. Your oncologist will monitor hearing with audiograms and nerve function tests before, during, and after treatment. If you develop symptoms, dose adjustments, slower infusion, or protective agents (e.g., sodium thiosulfate) may be offered. Most patients tolerate the regimen without lasting damage, but it’s important to report any ringing, muffled hearing, or numbness early so adjustments can be made.",
          "order": 5,
          "qid": "S28-Q05"
        },
        {
          "q": "Can I swim with a stoma?",
          "gt": "Yes—you can swim after a cystectomy, but you’ll need a few precautions to keep your stoma and pouch dry and comfortable.\n\n1. **Use a waterproof pouch** that seals tightly around the stoma. A pouch with a valve or a “water‑proof” pouch is ideal. Test it in shallow water before heading into deeper water.  \n2. **Keep the stoma clean** before swimming. Wash with mild soap, rinse, and pat dry.  \n3. **Avoid high‑pressure water** (e.g., scuba diving or jet‑scooters) until you’re sure the pouch stays sealed.  \n4. **Check for leaks** after each swim; a small leak can irritate the skin and increase infection risk.  \n5. **Consult your surgeon** if you notice redness, swelling, or drainage, and follow any specific instructions they give.\n\nWith a good pouch and careful care, swimming can be a safe, enjoyable activity that preserves your dignity and quality of life.",
          "order": 6,
          "qid": "S28-Q06"
        },
        {
          "q": "What if I can’t pee with a neobladder at first?",
          "gt": "If a neobladder doesn’t work right away, it’s usually a temporary problem. Early on you’ll need to use intermittent catheterization (every 3–4 hours) to empty the reservoir until the bowel‑derived bladder learns to contract and relax. Most patients regain spontaneous voiding within 3–6 months, but some may need a longer training period or a small, temporary urinary diversion (e.g., a ureterostomy or a small ileal conduit) while the neobladder matures. Your surgeon will monitor residual urine, kidney function, and infection risk. If the neobladder never functions adequately, a permanent ileal conduit is the next best option—simple, reliable, and preserves dignity. Discuss your concerns with the urologist so they can tailor the plan to your recovery pace.",
          "order": 7,
          "qid": "S28-Q07"
        },
        {
          "q": "How often are follow-ups after surgery?",
          "gt": "After a radical cystectomy, most surgeons schedule a structured follow‑up plan that balances early detection of recurrence with practicality:\n\n| Time after surgery | Typical visits | Key assessments |\n|--------------------|----------------|-----------------|\n| **0–3 months** | 2–3 visits | Physical exam, labs (CBC, CMP, creatinine), imaging (CT chest/abdomen/pelvis if indicated), review of diversion function (stoma care or neobladder function). |\n| **3–12 months** | Every 3 months | Same as above; for a neobladder, add a cystoscopy at 6 months and then every 6–12 months. |\n| **1–3 years** | Every 6 months | Continue labs, imaging, and cystoscopy (neobladder). |\n| **After 3 years** | Annually | Routine exam, labs, imaging; cystoscopy only if symptoms arise. |\n\n**Practical tips**\n\n- **Ileal conduit**: No cystoscopy needed; focus on stoma care, renal function, and imaging for recurrence.  \n- **Neobladder**: Cystoscopy is routine; discuss any urinary symptoms promptly.  \n\nAlways tailor the schedule to your surgeon’s recommendations and any individual risk factors (e.g., high‑grade disease, lymph node involvement). This plan helps maintain dignity and practicality while keeping recurrence detection early.",
          "order": 8,
          "qid": "S28-Q08"
        },
        {
          "q": "Will I smell or leak?",
          "gt": "**Short answer:**  \n- **Ileal conduit:** No leakage from the stoma—urine drains continuously into a bag. The bag can have a mild urine odor, but it’s usually manageable with a good seal and regular bag changes.  \n- **Neobladder:** You’ll have a small, bladder‑like pouch made from intestine. It can hold urine and empty with a normal voiding pattern, but early on you may experience occasional dribbling or the need for a “clean intermittent catheterization” if the pouch doesn’t empty fully. The odor is similar to normal urine, but you may notice a slight “intestinal” scent because the pouch uses bowel tissue.\n\n**Practical tips**  \n- **Ileal conduit:** Choose a bag with a secure, low‑profile valve; change the bag every 3–4 days.  \n- **Neobladder:** Practice timed voiding, pelvic‑floor exercises, and keep a catheter kit handy for “emptying” if needed.  \n\nBoth options can be dignified and functional; the choice depends on your lifestyle, willingness to manage a bag or a pouch, and your surgeon’s recommendation.",
          "order": 9,
          "qid": "S28-Q09"
        },
        {
          "q": "If pathology shows worse disease than expected, do we have backup options?",
          "gt": "If the final pathology shows a higher stage (e.g., pT3‑T4, nodal involvement, or positive margins), the plan usually shifts from a purely curative intent to a multimodality approach:\n\n1. **Adjuvant chemotherapy** – most patients receive a 4‑cycle cisplatin‑based regimen if they are fit.  \n2. **Radiation therapy** – considered for positive nodes or margins, often combined with chemotherapy (chemoradiation).  \n3. **Extended pelvic lymphadenectomy** – may be performed intra‑operatively if nodes are suspicious.  \n4. **Palliative diversion** – if the disease is metastatic or the patient is unfit for further treatment, an ileal conduit or a continent cutaneous diversion can still be created to maintain dignity and practicality.  \n\nIf systemic disease is present, enrollment in a clinical trial or best‑supportive care may be the next step. Discuss each option with your oncology team to tailor the best plan for your situation.",
          "order": 10,
          "qid": "S28-Q10"
        }
      ]
    },
    {
      "id": "S29",
      "title": "Swallowing my fear (esophageal cancer)",
      "diagnosis": "Locally advanced esophageal or gastroesophageal junction cancer",
      "treatment_plan": "Neoadjuvant chemoradiation followed by surgery when appropriate; nutrition support",
      "narrative": "I'm 60 and losing weight because food gets stuck. Treatment is chemoradiation and possibly surgery. I want to eat with my family again.",
      "qa": [
        {
          "q": "How do I keep weight on when every bite scares me?",
          "gt": "I’m sorry you’re facing this. Here are practical steps that can help you maintain weight and still enjoy meals with your family:\n\n1. **Small, frequent meals** – 5–6 mini‑servings a day instead of 3 large ones.  \n2. **High‑calorie, nutrient‑dense foods** – smoothies, protein shakes, nut‑butter‑filled bananas, avocado, cheese, and oatmeal. Add a tablespoon of olive oil or coconut milk to soups and sauces.  \n3. **Texture modification** – pureed or finely chopped foods reduce the effort needed to swallow.  \n4. **Temperature & flavor** – use lukewarm or room‑temperature foods; avoid very hot, spicy, or acidic items that irritate mucositis.  \n5. **Swallow‑support** – practice gentle head‑tilt forward or “chin‑to‑chest” positioning; a speech‑language pathologist can teach specific techniques.  \n6. **Pain control** – use prescribed anti‑inflammatory or opioid medications, mouth rinses, and topical anesthetics as directed.  \n7. **Consider a feeding tube** if weight loss continues or oral intake is unsafe; it can be temporary or long‑term.  \n8. **Family meals** – keep portions small, let others feed you, and use distraction (music, conversation) to reduce anxiety.  \n\nWork closely with your dietitian and oncology team to tailor these strategies to your tolerance and treatment schedule.",
          "order": 1,
          "qid": "S29-Q01"
        },
        {
          "q": "Will chemoradiation make swallowing worse before it gets better?",
          "gt": "Chemoradiation can indeed make swallowing feel worse at first. The radiation and chemotherapy often cause mucositis, swelling, and irritation of the esophageal lining, which can make food feel stuck or painful for the first 2–4 weeks. Most patients notice improvement once the acute inflammation subsides—usually after the treatment course ends and a few weeks of recovery. In the meantime, a dietitian can help you plan soft or liquid meals, and a speech‑language pathologist can teach swallowing exercises. If swallowing remains difficult, a temporary feeding tube may be needed to maintain nutrition. Once the inflammation resolves, many people find their swallowing improves enough to enjoy meals with family again.",
          "order": 2,
          "qid": "S29-Q02"
        },
        {
          "q": "If surgery is needed, will I ever eat normally?",
          "gt": "After an esophagectomy the anatomy of your swallowing tract is altered, so “normal” eating often means a new routine rather than a return to the exact same diet you had before cancer. Most people can resume oral intake, but it usually starts with small, soft, well‑hydrated meals and gradually progresses to regular foods. Swallow‑therapy, dietary counseling, and sometimes temporary feeding tubes are common. Some patients develop strictures or reflux that require dilation or medication, and the taste of food may change. With careful follow‑up, most patients learn to eat comfortably with family again, though the pattern of eating may be different from before.",
          "order": 3,
          "qid": "S29-Q03"
        },
        {
          "q": "Am I going to choke or aspirate at home?",
          "gt": "**Short answer:**  \nYou’re not guaranteed to choke or aspirate, but the risk is real while you’re dealing with a large tumor and the side‑effects of chemoradiation. With the right precautions—small, well‑chewed bites, thickened liquids if needed, sitting upright, and a swallow‑therapy plan—you can eat safely at home most of the time.  \n\n**What to do:**  \n1. **Get a swallow assessment** from a speech‑language pathologist. They’ll recommend texture‑modified foods and safe‑swallow techniques.  \n2. **Follow a dietitian’s plan**: start with pureed or soft foods, then gradually reintroduce solids as tolerated.  \n3. **Eat slowly, take small bites, and chew thoroughly.**  \n4. **Sit upright for at least 30 minutes after meals** and avoid lying down.  \n5. **Watch for red flags**—coughing, choking, wheezing, or a wet, gurgly voice after swallowing. If any occur, seek medical help immediately.  \n\nWith these steps, most patients avoid aspiration and can enjoy meals with family again.",
          "order": 4,
          "qid": "S29-Q04"
        },
        {
          "q": "Can I still drink coffee or wine?",
          "gt": "During neoadjuvant chemoradiation and after surgery the esophagus is very sensitive.  \n**Coffee** – the caffeine and acidity can irritate the lining and worsen pain or reflux. If you want to keep a cup, use a low‑acid, decaf or “smooth” blend, and limit to 1–2 cups a day, preferably after meals.  \n**Wine** – alcohol is a known irritant and can delay healing. It’s safest to avoid wine (and other alcoholic drinks) while you’re receiving treatment and for at least 4–6 weeks after surgery, or until your surgeon confirms the incision is fully healed.  \n\nIf you miss these drinks, try warm water, herbal teas, or non‑caffeinated, low‑acid alternatives to stay hydrated and comfortable. Always check with your oncology team before making changes.",
          "order": 5,
          "qid": "S29-Q05"
        },
        {
          "q": "How long before I know if surgery is on the table?",
          "gt": "After you finish the chemoradiation course (usually 5–6 weeks of treatment), your team will schedule a restaging evaluation—CT, PET/CT, and often an endoscopy with biopsy—to see how the tumor has responded. That imaging and pathology review typically takes about 2–3 weeks. Once the results are in, the multidisciplinary tumor board will decide whether the cancer has shrunk enough for surgery. If the plan is to proceed, surgery is usually arranged 4–6 weeks after the end of chemoradiation, giving you time to recover and get nutrition support. So, you can expect a clear answer about surgery roughly 6–8 weeks after you finish the initial treatment.",
          "order": 6,
          "qid": "S29-Q06"
        },
        {
          "q": "Do I need to sleep upright forever?",
          "gt": "After chemoradiation (and especially after esophagectomy) many patients find that sleeping upright—using a wedge, recliner, or raising the head of the bed 30–45 °—helps keep food from refluxing into the airway and eases swallowing. It is usually a **temporary** measure, not a lifelong requirement. Most people can gradually lower the incline as healing improves and swallowing function returns. Work with your dietitian and surgeon to set a schedule: start with a firm wedge, then try a 15‑degree incline, and finally a standard bed once you’re tolerating meals without pain or regurgitation. If you still feel food getting stuck or have aspiration symptoms, keep the upright position until your doctor clears you.",
          "order": 7,
          "qid": "S29-Q07"
        },
        {
          "q": "How do you keep me safe from dehydration?",
          "gt": "**Stay hydrated during chemoradiation and before/after surgery**\n\n1. **Small, frequent sips** – 1–2 oz (30–60 ml) every 15–20 min, even if you feel full.  \n2. **Choose low‑osmolar drinks** – water, oral rehydration solutions, clear broths, or electrolyte drinks (avoid sugary sodas).  \n3. **Use a straw or sip‑cup** to reduce throat irritation.  \n4. **Monitor urine** – aim for pale yellow; dark urine signals dehydration.  \n5. **Track weight** daily; a 2–3 % loss warrants medical review.  \n6. **If oral intake is insufficient**, ask your team about a percutaneous endoscopic gastrostomy (PEG) or jejunostomy tube for continuous feeding.  \n7. **Avoid caffeine, alcohol, and very hot drinks**; they can worsen mucositis and fluid loss.  \n8. **Ask for IV fluids** if you develop nausea, vomiting, or severe mucositis—your oncology team can adjust the plan.  \n\nKeep a hydration log and bring it to appointments; early detection of dehydration keeps you safer and improves treatment tolerance.",
          "order": 8,
          "qid": "S29-Q08"
        },
        {
          "q": "What does a 'good day' look like during treatment so I can plan moments with my spouse?",
          "gt": "A “good day” during chemoradiation is one where you feel physically stable, mentally calm, and able to share a few moments with your spouse.  \n**Morning** – start with a light, protein‑rich breakfast (e.g., yogurt with fruit or a smoothie). Take your medication and a short walk if you feel up to it; gentle movement helps digestion and mood.  \n**Mid‑day** – have a small, easy‑to‑eat lunch (e.g., a soft sandwich or soup). Use this time to chat with your spouse about a favorite memory or a light topic—keep it positive.  \n**Afternoon** – rest or nap if needed; avoid heavy meals. If you’re scheduled for a treatment session, bring a small snack or a comforting drink.  \n**Evening** – finish with a light dinner (e.g., mashed potatoes or a soft pasta). End the day with a brief, relaxed conversation or a shared activity like watching a favorite show.  \n\nPlan your meals and rest around your treatment times, and use the quieter moments to connect with your spouse—this helps maintain both nutrition and emotional support.",
          "order": 9,
          "qid": "S29-Q09"
        },
        {
          "q": "If I can’t face surgery, is there still a path?",
          "gt": "I’m sorry you’re feeling so overwhelmed. If surgery isn’t an option, you still have several evidence‑based paths:\n\n1. **Definitive chemoradiation** – Many patients with locally advanced disease receive high‑dose radiation plus chemotherapy (often cisplatin/5‑FU or carboplatin/paclitaxel). In selected cases this can achieve long‑term control and even cure, especially if the tumor is confined to the esophagus or junction.\n\n2. **Endoscopic therapies** – Endoscopic mucosal resection or radiofrequency ablation can be used for small, superficial lesions, sometimes combined with radiation.\n\n3. **Stenting & nutrition** – A self‑expanding metal stent can relieve obstruction, and enteral feeding (PEG or jejunostomy) can maintain weight and strength.\n\n4. **Palliative care** – Focus on pain, dysphagia, and nutrition while preserving quality of life.\n\n5. **Clinical trials** – New radiosensitizers, immunotherapy combinations, or targeted agents may be available.\n\nDiscuss these options with your oncologist; they can tailor a plan that balances effectiveness with your comfort and goals.",
          "order": 10,
          "qid": "S29-Q10"
        }
      ]
    },
    {
      "id": "S30",
      "title": "Fast and furious (extensive-stage small cell lung cancer)",
      "diagnosis": "Extensive-stage small cell lung cancer",
      "treatment_plan": "Platinum/etoposide chemotherapy with immunotherapy; symptom control; imaging to assess response",
      "narrative": "I'm 63 and this cancer showed up fast. They want to start chemo-immunotherapy now. I need relief and a plan that keeps my days meaningful.",
      "qa": [
        {
          "q": "How quickly might my cough and breathlessness improve?",
          "gt": "In most patients with extensive‑stage SCLC treated with platinum/etoposide plus a PD‑L1 inhibitor, symptom relief can begin within the first 2–4 weeks after starting therapy. Some people notice a modest reduction in cough or shortness of breath after the first cycle (≈3 days to a week) because the drugs start shrinking tumor cells quickly, but meaningful improvement—enough to breathe easier and talk more comfortably—usually appears after 2–3 weeks of continuous treatment.  \n\nIf symptoms persist or worsen, your team will add supportive measures (e.g., bronchodilators, steroids, oxygen) and reassess with a CT scan in 6–8 weeks to confirm a response. Keep close contact with your oncologist; early reporting of any new or worsening cough or breathlessness helps adjust therapy promptly.",
          "order": 1,
          "qid": "S30-Q01"
        },
        {
          "q": "What makes this cancer different from the others I read about?",
          "gt": "Small‑cell lung cancer (SCLC) is distinct because it behaves like a “fast‑growing, early‑spreading” tumor. Its cells divide every 6–8 days, so it can become metastatic within weeks of detection. Unlike most non‑small‑cell cancers, SCLC rarely responds to targeted drugs or surgery; instead it is highly chemosensitive but usually relapses quickly. It also produces neuroendocrine hormones (e.g., ACTH, ADH), causing paraneoplastic syndromes that can dominate symptoms. Because of this rapid spread, the standard of care is a platinum‑based chemotherapy (cisplatin or carboplatin) plus etoposide, now routinely combined with the immune‑checkpoint inhibitor atezolizumab or durvalumab. The goal is to shrink the tumor quickly while preserving quality of life, rather than long‑term local control.",
          "order": 2,
          "qid": "S30-Q02"
        },
        {
          "q": "Will I be stuck in bed after each cycle?",
          "gt": "After a cycle of platinum‑etoposide plus immunotherapy you’ll usually feel tired, but most people can get out of bed within 24–48 hours. The chemotherapy is given every 3 weeks, so you’ll have a few days to rest between cycles. Fatigue, nausea, and low blood counts are the main reasons you might need a day or two of light activity, but you can usually return to normal activities—walking, light chores, or even a short drive—once the nausea subsides and your blood counts stabilize. Keep a symptom diary, stay hydrated, and let your oncology team know if you feel unusually weak or have trouble breathing; they can adjust supportive care (e.g., anti‑nausea meds, growth factors, or dose modifications) to keep you moving and meaningful.",
          "order": 3,
          "qid": "S30-Q03"
        },
        {
          "q": "Can immunotherapy cause dangerous side effects?",
          "gt": "Yes, immune‑checkpoint inhibitors (the immunotherapy used with platinum/etoposide for extensive‑stage SCLC) can produce serious side effects, although they are uncommon. The most concerning are immune‑related adverse events (irAEs) that can affect any organ system:\n\n| System | Typical irAE | Severity | Management |\n|--------|--------------|----------|------------|\n| Skin | Rash, pruritus | Mild–severe | Topical steroids; systemic steroids if severe |\n| GI | Colitis | Mild–severe | Oral/IV steroids; stop drug if severe |\n| Lungs | Pneumonitis | Mild–life‑threatening | Steroids, oxygen, sometimes drug discontinuation |\n| Liver | Hepatitis | Mild–severe | Steroids, monitor LFTs |\n| Endocrine | Hypothyroidism, adrenal insufficiency | Mild–severe | Hormone replacement, steroids |\n| Neurologic | Myasthenia gravis, neuropathy | Rare but severe | Immediate steroids, supportive care |\n\nMost patients tolerate therapy well, but prompt recognition and treatment of irAEs are essential. Your oncology team will monitor blood tests, imaging, and symptoms closely, and will intervene early if any of these complications arise.",
          "order": 4,
          "qid": "S30-Q04"
        },
        {
          "q": "Should I quit smoking now, or is it too late to matter?",
          "gt": "Quitting now is still a powerful step—yes, it’s “too late” to cure the cancer, but it can improve your treatment response, reduce complications, and protect your remaining health.\n\n**Why it matters now**\n\n| Benefit | How it helps |\n|---------|--------------|\n| **Better chemo tolerance** | Smoking damages the lungs and immune system, making side‑effects worse. Stopping can lower infection risk and improve blood flow to the tumor. |\n| **Reduced risk of new cancers** | Every day you smoke adds to the chance of second primary tumors. |\n| **Improved quality of life** | Less shortness of breath, cough, and fatigue. |\n| **Enhanced immune‑checkpoint response** | Some studies suggest smokers have a blunted response to immunotherapy; quitting may help. |\n\n**Practical steps**\n\n1. **Call your oncologist or a smoking‑cessation hotline (e.g., 1‑800‑QUIT‑NOW).** They can prescribe nicotine replacement or medications (bupropion, varenicline) that work even during chemo.\n2. **Set a quit date—today is a good start.** Remove cigarettes, ashtrays, and triggers from your environment.\n3. **Use support tools:** apps, counseling, or a quit‑smoking support group.\n4. **Track your progress** and celebrate milestones—each day without smoke is a win.\n\nEven after diagnosis, quitting can improve your treatment outcomes and help you live more fully during and after therapy. It’s never too late to make a positive change.",
          "order": 5,
          "qid": "S30-Q05"
        },
        {
          "q": "If my brain scan later shows spots, what then?",
          "gt": "If a later brain scan shows new “spots,” they are most often small‑cell lung cancer metastases or treatment‑related changes. The next steps are:\n\n1. **Confirm the finding** – a dedicated brain MRI with contrast is the gold standard.  \n2. **Assess symptoms** – headaches, seizures, focal deficits, or cognitive changes change the urgency.  \n3. **Start steroids** (e.g., dexamethasone) if there is edema or symptoms, to reduce swelling and improve comfort.  \n4. **Discuss prophylactic cranial irradiation (PCI)** – for extensive‑stage disease, PCI (25 Gy in 10 fractions) is standard if the lesions are small, asymptomatic, and you’re fit for it.  \n5. **Consider focal radiotherapy** (e.g., stereotactic radiosurgery) if there are a few, well‑defined lesions.  \n6. **Re‑evaluate systemic therapy** – continue or adjust chemo‑immunotherapy based on overall disease control.  \n\nKeep your oncologist and a neuro‑oncology team in the loop; they’ll tailor the plan to keep you comfortable and active.",
          "order": 6,
          "qid": "S30-Q06"
        },
        {
          "q": "Can I keep my morning walks with my dog?",
          "gt": "It’s usually safe to keep walking your dog, and the fresh air can help you feel better.  \n**What to keep in mind**  \n- **Energy & fatigue**: If you feel very tired, shorten the walk or walk at a slower pace.  \n- **Infection risk**: Immunotherapy can lower your immune defenses. Keep your hands clean, avoid crowded parks, and make sure your dog is up‑to‑date on vaccines.  \n- **Weather & safety**: Stay hydrated, avoid extreme heat or cold, and wear a reflective jacket if you walk early or late.  \n- **Side‑effects**: Watch for new fevers, chills, or breathing changes; report them to your oncology team.  \n\nTalk to your oncologist about any specific concerns, but a gentle walk with your dog is generally a good way to stay active and maintain a sense of normalcy.",
          "order": 7,
          "qid": "S30-Q07"
        },
        {
          "q": "How long does this treatment last?",
          "gt": "**Typical course for extensive‑stage small‑cell lung cancer (ES‑SCLC) with platinum/etoposide plus immunotherapy**\n\n| Phase | What happens | Duration |\n|-------|--------------|----------|\n| **Induction** | 4–6 cycles of cisplatin or carboplatin + etoposide, given every 3 weeks, with a checkpoint inhibitor (atezolizumab or durvalumab) started on the same day as each cycle. | 12–18 weeks (≈ 4–6 cycles) |\n| **Maintenance** | After the last chemotherapy cycle, the checkpoint inhibitor is continued alone (usually every 3 weeks) until disease progression, unacceptable toxicity, or a maximum of about 1 year. | Up to 12 months (or until progression/side‑effects) |\n\n**Key points**\n\n- The exact number of induction cycles is tailored to your response and tolerance; most patients receive 4–6 cycles.\n- Maintenance immunotherapy can extend overall treatment to roughly 1 year, but many patients stop earlier if the cancer progresses or if side‑effects become problematic.\n- Your oncologist will adjust the schedule based on imaging, blood tests, and how you feel.",
          "order": 8,
          "qid": "S30-Q08"
        },
        {
          "q": "What happens if it grows back fast?",
          "gt": "If the tumor recurs quickly after the initial platinum‑etoposide plus immunotherapy, it is usually considered **relapsed or refractory disease**. The cancer has shown resistance to the drugs you just received, so the next steps are:\n\n1. **Re‑staging scan** – to confirm the extent of recurrence and rule out new sites.  \n2. **Second‑line therapy** – options include topotecan, irinotecan, or a platinum‑based regimen with a different agent (e.g., carboplatin plus paclitaxel).  Newer targeted or antibody‑drug conjugates (e.g., amivantamab‑IRDye) are being studied.  \n3. **Clinical trials** – many trials are enrolling patients with relapsed SCLC; they can offer access to novel agents.  \n4. **Palliative care** – symptom control (pain, dyspnea, fatigue) and psychosocial support remain essential to keep your days meaningful.  \n\nThe prognosis after rapid relapse is poorer, but early re‑assessment and a tailored second‑line plan can still provide benefit and maintain quality of life. Discuss these options with your oncologist to choose the best path for you.",
          "order": 9,
          "qid": "S30-Q09"
        },
        {
          "q": "How do we protect good days for time with my family?",
          "gt": "I’m sorry you’re facing this. Here are practical ways to keep the days you spend with family meaningful while you’re on platinum‑etoposide plus immunotherapy:\n\n1. **Plan around treatment days** – Chemotherapy is usually every 3–4 weeks. Schedule family visits or meals on the days after a cycle when you feel strongest.  \n2. **Use supportive meds early** – Anti‑nausea, anti‑emetic, and pain‑control drugs can reduce fatigue and allow you to stay active. Ask your oncologist about prophylactic doses.  \n3. **Set realistic expectations** – Communicate with family about what you can handle each day. A simple “I’ll be up for a short walk, then need rest” keeps everyone on the same page.  \n4. **Incorporate palliative care** – Early palliative support can help manage symptoms, coordinate care, and give you more energy for family time.  \n5. **Create a “good‑day” routine** – A short morning stretch, a favorite snack, and a brief chat with a loved one can anchor the day.  \n6. **Use technology for quick check‑ins** – If you’re too tired to meet in person, a video call or text can still share moments.  \n\nBalancing treatment and quality time is doable with clear planning, symptom control, and open communication.",
          "order": 10,
          "qid": "S30-Q10"
        }
      ]
    }
  ]
}